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ABSTRACT 
 
Cardiac Resynchronisation Therapy (CRT) is now an established therapeutic option for 
patients with symptomatic left ventricular systolic dysfunction, broad QRS duration (>120 
milliseconds on surface electrocardiogram) and on optimal tolerated medical therapy. The 
numbers of implants are rising throughout the Westernised world. The United Kingdom has 
also had a rapid increase in the rate of CRT implantation.  
 
Despite the large randomised trials which prove clinical effectiveness, there is a realisation 
that a significant minority of patients who undergo CRT implantation do not derive the 
anticipated clinical benefit. This has been labelled as non-response with up to 40 percent of 
patients being affected depending on diagnostic criteria. 
 
However potential solutions to a lack of clinical benefit do exist. These include medical 
optimisation of the patient’s heart failure pharmacotherapy following CRT implantation, and 
device based optimisation adjusting atrioventricular and ventriculo-ventricular (AV and VV)  
intervals. Other reasons for a lack of clinical improvement may be explained by 
pathophysiology which is currently not accounted for in the guidelines and selection criteria.  
 
The thesis is therefore dedicated to the exploration of these issues using the dataset from the 
specialist heart failure pacing clinic at the Royal Brompton Hospital.  
 
The study of medical optimisation following CRT implantation observed increased rates of 
neurohormonal antagonists and anticoagulants when a systematic structured clinical approach 
was adopted.  
 
One potential method of evaluating device based optimisation is impedance cardiography and 
within chapter V, a cohort of 44 patients underwent device based optimisation with either 
conventional echocardiographic techniques or impedance cardiography. Though 
underpowered and a pilot study, the impedance cardiographic method within this cohort 
performed adequately.  
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Heart failure remains a complex syndrome with complex pathophysiology. One of the 
potential reasons for non-response is the lack of acknowledgement of other physiological 
criteria in the selection criteria. The study performed using cardiac magnetic resonance 
(CMR) imaging to evaluate right ventricular function on cardiovascular outcomes in patients 
following CRT implantation.  Here it was demonstrated that right ventricular dysfunction as 
assessed by CMR is a powerful predictor of adverse outcomes and of a failure to undergo left 
ventricular remodelling.  
 
The last study chapter was a small pilot study which compared impedance cardiographic 
performance to echocardiography within an intensive care setting. Whilst the numbers of 
patients recruited were small (n=6), the adjustment of atrioventricular and ventriculo-
ventricular delays did induce a change in haemodynamics.  
 
In conclusion the thesis represents studies and work focussed on the problem of lack of 
clinical benefit experienced by patients following CRT implantation. It has covered a 
prognosticator and two potential methods for improving the rate of clinical response 
following CRT implantation.  
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Introduction 
 
Heart Failure (HF) is a widely prevalent, costly and lethal condition. It is responsible for 
approximately 1-2% of healthcare expenditure in developed countries. (1) Heart failure is a 
chronic condition where the metabolic demands of the body are not adequately met due to 
impairment of cardiac function. The most common causes are ischaemic heart disease, 
inherited cardiomyopathies including hypertrophic cardiomyopathies, dilated 
cardiomyopathy, hypertension, toxins including alcohol and prescribed drugs e.g. 
chemotherapy. However, any disease process which affects the heart can, in its advanced 
stages, lead to the heart failure phenotype. This can be subdivided into systolic impairment of 
the left ventricular function- left ventricular systolic dysfunction (LVSD) and those with 
preserved systolic function- heart failure with preserved ejection fraction. (HFpEF) 
 
Heart failure is predominately a disease which affects the elderly, with the median age at 
presentation in the United Kingdom being 78 years.(2) The past three decades have witnessed 
the development of neurohormonal antagonists such as angiotensin converting enzyme 
inhibitors (ACEI), angiotensin II receptor antagonists (ARBs), beta adrenoceptor antagonists 
‘Beta blockers’ (BB) and mineralocorticoid receptor antagonists (MRA). Cardiac 
resynchronisation therapy (CRT) and implantable cardiac defibrillators (ICDs) have also 
become established as treatment options for selected patients with heart failure. Despite the 
technological and pharmacological advances, heart failure remains a condition with a poor 
prognosis. Recent data from England and Wales demonstrates that inpatient mortality 
amongst patients with heart failure is 12 percent.(2) This is in comparison to data from the 
EuroHeart HF II Study, which represents 24 European countries, which shows an in hospital 
mortality rate of 6.6 percent and US data from the OPTIMISE HF registry which 
demonstrates a mortality rate of 4 percent of in-patients.(3, 4)  CRT has been proven, through 
randomised controlled clinical trials to be efficacious in the improvement of symptoms and 
mortality in selected populations with advanced heart failure.(5-7) Since the initial 
publications of large randomised controlled trials, the emphasis has shifted to investigating 
the role of CRT in less symptomatic disease.(8, 9) In certain individuals it may be beneficial, 
with some patients showing a marked improvement in symptoms allied with features of 
advantageous structural change e.g. left ventricular remodelling.  
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The effect of CRT however in other patients may be unpredictable with some failing to 
experience the anticipated clinical benefit. A better understanding of the post implantation 
period would yield the possibility of ensuring optimal device based care for patients with 
heart failure, which should translate into improved clinical outcomes, better quality of life and 
a reduction in costly hospitalisations. Healthcare professionals may be able to exploit the 
beneficial effects following CRT implantation by careful surveillance with renewed focus on 
electrical optimisation of the timing cycles within the device and review of the concurrent 
medication. These concepts will be discussed in more detail later in the introduction. For the 
purpose of this thesis ‘device therapy’ refers to both cardiac resynchronisation therapy and/or 
implantable cardioverting defibrillators.  
 
1.1 Definition of Heart Failure  
The current European Society of Cardiology guidelines define heart failure as ‘a syndrome in 
which patients have typical symptoms (e.g. breathlessness, ankle swelling and fatigue) and 
signs (e.g. elevated jugular venous pressure, pulmonary crackles and displaced apex beat) 
resulting from an abnormality of cardiac structure or function.(10) The definition places 
emphasis on the collection of symptoms in association with disorder of cardiac structure. 
Hence both national and international guidance stress the need for echocardiography in 
suspected cases of HF as the more readily available method for confirming and assessing the 
underlying cardiac disorder.(10, 11) 
 
1.2 Epidemiology 
The original prospective cohort studies from Framingham, Massachusetts, US and the "Men 
born in 1913", Gothenburg, Sweden demonstrated an increased incidence of HF with age.(12, 
13) More recently within the Hillingdon Heart Failure Study, in West London, using a 
rigorous definition of heart failure, the incidence was documented to rise significantly with 
age.(14) The incidence rose from 0.02 cases per 1000 in the age group 25-34 years of age to 
11.6 cases per 1000 in the >85 years category. The median age at presentation within this 
study was 76 years of age. (See Figure 1)   
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Figure 1: Incidence of Heart Failure categorised by age groups: Data and Figure from Hillingdon Heart 
Failure Study(14) 
Several further studies have documented that heart failure remains a condition which 
primarily affects the elderly. Contemporary national audit data of hospitalised patients reveals 
a current median age of presentation of 78 years of age within England and Wales.(2) It is 
estimated that in European healthcare economies HF management is responsible for up to 2% 
of all direct healthcare expenditure.(15) Within the United Kingdom this would currently be 
approximately £2 billion. A large proportion of this cost is due to expensive prolonged and 
repeated hospitalisation. Within the UK HF is responsible for a million in-patient bed days 
and accounts for 5% of all emergency admissions within the National Health Service (NHS).  
 
American data are suggestive of an increasing trend towards hospitalisation with HF 
hospitalisations trebling between 1979 and 2004.(16)  The configuration of European health 
services is different with significant variance between primary and secondary care. Recent 
Scottish and Dutch data suggests that the trend towards heart failure hospitalisation has 
reduced.(17, 18) The Scottish data are the most recent and indicates that HF hospitalisations 
reached a peak in the mid 1990s and have subsequently declined. (See Figure 2) 
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Figure 2: Age-adjusted trends in discharges for a first hospitalization for HF according to sex(17) 
 
Despite the national and international guidance, many patients remain sub optimally 
treated.(19) Hospital admission carries an increased risk of mortality, with the recent national 
data indicating a projected one year mortality of 26% for patients below the age of 75 and 
56% for those above the age of 75.(2)  
 
1.3 Diagnosis 
Heart failure is a syndrome characterised by a collection of symptoms which may include 
fatigue, breathlessness, reduction in exertional capability, decreased appetite and fluid 
retention. In certain patients, particularly the elderly, it may present more insidiously with 
cognitive decline, delirium, anorexia, cachexia, insomnia or malaise. Due to the variation in 
symptoms, the clinician needs to have a degree of suspicion to activate further appropriate 
investigations.  
 
Guidelines from NICE and the ESC suggest that patients with suspected heart failure should 
be evaluated by a physician with specialist expertise within the field.(10, 11)  Initially the 
patient should have a full history, physical examination, electrocardiogram, chest radiograph 
and natriuretic peptide measurements. (See Figure 3) Though this process may reveal 
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characteristics consistent with a possible diagnosis of heart failure, ultimately the patient 
should have cardiac imaging to produce detailed information on cardiac structure and 
function. The most commonly used imaging modality is transthoracic echocardiography. A 
clinical response to therapy is no longer part of the definition of heart failure; though a degree 
of improvement may help corroborate the diagnosis.  
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Figure 3: Diagnostic Algorithm from National Health and Clinical Excellence Guidelines for suspected 
heart failure (2010)(11) 
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1.4 Aetiology 
The most common causes for heart failure in the Western world remain ischaemic heart 
disease and hypertension. However there are numerous other conditions which may result in 
left ventricular systolic dysfunction, which are listed in table 1.1. 
 
Using cardiac imaging, patients may be divided into groups with LVSD (Left Ventricular 
Ejection Fraction (LVEF) <45%) and preserved left ventricular systolic function. Having 
confirmed the diagnosis of heart failure, the aetiology needs to be identified. Once this has 
been identified appropriate treatment needs to be focussed on the underlying cause and the 
concomitant ventricular impairment. Additionally the severity of heart failure should be 
assessed, the prognosis should be defined and relevant concomitant disease such as anaemia, 
diabetes mellitus and hypertension should be identified and managed.  
 
 
Causes of Left Ventricular Systolic Dysfunction 
Ischaemic Heart Disease 
Hypertension 
Cardiomyopathy (Inherited/Acquired): Hypertrophic, Dilated, Arrythmogenic 
Peri-partum cardiomyopathy; Tako-Tsubo Cardiomyopathy 
Right Ventricular; Restrictive 
Drugs: Chemotherapy; Alcohol 
Others: 
Endocrine; Diabetes Mellitus; Hyper/Hypothyroidism; Adrenal Insufficiency 
Phaeochromocytoma 
Nutritional: Selenine, Thiamine, Carnitine Deficiency 
Infiltrative: Sarcoidosis, Amyloidosis, Haematochromatosis 
Infective: Chagas Disease, Human Immunodeficiency Virus 
Table 1: Causes of Left Ventricular Systolic Dysfunction quoted from ESC Guidelines for 
Acute and Chronic Heart Failure (2012)(10) 
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1.5 Bedside & Laboratory Investigations 
Patients with suspected heart failure should have urinalysis performed. This is to detect 
proteinuria and glycosuria. The suggested laboratory investigations should include a full 
blood count, urea and electrolytes, thyroid function, liver function and lipid profile. If the 
patient is anaemic then full haematinics should be performed including complete iron studies, 
serum B12 and folate.  
 
1.5.1  Natriuretic Peptides 
The family of natriuretic peptides are important biomarkers of heart failure. The most widely 
investigated and evaluated is B type natriuretic peptide (BNP). Previous work has 
demonstrated that higher concentrations of circulating BNP are to be found in individuals 
with HF. Currently they are advocated within the national and international guidelines to be 
used as a diagnostic tool to aid the diagnosis of incident cases of heart failure.(10, 11) 
 
Natriuretic peptides are released in response to myocardial stress and raised levels underline 
the need for clinical assessment and cardiac imaging to identify the underlying cardiac 
dysfunction. Due to its release in response to myocyte stretch and volume overload, BNP has 
also been shown to have prognostic value. Others have investigated whether it should dictate 
levels of HF pharmacotherapy and be used to monitor the control of the HF syndrome, but 
thus far there is no consistent evidence within this area.(20, 21) 
 
1.5.2  Electrocardiogram 
This should be performed for every patient with suspected heart failure. A normal 
electrocardiogram (ECG) makes HF with LVSD unlikely. An abnormal ECG has relatively 
poor predictive value in heart failure, but suggests the need for further investigation. Many 
potential ECG abnormalities exist within patients with heart failure. Some, such as QRS 
duration carry prognostic value and also may identify potential candidates for device based 
therapy.(22) 
 
The current National Institute for Health and Clinical Excellence (NICE) guidelines state that, 
in a patient with a prior history of ischaemic heart disease, symptoms and abnormal ECG, 
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there is sufficient justification for further specialist assessment and that in such patients a 
measurement of plasma natriuretic peptides is not necessary as this will not change the pre-
test probability of disease.(11) 
 
1.5.3  Echocardiography 
Transthoracic echocardiography is the most widely available cardiac imaging modality. This 
is due to its portability, ease of access and safety in that it does not involve ionising radiation. 
It should be performed in those patients with suspected heart failure to delineate biventricular 
function and status of the valves and pericardium. Echocardiography may be used to 
determine whether the phenotype is one consistent with LVSD, or HF with preserved systolic 
function. (HFpEF) 
 
1.5.4  Further Imaging  
Further, more advanced cardiac imaging, may be necessary in patients with heart failure to 
accurately define and ascertain the underlying aetiology. An example is that coronary artery 
disease may mandate further investigation with radionuclide studies, cardiac magnetic 
resonance imaging and coronary angiography. Other supplemental investigations may be 
deemed necessary. These include pulmonary function tests, cardiopulmonary exercise testing 
and Holter monitoring. Other investigations may aid in formulating a diagnosis and/or help 
with risk stratification and prognostication.  
 
Cardiac magnetic resonance imaging (CMR) when available has become an important 
imaging modality to consider within patients with heart failure. It offers a technique which is 
highly reproducible in terms of bi ventricular volumes, function, myocardial mass, intra- 
cardiac pathology and pericardial disease.(23, 24) Further information may also be added by a 
CMR study with the concurrent administration of a gadolinium based contrast. Patterns of 
gadolinium enhancement and distribution may signify areas of infarction, infiltration or 
myocardial fibrosis. Current experience with gadolinium enhancement suggests that it is of 
clinical importance amongst the cardiomyopathy population and also patients with prior 
ischaemic heart disease.(25-27) 
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1.5.5  Heart failure with Preserved Ejection Fraction (HFpEF) 
The increasing use of echocardiography and CMR has demonstrated that a cohort of patients 
exist who possess signs and symptoms consistent with heart failure but who have normal or 
near normal left ventricular systolic function.  
 
Demographical data indicates a prevalence of 30-50% of this group of patients among 
populations with heart failure. The pathophysiology of heart failure in such patients is less 
understood, but higher rates of hypertension, atrial fibrillation and diabetes have been 
observed within the group.(28) 
 
The absolute mortality rate remains high in this group of patients with an observed mortality 
rate at five years of 68%.(29) A recent meta-analysis, which covered 41,972 patients 
demonstrates however that when such populations are compared to patients with LVSD, the 
mortality rate within the HFpEF population is lower.(30) The meta-analysis included 10,347 
patients with HFpEF versus 31,625 with LVSD. Those with preserved ejection fraction were 
more likely to be older, female and have a history of hypertension. There were 121 [95% 
confidence interval (CI): 117, 126] deaths per 1000 patient-years in those with HF-PEF and 141 (95 
percent CI: 138, 144) deaths per 1000 patient-years in those with HF-REF. HF-PEF had lower 
mortality than those with HF-REF (adjusted for age, gender, aetiology, and history of 
hypertension, diabetes, and atrial fibrillation); hazard ratio 0.68 (95 percent CI: 0.64, 0.71). 
Unfortunately the success of neurohormonal antagonists for patients with reduced ejection 
fraction has not been replicated for this group.(31-33) Further studies exploring therapeutic 
options are ongoing in this field.(10) 
 
The literature has included only patients with LVSD within studies of device therapy. Hence 
there are no recommendations for device therapy within such populations, though studies are 
ongoing within this subgroup. Within this thesis no patient with HFpEF was studied. 
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1.6 Pathophysiology of Heart failure  
 
The cardiovascular system is responsible for supplying oxygen via the circulation at both rest 
and exercise. It therefore has to be physiologically adaptive and this response may become 
blunted in most types of cardiovascular disease.  
 
Heart failure is a complex clinical and pathophysiological syndrome characterised by cardiac 
dysfunction with subsequent systemic disruption.(34) The pathophysiology may be 
considered on a macroscopic, cellular and sub cellular level, including the effect on signalling 
pathways and protein expression.  
 
Though clinically recognised for a number of years much is still unknown at cellular and 
subcellular levels in terms of mechanisms of dysfunction. Macroscopically, the clinical signs 
and symptoms of heart failure have long been associated with clear overt changes 
demonstrated with modern cardiac imaging techniques.  The field is under intensive 
investigation, with the knowledge that once mechanisms have been reliably documented, they 
become a target for the design of future therapies. 
 
1.6.1  Macroscopic changes in heart failure 
The hallmark of late stage heart failure is a marked dilatation of the atria and ventricles. (See 
Figure 4: Demonstrates the diagramatic progression of macroscopic left ventricular 
dysfunction(34)) This phenomenon has been observed previously, with it being the end stage 
of multiple aetiologies. The atria and ventricles may alter dimensions and shape in response to 
acute insults e.g. myocardial infarction and chronic conditions e.g. valvular heart disease.  
 
The changes may be induced by changes in haemodynamic load and increased wall stress.(35) 
The end stage of this process macroscopically is a dilated spherical shape with enlarged 
cardiac dimensions. The dilated globular left ventricle is associated with severely impaired 
systolic and diastolic function, a reduced cardiac output at both rest and on exercise and 
progressive annular dilatation resulting in marked atrioventricular valve regurgitation. It may 
co-exist with activation disturbance such as left bundle branch block. Acute myocardial 
insults may result in localised disruption which leads to regional territories of macroscopic 
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dysfunction, which in the longer term may become permanent due to myocardial scar or 
fibrosis.  
 
Modern cardiac imaging techniques include echocardiography, cardiac magnetic resonance 
imaging, computed tomography and radionuclide imaging. With these methods, it is possible 
to record such changes in patients with heart failure and the progression of such change. The 
response to treatment can also be easily followed up with such imaging techniques. Regional 
macroscopic myocardial dysfunction can be easily demonstrated acutely with such 
techniques.  
 
An alternative phenomenon is the myocardial response to increased intra-cardiac pressure. 
Pressure overload chronically will induce concentric left ventricular hypertrophy. Initially 
systolic function will be preserved, with visible abnormalities of relaxation and diastole. As 
the myopathic disease progresses, systolic function may become impaired with progressive 
dilatation and thinning of the ventricular walls. The ultimate phenomenon is similar to that 
described above with the ‘dilated cardiomyopathy’ phenotype.  
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Figure 4: Demonstrates the diagramatic progression of macroscopic left ventricular 
dysfunction(34) 
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Figure 5: Molecular signalling pathways targeted by novel approaches to reverse remodel the heart. 
Abbreviations:AC adenylate cyclase;βARK2,β-adrenergic receptor kinase;CaM, Calmodulin;CaMKII, 
calcium/Calmodulin-dependent protein kinase II;CC, calcium channel; CN, calcineurin; DAG, diacyl 
glycerol;GPCR, G protein coupled receptor; HDAC, histone deacteylase;MMP, matrix 
metalloproteinase;NFAT, nuclear factor of activated T cells; NOS, phosphodiesterase-5; PKA, protein 
kinase A; PKC, Protein Kinase C; PLN, phospholamban;rGc, receptor guanlyate cyclase;RyR2, 
ryanodine receptor 2;SERCA2a, sarcoplasmic/endoplasmic reticulum calciumATPase 2 isofrom2;SR, 
sarcoplasmic reticulum(35) 
 
 
1.6.2 Cardiomyocyte 
Initially cardiomyocytes were thought to be terminally differentiated cell lines which were 
unable to undergo further cellular division. There is now increasing evidence that this may not 
be correct and some myocytes do undergo cell division but it is uncommon.(36) Published 
data corroborates this statement, with the observation that some precursor cells do occur in 
the myocardium. It remains unknown whether this represents a population of cells which are 
present from birth onwards or are derived from a circulating pool of stem cells which become 
myocytes following appropriate stimulation.  
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The potential therapeutic option of stem cells and cellular regeneration has been investigated 
previously.  A recent meta-analysis, published in 2012 has reviewed the literature with 
regards to stem cells and their role in myocardial regeneration following myocardial 
infarction.(36) Having reviewed thirty-three randomised controlled trials and analysed data 
from 1765 patients, stem cells seemed to have some effect on left ventricular reverse 
remodelling, which was sustained into the longer term. However the authors noted a high 
degree of heterogeneity among the included studies which made direct comparison of the data 
difficult.  
 
Cardiomyocytes may undergo structural change in either their longitudinal or transverse 
diameters. The change in appearance is related to the exposure of the myocyte to stimuli. 
Longitudinal change is more often observed in dilated cardiomyopathy. Altered gene 
expression affects both the cellular cytoskeleton and the contractile proteins. However the 
lengthening of the myocyte alone cannot explain the macroscopic change in ventricular 
dimensions and cavity size. There may be insertion of the myocytes between muscle fibres 
which are normally tightly apposed.  
 
Cardiomyocyte hypertrophy is observed in conditions with chronic pressure overload such as 
hypertension or aortic stenosis. There is minimal longitudinal change in the myocyte with 
compensatory cellular hypertrophy observed. Sub nuclear changes may be observed, with 
alterations in the intracellular signalling pathways and transcription factors.  
Gap junctions are the link between the individual myocytes and represent a series of 
transmembrane channels which permit electrical communication and cross talk. The 
constituent proteins of a gap junction are connexins. Anomalies of connexins have been 
observed in patients with heart failure.(37) Connexin-43 is the principal connexin in healthy 
human hearts, but its expression in patients with heart failure has been found to be down 
regulated. This may then underpin the electrical disarray with potential tendencies to generate 
arrhythmias.  
 
Apoptosis is the process of programmed cellular death. This is part of normal physiology and 
is reliant on intracellular signalling pathways. The main signalling pathway for apoptosis is 
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the caspase pathway.(38) This leads to the eventual fragmentation of nuclear and cytoplasmic 
contents. Cardiac necrosis however is normally induced by a severe insult e.g. acute 
myocardial infarction in which there is no time for compensatory hypertrophy to take place. 
Chronically cells may undergo necrosis from an ongoing process of increased oxidative 
stress, the rupture of such myocytes leads to a spontaneous release of intracellular contents 
which induces a pro-inflammatory reaction which eventually leads to myocardial fibrosis.  
 
1.6.3 Myocardial Fibrosis  
The use of modern cardiac imaging techniques has led to the in vivo demonstration of 
myocardial scar/fibrosis in situ in living patients. This is especially true for cardiac magnetic 
resonance imaging with concurrent gadolinium contrast. The delayed enhancement of 
segments of myocardium leads to ‘late gadolinium enhancement (LGE)’ which is a 
macroscopically visible marker of cardiac fibrosis or scar. Certain pathological patterns of 
LGE have been associated with different aetiologies of heart failure. The LGE represents a 
reduction in washout of the gadolinium contrast from within the extracellular matrix.  
 
The presence of myocardial fibrosis requires increased numbers of fibroblasts which undergo 
transformation to myofibroblasts with release of signaling molecules, cytokines and enzymes. 
Excessive collagen deposition eventually leads to diastolic interference with eventual impact 
on cardiac systole.  
 
The extracellular matrix is regulated by a constant balance between matrix metalloproteinases 
(MMPs) and tissue inhibitors of matrix metalloproteinases. (TIMPs) MMPs represent a 
family of proteolytic enzymes which degrade extracellular matrix proteins. There is normally 
a balance between different  isoforms of MMPs, with a major MMP being MMP-13. Within 
healthy hearts, there is limited expression of such isoforms, however in diseased hearts; levels 
have been noted to be unregulated. Conversely MMPs found in the normal heart are 
downregulated. The imbalance in MMP expression leads to extracellular matrix degradation 
which in turn leads to increased rates of myocardial fibrosis. Some potential stimulants of 
collagen synthesis and turnover are cytokines, oxidative stress, angiotensin II and aldosterone.  
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1.6.4  Depolarisation of the myocytes and electro-mechanical coupling 
The coupling process of electromechanics in relation to the myocytes is dependent on the 
movement of intracellular calcium. It is recognised that action potentials are prolonged in 
heart failure.(39) 
 
The depolarisation of a myocyte may be viewed in several stages. Initial depolarisation leads 
to the entry of extracellular calcium through the L type voltage dependent channels (See 
Figure 5). Further calcium is then released from intracellular stores, predominately from the 
sarcoplasmic reticulum (SR). The initial influx of calcium acts as a signal on the surface of 
the SR via the cardiac ryanodine receptor (RyR-isoform 2). These receptors are adjacent to 
DHPR channels in the sarcolemma membrane. The influx of calcium ultimately causes a 
synchronised release of calcium - a calcium ‘spark’. The wave of calcium release induces 
depolarisation and contraction. Diastole represents the reverse of this process with a rapid 
uptake of the intracellular calcium into the SR via the Ca2+/ATPase (SERCA) or by its 
removal from the cell via the surface membrane Na+/Ca2+ exchanger.  
 
Beta adrenoceptors mediate intracellular signalling pathways which govern parts of the 
process described above via phosphorylation. Specific steps of the pathway may become 
hyperphosphorylated e.g. RyR2(40) The overall effect is a reduction in intracellular calcium 
stores particularly from the SR. SERCA has also been observed to be downregulated with a 
lack of removal of calcium and hence a prolonged diastolic component of the cardiac cycle.  
 
There may also be structural change in the t-tubule, ryanodine receptor and DHPR channels. 
The t tubular system runs from deep within the cell and brings the SR membrane into close 
contact with the other components of intracellular coupling. Hence a loss of the t tubule 
network in heart failure may impair efficient electromechanical coupling.  
 
1.6.5  Myocardial Energy Metabolism  
Normal physiology relies on the delivery of oxygen and energy substrate to the cell for the 
production of adenosine-triphosphate (ATP) via aerobic respiration. The majority of normal 
energy metabolism is derived from β phosphorylation of fatty acids, with a significant 
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minority being derived from the glycolysis pathway. An alternative pathway is the 
phosphocreatine/creatine pathway which supplies a high energy phosphate energy store from 
the mitochondria to the myofibril myosin ATPase.  
 
Under abnormal conditions including ischaemia, metabolism switches to the glycolysis 
pathway with the change in energy substrate leading to the production of lactic acidosis. 
Within models of heart failure, abnormalities of myocardial metabolism have been noted. Left 
bundle branch block itself is associated with an imbalance in myocardial metabolism which 
may be corrected by the implantation of CRT.(41) This offers one potential mechanism for 
the beneficial effects of CRT.  
 
Free radicals, including the superoxide anion and hydroxyl radical, are transiently generated 
during normal myocardial metabolism. In health, free-radical scavengers (super-oxide 
dismutase and catalase) remove these molecules prior to any damage occurring. Within heart 
failure, there is both an increase in free radical generation and also a down regulation of the 
scavenger system, the overall impact is an increase in oxidative stress.(42) The term defines 
the damage to intra-cardiac structure mediated by the free radicals.  
 
1.6.6 Contractile Protein Dysfunction 
Abnormalities of sarcomeric protein expression have been found in patients with heart failure. 
Hereditary cardiomyopathies such as hypertrophic cardiomyopathy have been linked with 
anomalies of the beta-myosin heavy chain.  
 
An imbalance between alpha and beta myosin chains has been noted with an upregulation of 
beta myosin proteins with an accompanying downregulation in alpha proteins. The imbalance 
in levels of expression results in dysfunctional myosin expression which ultimately reduces 
myosin-ATPase activity and leads to systolic impairment.(43) A precursor phase of myosin 
abnormal expression exists prior to the overt manifestation of systolic impairment.  
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1.6.7  Systemic Manifestations of Heart Failure 
Though molecular and cellular pathways are now being intensively researched and targetted 
for potential therapies, it has long been recognised that heart failure represents a complex 
syndrome of cardiac and systemic dysfunction. The pathways of systemic dysfunction have 
been better characterised, and the selective inhibition of such pathways now forms the 
cornerstone of current heart failure pharmacological management.  
 
1.6.8  Sympathetic Nervous System 
The sympathetic nervous system forms half of the autonomic system and hence plays critical 
roles in the maintenance of homeostasis. Hence an acute deterioration or insult to the 
cardiovascular system results in increased sympathetic tone mediated by an increased release 
in adrenaline and noradrenaline. These hormones then, via direct and indirect effects, mediate 
an increase in cardiac output. The effect on the myocardium is mediated by catecholamine 
responsive intracellular signalling pathways that promote increased myocardial excitation 
coupling and an increased contractile response. The release of such hormones is governed by 
central and peripheral baroceptors which regulate blood volume, pressure and cardiac output.  
 
Initially this response promotes a beneficial effect on the myocardium, vasculature and renal 
system. However, continual stimulation leads to a maximal effect on the signalling pathways 
and a down regulation of the adrenoceptors.  The continuous release of catecholamines leads 
to a tachyphylaxis like phenomenon.  
 
The effects on intracellular signalling pathways are an upregulation of the beta-adrenergic 
receptor kinase-1 (β-ARK-1), upregulatory expression of inhibitory G proteins and increased 
turnover of cyclic AMP. All of which result in interrupted intracellular signalling and a 
decreased efficacy of β receptors.  
 
1.6.9  Renin-Angiotensin-Aldosterone-System 
Activation of the renin-angiotensin-aldosterone system is mediated by catecholamine release 
and subsequent effects on the juxtaglomerular apparatus. The release is stimulated by reduced 
circulatory volume and is an intrinsic response to hypovolaemia. The physiological effect of 
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stimulation of the RAAS pathway is sodium and water retention and maintenance of 
ventricular filling pressures. In health a negative feedback cycle exists which permits the 
termination of such hormone production.  
 
Within heart failure, the regulatory cycles become disturbed and lead to a continual 
expression of renin. Ultimately the pro-hormone is cleaved to form angiotensin II and 
aldosterone. These potent steroid based hormones have deleterious effects on vasculature, 
renal tract and myocardium. The expression of aldosterone promotes abnormalities of 
collagen synthesis and turnover which ultimately leads to myocardial fibrosis. Angiotensin II 
is a potent vasoconstrictor and hence potentiates an already abnormal cardiovascular disease 
state.  
 
Aldosterone also leads to the recruitment of pro-inflammatory mediators and increased levels 
of NADPH oxidase which leads to increased oxidative stress. The overall environment 
created by the release of angiotensin II and aldosterone is pro fibrotic.(44) Clinical trials using 
aldosterone antagonists in patients with LVSD have demonstrated significant effects upon 
cardiovascular mortality and morbidity. The randomised trials will be discussed in more detail 
in section 1.7.5. A potential mechanism which may explain the beneficial effects of 
aldosterone antagonists are their effects on myocardial and systemic fibrosis.  
 
1.6.10  Endothelium in Heart Failure 
The endothelium in arteries and larger arterioles is a constant local source of regulation of 
peripheral vascular resistance. The release of endothelium derived nitric oxide promotes 
vasodilatation via smooth muscle relaxation and the peptide, endothelin counter balances this 
with effects of vasoconstriction.  
 
Hence in health there is a continual balance between the two. However, in heart failure there 
is down regulation of nitric oxide expression with a corresponding increase in endothelin 
release. This has been demonstrated to induce myocardial fibrosis. The available amount of 
nitric oxide is further diminished by the scavenged reactive oxygen species.   
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1.6.11  Overview 
The clinical syndrome of heart failure comprises a collection of cellular, molecular and 
macroscopic dysfunction. Macroscopic changes are easily charted with current imaging 
techniques and progression of such changes can be tracked. The molecular side of the field is 
less well characterised. It represents a complex network of pathways, protein expression and 
receptors which, though they have been investigated, have yielded little in terms of 
therapeutics. It remains to be seen whether selective targeting of such cellular and sub cellular 
pathological dysfunction results in meaningful clinically relevant treatments for patients with 
heart failure.  
 
1.7 Management of Heart Failure 
 
Contemporary management of heart failure is based on a cohesive multi-disciplinary 
approach to patient centred care utilising amendments in lifestyle factors, pharmacological 
evidence based therapies, appropriate device based therapies, cardiac and surgical 
intervention where appropriate, cardiac transplantation and mechanical assist devices and 
palliative care. NICE has produced guidance within the area since 2003, with an updated set 
of guidelines issued in 2010.(11, 45)  
 
These are similar to the ESC guidelines which were most recently revised and published in 
2012 (See Figure 6), having been previously issued in 2005.(10, 46, 47) American guidelines 
were most recently released in 2010 by the Heart Failure Society of America (HFSA).(48) 
 
1.7.1  Lifestyle Management 
Patients with heart failure should be educated in terms of their disease and its practical daily 
management. This includes attention to fluid and salt consumption, daily and weekly alcohol 
intake, smoking status and participation in aerobic exercise. Alcohol excess may also promote 
fluid retention; in cases where it is deemed to be the cause of ventricular dysfunction  
complete abstinence is the recommendation. For patients, particularly those with ischaemic 
heart disease, smoking status should be reviewed and patients offered assistance for smoking 
cessation.  
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Figure 6: Figure demonstrating the treatment algorithm as per ESC guidelines-2012.(10) Angiotensin 
Converting Enzyme; ARB = Angiotensin Receptor Blocker; CRT-D = Cardiac Resynchronisation 
Therapy Defibrillator; CRT = Cardiac Resynchronisation Therapy; H-ISDN = Hydralazine and 
Isosorbide dinitrate; HR = Heart rate; ICD= Implantable Cardioverter Defibrillator; LBBB = Left 
Bundle Branch Block; LVAD = Left Ventricular Assist Device; LVEF = Left Ventricular Ejection 
fraction; MRA = Mineralocorticoid Receptor Antagonist; NYHA = New York Heart Association  
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1.7.2   ACEI 
The initial neurohormonal antagonists which were used in LVSD were ACEI.(49, 50) They 
are effective at improving heart failure morbidity and mortality. They should be started at low 
doses and cautiously uptitrated to the recommended target dose as used in the randomised 
controlled trials. During the adjustment period, one should monitor patient’s symptoms 
(including cough), blood pressure and renal function. Though the recommendation is for 
patients to achieve target dose, a lower dose of ACE inhibitor is still effective and some 
patients may not reach target dose. The maximal tolerated dose is described as the ‘optimal’ 
dose providing uptitration has been trialled.  
 
1.7.3  ARB 
Angiotensin II receptor blockers are now used as an alternative therapy for patients intolerant 
of ACEI. The largest trial to date which demonstrates efficacy of such agents was the 
CHARM- Alternate study, which demonstrated that candesartan in this patient population 
improved morbidity and mortality compared to placebo (and for patients intolerant of 
ACEI)(51) Similar caveats exist with regards to uptitration of dosage. The side effect profile 
of ARBs is similar to ACEI except for the occurrence of cough which is rare in patients on 
ARBs.  
 
1.7.4  ß- Adrenoceptor Antagonists ‘Beta Blockers’  
Originally reservations existed regarding the use of BB for patients with heart failure due to 
the short term negative inotropic effects of BB. However, several large randomised controlled 
trials have shown an improvement in both morbidity and mortality with such agents.(52-54) 
However it should be noted that this effect is not a class wide effect and hence the 
recommendations are only to utilise beta adrenoceptor antagonists which are proven for heart 
failure.(10)  Within the UK this includes carvedilol, bisoprolol and nebivolol. They should be 
initiated at a low dose when the patient is in a clinically euvolaemic state and should be 
carefully uptitrated with a view to achieving target dose.(11) 
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1.7.5  Mineralocorticoid Antagonists 
In current UK practice, this class of drug includes spironolactone and eplerenone. The 
landmark trial in the area was RALES published in 1999, which demonstrated efficacy of 
spironolactone in patients with severe symptomatic heart failure due to LVSD.(55) This 
provoked an initial over prescription of spironolactone with resultant increased rates of 
hyperkalaemia and acute kidney injury.(56) This is due to the direct effects on the androgenic 
receptor and other remote actions which lead it to have some pro-oestrogenic properties.  
 
Eplerenone is a more refined molecule which was initially trialled in the EPHESUS 
study.(57)  This was a population with post myocardial infarct heart failure. Having 
demonstrated efficacy at reducing mortality and morbidity, EMPHASIS-HF then investigated 
the use of eplerenone in patients with less symptomatic disease.(58) This reported a reduction 
in cardiovascular hospitalisation and mortality with eplerenone in patients with much milder 
symptoms (NYHA II) and who were already on optimal ACEI and BB therapy.  
 
Ultimately a patient should be considered for aldosterone antagonism after having been 
established on other neuro-hormonal antagonists detailed above firstly. Caution should be 
exercised with regards to initiation of such drugs in patients with poor renal function. Careful 
monitoring is necessary to ensure hyperkalaemia is detected and managed appropriately.  
 
1.7.6  Ivabradine 
With the increasing uptake of beta blocker therapy, there were certain patients with left 
ventricular systolic dysfunction who could not tolerate such agents. Ivabradine is a novel If 
channel inhibitor. If channels being predominately located within the sino-atrial node. After 
experimental studies confirmed that ivabradine mediated a heart rate reduction, it was studied 
in two large in vivo studies. BEAUTIFUL was designed to assess its capabilities within 
patients with ischaemic heart disease.(59) Its effect was most marked in patients with heart 
rates >70 beats per minute (bpm). To evaluate this relationship further it was investigated in 
SHIFT.(60) Using 6,505 participants, ivabradine significantly reduced the composite endpoint 
of HF hospitalisation and cardiovascular death. The findings were strongest in those patients 
with a heart rate which was higher at rest. These findings have been incorporated into the 
latest guidance issued by NICE and the ESC.(10, 11)  The recommendation is that ivabradine 
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should be considered as an agent for those patients with heart failure due to LVSD who 
remain symptomatic despite ACEI, BB and MRA, with a heart rate >70 bpm in sinus rhythm 
and on maximally tolerated BB.  
 
1.7.7  Digoxin 
Digoxin has been widely used for more than two hundred years as a treatment for ‘dropsy’ - 
heart failure. The only major randomised controlled trial to date suggests that it did not reduce 
overall mortality but did improve rates of cardiovascular hospitalisation (in patient with sinus 
rhythm). Currently it is recommended as adjunctive therapy beyond the standard 
neurohormonal pathway.(10) It is also indicated in patients with concomitant atrial fibrillation 
and systolic dysfunction due to its potential control of the ventricular response to atrial 
fibrillation.  
 
1.7.8  Diuretics 
Currently two classes of diuretics are used in the modern treatment of heart failure. Loop and 
thiazide diuretics exert their effects on different parts of the nephron. They promote excretion 
of sodium and water and relieve fluid retention and hence consequently may reduce 
ventricular filling pressures. However, they may also induce neurohormonal activation. There 
is no evidence with regards to either group of medication on mortality benefit within patients 
with heart failure.(61) 
 
1.7.9  Hydralazine and Isosorbide Dinitrate 
The awareness that differences existed in RAAS pharmacokinetics and pathophysiology 
within African –Americans led to the consideration of alternative therapies. Another 
mechanism of inducing systemic vasodilatation was to use therapies which exploited the 
endothelial nitric oxide pathway. The combination of hydralazine and Isosorbide Dinitrate 
(ISDN) were studied in A-HeFT and V-HeFT studies and were found to be efficacious at 
reducing mortality and morbidity particularly in those patients of African-American 
origin.(62, 63) The initial study which was performed was the Vasodilator Therapy on 
Mortality in Chronic Congestive Heart Failure (V-HeFT) which evaluated the effects of the 
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combination of isosorbide dinitrate and hydralazine. Using a cohort of 642 patients, the group 
was randomised to either placebo, prazosin 20 mg once daily, or a combination of hydralazine 
(300mg once daily) and isosorbide dinitrate (160mg per day). The risk reduction in patients at 
two years was 34 percent for those randomised to the combination of vasodilators as 
compared to the other groups. (P<0.028) On non specified sub group analysis it was noted 
that the African American population within this study had an increased longevity. Hence a 
dedicated study was created. The A-HeFT (Combination of Isosorbide Dinitrate and 
Hydralazine in Blacks with Heart Failure) was tasked to investigate the effect of the 
combination therapy in an African American population. Using a group of 1050 patients, who 
were randomised to either the combination or placebo in addition to conventional medical 
therapy, it was noted that there was a significant mortality benefit between the two arms. 
(P=0.02) (62) 
 
1.7.10  Cardiac Surgery and Percutaneous Valve Techniques 
Cardiac transplantation is a therapeutic option for patients with advanced symptomatic 
disease who fulfil prespecified criteria. The rate of cardiac transplantation is diminishing, due 
to poor organ availability.(64) Mechanical assist devices have gradually improved in 
technological capability and reliability and are increasingly being implanted worldwide. 
Within the UK, currently such devices can only be considered for patients who ultimately 
have potential to enter the active cardiac transplantation list i.e. ‘bridge to transplant’  
 
Valvular disease is an aetiology of HF which is increasingly common amongst elderly 
patients. Traditional surgery remains a viable option for certain patients, but more novel 
approaches now exist. For aortic valvular disease, there is now the option of transcutaneous 
aortic implants (TAVI) and for functional mitral regurgitation, a percutaneous clip device 
may be considered.(65, 66)  
 
The indications for revascularisation and HF remain controversial. The fundamental principle 
is that revascularisation may aid the recovery of ‘hibernating’ myocardium. Hibernation is 
where the myocardium is alive but not contracting. It may be demonstrated by a variety of 
cardiac imaging modalities including radionuclide imaging, cardiac magnetic resonance 
imaging and stress echocardiography. The recent STICH randomised controlled trial did not 
demonstrate a clear improvement in patients with ischaemic heart disease and reduced left 
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ventricular systolic function who were randomised to bypass grafting versus medical 
therapy.(67) 
 
1.7.11  Disease Monitoring 
The traditional hospital based model of heart failure care is gradually changing. Due to 
increasing prevalence and the high rates of co- morbidities amongst elderly patients- it is 
recognised that there is a need to amend current care pathways.  
 
Due to the complexity of patients with heart failure, multidisciplinary care is essential. A 
dedicated specialised nurse service has been shown to reduce hospitalisation and 
mortality.(68, 69) A suggested model of multidisciplinary care should include specialist 
physicians, general practitioners, nurses, palliative care input and other relevant members e.g. 
geriatricians or social workers.  
 
Careful dedicated follow up should detect adverse symptoms e.g. a reduction in exercise 
tolerance or signs e.g. increasing peripheral oedema. Natriuretic peptides may also be used to 
monitor progress.  
 
Remote telemonitoring has also been shown to have a role in the care of these patients. 
Several challenges exist to optimal care including, frail elderly patients with physical 
limitations, geographical distance from the secondary care institution and brittle unstable 
disease. Telemonitoring may aid in their care, by the transmission of physiological variables 
including weight, blood pressure and heart rate to a monitoring centre. This may reduce the 
need for physical consultations. A number of systems are commercially available and the 
initial work within the area is promising.(70, 71) Further studies are ongoing as to how best to 
deploy the current technology, the optimal method of harnessing transmitted information and 
to characterise which variables should be collected and transmitted. Nevertheless remote 
monitoring offers a sophisticated method of patient follow up.  
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1.8 Device Based Therapies 
 
For the purpose of this thesis ‘device based therapies’ refers to CRT and/or ICD therapy. 
Patients with heart failure are at increased risk of sudden cardiac death as compared to the 
general population. A proportion of these deaths are attributable to arrhythmia.  
 
The rates of sudden cardiac death (SCD) have been reduced by pharmacotherapy yet many 
patients still suffer this as a mode of death. Hence device therapy has become an important 
part of HF management in addition to the optimal tolerated evidence based medical therapy.  
 
1.8.1 Implantable Cardioverting Defibrillators 
Implantable cardioverting defibrillators (ICD) are implanted to counteract life threatening 
ventricular arrhythmias by a combination of internal DC cardioversion or anti-tachycardia 
pacing. Dual chamber ICDs may also provide univentricular back up pacing. A potential ICD 
implant may be a dual chamber system with right atrial and right ventricular leads or a 
biventricular with an additional left ventricular lead system. Randomised studies have 
demonstrated the efficacy of ICDs in a range of populations and they are now an established 
therapy for patients with HF. (72-74) 
  
The concept of an implantable cardioverting defibrillator was first reported in the late 1960’s 
and pioneering work by a group in Sinai Hospital, Baltimore translated the concept into 
clinical technology with the first case report occurring in 1980, the successful implantation of 
a functioning ICD at John Hopkins Hospital, Baltimore.(75) During this period of time a rival 
group from the University of Missouri was also working on such technology(76) The 
realisation that ventricular arrhythmias could be successfully cardioverted with external 
defibrillators and pads had led the drive towards the development of ICDs.  
 
Throughout the 1980s and 1990s ICD technology was continuously refined so that battery life 
became more prolonged, leads became robust and less prone to displacement or fracture and 
size of generator box was reduced, and by the 1990s there was a sufficiently technologically 
competent device to permit phase III randomised clinical trials to take place.  
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In terms of ICD therapy, the scientific community was interested in primary prevention (i.e. 
those with history of non-sustained ventricular arrhythmias with other risk factors for sudden 
cardiac death) and secondary prevention (i.e. prior history of ventricular arrhythmia mediated 
cardiac arrest or significant ventricular arrhythmias inducing haemodynamic compromise.)  
 
Hence initial studies focused on either of these two aspects with numerous studies being 
published in the late 1990s. For secondary prevention the cumulative evidence from the 
studies performed in the late 1990s was strongly suggestive that ICD therapy should be 
considered in such survivors.(77, 78) However the different inclusion criteria amongst the 
individuals recruited to the primary prevention trials meant this aspect of ICD therapy was 
less clear.  
The landmark study in the area for those patients with left ventricular systolic dysfunction and 
prior history of ischaemic disease (myocardial infarction) was MADIT II (Multicentre 
Automatic Defibrillator Implantation Trial II) published in 2002.(74) 
This North American trial randomised patients who had suffered myocardial infarction with 
sustained areas of myocardial scar and a residual LVEF of <30 percent. Crucially whereas 
previous primary prevention trials had included cumbersome, expensive and potentially 
dangerous electrophysiology studies, MADIT II did not require such information as part of its 
inclusion criteria. 
 
1232 patients were recruited and randomised in a 3:2 manner to either ICD therapy or 
conventional medical therapy. The primary endpoint was all cause mortality. Following a 
mean period of 20 months (range 6 days to 53 months) ICD therapy significantly reduced 
deaths HR= 0.69 (95 percent confidence interval, 0.51 to 0.93; P=0.016). The findings from 
this study were unquestionably significant but alarmed health economists as the inclusion 
criteria primarily hinged on prior history of myocardial infarction and reduced left ventricular 
ejection fraction. This meant large numbers of patients on this basis could be considered for 
ICD therapy which even by the turn of the century remained relatively expensive. However 
nonetheless the trial had demonstrated ICD therapy was potentially a therapeutic option in 
such individuals.  
 
The studies performed in patients with non ischaemic dilated cardiomyopathy were less 
uniform in their findings. The CAT (The Cardiomyopathy Trial) was one of the first within 
the area and focused on patients with dilated cardiomyopathy and reduced LVEF <30 
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percent.(79) The CAT study was also published in 2002 and took a cohort with recent onset 
dilated cardiomyopathy (<9 months) and unobstructed coronary artery disease (deemed by 
coronary angiogram) and in NYHA II/III heart failure. The trial recruited solely in Germany 
and the recruitment period ran from May 1991 until November 1997. The primary end point 
was all cause mortality at one year. Considering the recruitment period only a 104 patients 
were enrolled into the study and were randomised in a 1:1 manner to ICD therapy or 
conventional medical therapy. The effect of ICD therapy on all-cause mortality was non-
significant both at one year and in longer term follow up. The overall survival of the cohort 
was much greater than that originally predicted and hence the trial was clearly underpowered 
to detect differences. The findings hinted that ICD therapy may not be appropriate for patients 
with dilated cardiomyopathy but further larger studies were needed.  
 
The study which resolved the debate was the SCD-HeFT study published in 2005.(73) The 
SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) was deliberately conceived to 
answer the role of ICD therapy in all groups with symptomatic heart failure as compared to 
amiodarone and conventional medical therapy. From September 1997 until July 2001, a total 
of 2521 patients were randomised to medical therapy + placebo, medical therapy + 
amiodarone or medical therapy + single lead ICD. Inclusion criteria were a LVEF <35 percent 
and NYHA class II/III heart failure. ICD therapy was deliberately chosen to be single lead 
shock only with no dual or biventricular devices allowed to be implanted. The primary 
endpoint was all cause mortality. A total of 666 patients died: 244 (29 percent) in the placebo 
group, 240 (28 percent) in the amiodarone group and 182 (22 percent) in the ICD group. As 
compared with placebo, amiodarone therapy was associated with a similar risk of death 
(hazard ratio, 1.06; 97.5 percent confidence interval, 0.86 to 1.30; P = 0.53) and ICD therapy 
was associated with a decreased risk of death (hazard ratio, 0.77; 97.5 per- cent confidence 
interval, 0.62 to 0.96; P = 0.007). Hence a conservatively programmed ICD with shock only 
capacity had been shown to improve outcomes in heart failure populations. The authors 
stressed that these results should not be extrapolated to dual chamber or biventricular ICDs.  
 
The question then arose whether CRT-D would be superior to conventional ICD therapy in 
heart failure populations with the CRT component being helpful against left ventricular 
disease progression and the ICD being protective from ventricular arrhythmias. Two large 
trials have reported on this question.  
 
 51 
 
The first was MADIT-CRT, published in 2009, from the MADIT group and the same steering 
committee from the earlier MADIT studies.(80) A total of 1820 patients was recruited into the 
study providing they had NYHA I/II (underlying ischaemic aetiology) or NYHA II (dilated 
cardiomyopathy), sinus rhythm, LVEF <30 percent and prolonged QRS duration >130ms. 
Participants were then randomised to ICD implantation (mixture of single and dual chamber) 
or CRT-D (biventricular ICD). The primary endpoint was a composite of all-cause mortality 
and a heart failure event. The primary end point occurred in 372 patients: 187 of 1089 patients 
in the CRT–ICD group (17.2 percent) and 185 of 731 patients in the ICD-only group (25.3 
percent). These end-point events included 36 deaths (3.3 percent) and 151 heart-failure events 
(13.9 percent) in the CRT–ICD group and 18 deaths (2.5 percent) and 167 heart-failure events 
(22.8 percent) in the ICD-only group. (P=0.001) Hence the effect of CRT-D was superior to 
ICD but the effect was predominately driven by a 41 per cent reduction in heart failure events. 
The effect was most marked in a prespecified sub group analysis of those patients with a QRS 
duration >150ms. 
 
The RAFT study was the last study to report in the area and reported in 2010.(9) RAFT 
(Resynchronisation-Defibrillation for Ambulatory Heart Failure Trial) was an alternative 
study. It recruited from predominately Canadian centres but also included centres in Australia 
and Turkey. Patients were randomised to CRT-D or ICD in addition to conventional medical 
therapy. The inclusion criteria were NYHA class II/III, A LVEF <30 percent, intrinsic QRS 
duration >120ms and a paced QRS duration >200ms. The primary endpoint was all cause 
mortality and hospitalisation for heart failure. 
 
A total of 1798 patients were recruited and followed up for a mean of 40 months +/- 20 
months. The primary outcome occurred in 297 of 894 patients (33.2 percent) in the ICD–CRT 
group and 364 of 904 patients (40.3 percent) in the ICD group (hazard ratio in the ICD–CRT 
group, 0.75; 95 percent confidence interval [CI], 0.64 to 0.87; P<0.001). In the ICD–CRT 
group, 186 patients died, as compared with 236 in the ICD group (hazard ratio, 0.75; 95 
percent CI, 0.62 to 0.91; P=0.003), and 174 patients were hospitalized for heart failure, as 
compared with 236 in the ICD group (hazard ratio, 0.68; 95 percent CI, 0.56 to 0.83; 
P<0.001). 
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Hence the most recent European guidelines published this year suggest that patients being 
considered for ICD should be strongly considered for CRT-D providing they have met the 
other selection criteria.(22) (LVEF <35 percent and complete left bundle branch block) 
However what is less clear is whether a patient who is being considered for CRT-P should be 
considered for CRT-D. There has not been a published trial which has published on head to 
head basis - COMPANION did contain three arms with two of them containing CRT-P and 
CRT-D.(5) However the trial design meant that the study was not powered to allow a direct 
comparison. The sector needs further investigation and potentially even a trial which contains 
a direct comparison between CRT-P and CRT-D.  
 
1.8.2  Historical perspective 
Cardiac Pacing in humans was originally described in the 1950's.(81, 82) Modern 
percutaneous transvenous techniques have been developed and refined over the past thirty 
years. The concept of pacing in patients with heart failure has steadily evolved over this time 
period.  
 
One of the initial pilot studies was performed by Derek Gibson in 1971. It  demonstrated the 
acute effects of biventricular pacing.(83) Using six patients with Starr-Edwards aortic valve 
prostheses in the acute post-operative period, biventricular pacing using the surgical 
epicardial leads was shown to reduce the surface QRS duration on the electrocardiogram 
(ECG). Using the stroke distance as calculated by the movement of the ball in the prosthesis 
itself, the authors also demonstrated that biventricular pacing resulted in improved ventricular 
work. 
 
Other groups performed small limited pilot studies around this time period.(84, 85) but no 
further investigational work was performed in this area for the following thirty years. Though 
the large randomised controlled trials of heart failure pharmacotherapy started to report in the 
late 1980s and early 1990s, there was a large number of patients with symptomatic advanced 
disease. Hence a renewed focus was placed on pacing as a potential treatment for this cohort. 
 
Hochleitner, in 1990, demonstrated, using conventional dual chamber pacing set in dual 
chamber pacing mode (DDD), a marked clinical and haemodynamic improvement in sixteen 
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patients with dilated cardiomyopathy (DCM).(86) All patients had advanced symptomatic 
disease and had proven dilated cardiomyopathy with normal coronary angiography and 
myocardial biopsies. The severity of their disease meant that all 16 patients have been initially 
referred for cardiac transplantation with seven on the current transplant list. All patients were 
on the optimal tolerated medical therapy of the time (vasodilators, diuretics and digitalis). A 
total of seven patients had left bundle branch block (LBBB) on the surface electrocardiogram. 
(ECG) All patients underwent standardised implantation of a transvenous dual chamber 
system (right atrial and ventricular leads). Following the implantation of dual chamber 
pacemakers which were set at DDD mode with a ventricular rate of 50 beats per minute 
(BPM) with an atrioventricular (AV) delay of 100 milliseconds. The results demonstrated an 
improvement in clinical symptoms such as breathlessness, NYHA class improved from 3.6 ± 
0.4 to 2.1 ± 0.5 (P<0.001), left ventricular dimensions improved, left ventricular end diastolic 
diameter improved from 74 ± 11 mm to 72 ±10 mm (P<0.05). All patients were discharged 
from hospital three weeks following their pacemaker implantation and after one year of 
clinical follow up, 4 patients had died, 12 individuals had persistent clinical improvement and 
subsequently a third of these patients received cardiac transplants. In three patients the impact 
of pacing was so marked that they were removed from the transplant list all together. This 
cohort was then subsequently followed up for an extended period of time. The effects of 
pacing seemed to persist after the acute period and the median survival for the cohort was 22 
months. Three patients survived beyond the extended five year period of follow up.(87) 
 
Following this initial work others evaluated the role of dual chamber pacing in patients with 
heart failure, particularly due to dilated cardiomyopathy. Brecker and colleagues, in 1992, 
investigated the effect of atrioventricular delay in patients with dual chamber pacing and 
dilated cardiomyopathy.(88) A cohort of twelve patients was identified with dilated 
cardiomyopathy and concomitant mitral and tricuspid regurgitation. As a consequence of the 
regurgitation, all patients possessed shortened ventricular filling times. A shorter 
atrioventricular delay resulted in improved biventricular filling times (65 (35-95) ms and 90 
(60-120)ms, P<0.001). A shortened AV delay also resulted in an increased cardiac output (by 
1.1 [0.8-1.4] l/min, p < 0.01) and rises in exercise capacity (104 [45-165] s, P < 0.05) and 
maximal oxygen demand (2.1 [1.5-2.7] ml kg-1 min-1, P< 0.05). Linde and colleagues 
replicated the experiment in a smaller cohort of similar patients in 1995.(89) A day after 
successful DDD permanent pacemaker implantation, AV delay was optimised using Doppler 
flows across the aortic valve. The cohort was then re-evaluated at one, three, and six month 
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intervals following pacemaker implantation. Clinical data was collected at these time points 
including NYHA class, stroke volume, left ventricular ejection fraction and cardiac output. 
The initial optimisation did induce a short term improvement in haemodynamics (Baseline 
stroke volume = 22 ± 7 ml, day 1 = 28 ± 12 ml; p = 0.03: Baseline cardiac output = 1.9 ± 0.6 
L/min, day 1 = 2.2 ± 1.1 L/min; p = 0.10) however the authors found no longer term effect on 
any of the documented variables.  
 
Whilst some work, as described previously, had evaluated the role of predominately right 
atrial and ventricular pacing in patients with dilated cardiomyopathy, other groups decided to 
revisit the potential of biventricular pacing. Initial reports of multisite pacing started to 
emerge around this time. Cazeau and colleagues issued one of the first case series in 
1996.(90) This involved eight patients who had advanced symptomatic heart failure, a 
broadened QRS duration on the surface ECG and who had either been refused or had turned 
down a cardiac transplant. Using temporary pacing leads and a series of connectors and 
pacing boxes, multisite pacing (including biventricular pacing) was tested. Biventricular 
pacing increased the mean cardiac index (CI) by 25 percent (from a baseline of 1.83 +/- 0.30 
L/min per m2, P < 0.006) and decreased pulmonary capillary wedge pressure by 17% (from a 
baseline of 31 +/- 10 mmHg, P < 0.01). Notably half (50 percent) of the patients suffered 
either intra-procedure or peri-procedural death but for the four survivors there was an 
improvement in NYHA class. The remaining question about biventricular pacing was whether 
the effect on short term haemodynamics would translate into longer term clinical benefit and 
outcomes. 
Bakker and her colleagues were the first to release data in this area in 2000.(91) A series of 
twelve patients with end stage heart failure and aetiologies comprising both ischaemic (33 
percent) and non-ischaemic (67 percent) aetiologies with prolonged PR interval and QRS 
duration on their surface ECGs (PR interval 217 ± 20ms and QRS duration 194±21 ms). All 
patients had left bundle branch block (LBBB) on their surface ECG. They all had successful 
biventricular pacing systems implanted under general anaesthesia with a surgical epicardial 
left ventricular lead being implanted using a small left mini-thoracotomy. Clinical follow up 
was then performed at set intervals. The cumulative survival at one, two and three years was 
66.7 percent [40.0,93.4] at 1 year and 50  percent [21.8, 78.2] respectively. The median 
NYHA class improved from IV to II at 1 year. (P=0.008). There were improvements in LVEF 
and end diastolic diameter at one year, though these were non-significant (P=0.10 and P=0.20 
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respectively). There were significant changes observed in dP/dt and stroke volume at one year 
(466±130 to 243 ± 113 (p=0.03)) and 37±9 to 42± 10 (P=0.05))).  
 
The beneficial effects in these reports, led to further clinical trials, including randomised 
controlled trials. For the purpose of the rest of the thesis, atrio-biventricular pacing will be 
considered to be synonymous with cardiac resynchronisation therapy. (CRT) 
  
1.8.3  Randomised Controlled Trials of CRT 
The	  major	  randomised	  controlled	  trials	  investigating	  the	  effects	  of	  CRT	  have	  been	  summarised	  in	  
Table	  2.	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Table 2: List of all major trials to date performed evaluating cardiac resynchronisation therapy
Study! Year of Publication! Design! N! Inclusion Criteria!
Exclusion 
Criteria!
Primary/
Secondary 
Endpoints!
Results!
PATH-CHF! 2002!
Single Blind 
Randomised!
Crossover!
41 Patients!
NYHA III-IV 
Symptoms;Optimal 
tolerated medical 
therapy; PR 
interval 
>150ms;QRS 
duration>120ms;S
R >55bpm; dilated 
cardiomyopathy!
Severe Valvular 
disease;indications 
for an ICD 
implant; shortened 
life expectancy due 
to non-cardiac 
disease!
Primary: Peak 
oxygen uptake at 
exercise, 6MWT 
test distance and 
anaerobic 
threshold at peak 
exercise.!
Secondary: 
Changes in NYHA 
class and QOL!
Primary:!
P<0.001, P<0.001, 
P=0.037!
Secondary:!
P<0.001!
MUSTIC! 2001! Randomised Crossover!
47 Patients - Sinus 
Rhythm, 41 
patients in AF 
substudy!
Dilated or 
underlying 
ischaemia; LVEF 
<35%;LVEDD 
<60mm; NYHA 
III, QRS 
duration>150ms!
Severe Valvular 
disease;indications 
for an ICD 
implant; shortened 
life expectancy due 
to non-cardiac 
disease; Coronary 
intervention within 
the last three 
months or acute 
coronary syndrome 
within the last 
three months!
Primary Endpoint : 
6MWT distance!
 !
Secondary 
Endpoint: Peak 
Oxygen uptake; 
HF 
hospitalisations; 
death!
Primary: P<0.001!
 !
Secondary:!
P<0.004 and 
P<0.05!
MIRACLE! 2002!
Prospective, 
Randomised,Contr
olled Trial!
453 Patients!
Dilated or 
underlying 
ischaemia; LVEF 
<35%;LVEDD 
<55mm; NYHA 
III, QRS 
duration>130ms;
6MWT <450 m!
Indication for ICD 
implant, cardiac 
pacing; cardiac or 
cerebral event in 
last 3/12; atrial 
arrhythmia in last 
3/12; hypertension; 
Creatinine 
>265mmol/L;AST 
> *3 ULN!
Primary:NYHA; 6 
MWT; QOL!
 !
Secondary:peak 
oxygen con- 
sumption, time on 
a treadmill, left 
ventricular ejection 
fraction and end-
diastolic 
dimension, severity 
of mitral 
regurgitation, 
duration of QRS 
interval, and a 
clinical composite 
response,!
P=0.005, P=0.001, 
P=<0.001!
 !
P=0.009, P=0.001, 
P=0.001!
CONTAK-CD! 2003!
Prospective, 
Randomised, 
Double- Blind, 
Controlled Trial!
490 Patients!
Dilated or 
underlying 
ischaemia; LVEF 
<35%;NYHA III; 
QRS 
duration>120ms; 
Indication for ICD!
Atrial 
tachyarrhythmias; 
Indication for 
cardiac pacing; 
Recent cardiac and 
cerebral event in 
lst 3/12; Coronary 
revascularisation in 
last 3/12!
Primary:All-cause 
mortality; 
Hospitalisation for 
HF; Ventricular 
tachyarrhythmias 
requiring device 
therapy!
Secondary: 
NYHA, QOL, peak 
VO2, 6MWT!
Primary: Non-
Significant!
Secondary:!
P=0.003, P=0.029, 
P=0.006, P=0.017!
COMPANION! 2004!
Prospective, 
Randomised,  
Controlled Trial - 
randomised in 
1:2:2 manner 
randomised to 
optimal medical 
therapy, CRT-P, 
CRT-D!
1520 Patients!
Dilated or 
underlying 
ischaemia; LVEF 
<35%; NYHA III-
IV;QRS duration 
120ms;PR interval 
>150 ms, Sinus 
Rhythm!
Atrial 
tachyarrhythmias; 
Indication for 
cardiac pacing; 
Recent cardiac and 
cerebral event in 
lst 3/12; Coronary 
revascularisation in 
last 3/12!
Primary: All-cause 
mortality and all 
cause 
hospitalisation!
P=0.014 (HR 
=0.81)- CRT-P!
P=0.01 (HR=0.8)!
CARE-HF! 2005!
Prospective, 
Randomised,Contr
olled Trial!
813 Patients!
NYHA III-IV 
Symptoms;Optimal 
tolerated medical 
therapy;QRS 
duration>120ms 
(120-149 ms 
needed evidence of 
mechanical 
dyssynchrony)!
Atrial 
Arrhythmias; 
Major 
cardiovascular 
event in last 6/52; 
Indications for 
pacemaker and 
defibrillator; Heart 
Failure requiring 
continuous 
intravenous 
therapy!
Primary: All-cause 
mortality and 
cardiovascular 
hospitalisation!
Secondary: All-
cause mortality,!
Unplanned 
hospitlisation with 
heart failure, 
NYHA class and 
quality of life 
measured by 
Minnesota and 
EuroQol 5D!
Primary:!
Hazard ratio, 0.63; 
0.51 to 0.77; 
P<0.001!
Secondary: 
P<0.001!
MADIT-CRT! 2009!
Prospective, 
Randomised,Contr
olled Trial - 
randomised in 3:2 
manner to ICD or 
CRT-D!
1820 Patients!
NYHA I-II;dilated 
and underlying 
ischaemia;LVEF 
<30%; QRS 
duration>130 ms!
Existing indication 
for CRT; pre-
existent ICD or 
Pacemaker; NYHA 
III-IV, prev CABG, 
MI or PCI within 
the last 3/12, AF 
within last 1/12!
Primary: All-cause 
mortality or non-
fatal heart failure 
event.!
Hazard ratio in the 
CRT–ICD group, 
0.66; [CI], 0.52 to 
0.84; P=0.001!
REVERSE! 2008!
Prospective, 
Randomised, 
Crossover, Double 
Blind, Controlled!
610 Patients!
NYHA I-II;QRS 
>120ms;LVEF 
<40%!
Pacemaker 
dependence; Pre-
existing Pacemaker 
in situ; NYHA III-
IV; HF 
hospitalisation in 
last 3/12!
Primary: 
Worsening in 
clinical composite 
score (HF 
hospitalisation, 
worsening NYHA 
class or mortality)!
Secondary: Change 
in LVESVi!
Primary: P=0.10!
 !
Secondary: 
P=0.0001!
RethinQ! 2007!
Prospective, 
Randomised, 
Controlled, Double 
Blind!
172 Patients!
NYHA III;LVEF 
<35%; QRS <130 
ms; stable HF 
medical 
therapy;fulfil 
indication for ICD!
AF; unable to 
perform 6MWT; 
standard pacing 
indication; Recent 
CVA or TIA within 
3/12; CABG, MI 
or PCI within last 
40 days!
Primary: Peak 
VO2!
Secondary: NYHA 
class; QOL!
Primary: P=NS!
Secondary: P=NS!
RAFT! 2010!
Prospective, 
Randomised, 
Controlled; Double 
Blind; Randomised 
to 1:1 between 
ICD and CRT-D!
1798 Patients!
NYHA II-III; 
LVEF <30%, 
QRS>120 ms or 
paced QRS 
>200ms; AF or A. 
Flutter;SR!
Recent 
cardiovascular 
event in last 3/12; 
Major life 
threatening non 
cardiac disease!
Primary: All-cause 
mortality and HF 
hospitalisation!
Secondary: All-
cause mortality; 
HF hospitalisation; 
All cause 
cardiovascular 
mortality!
Primary: HR=0.75 
(CI = 0.64 -0.87 
P=<0.001)!
Secondary: 
HR=0.75 
(CI=0.62-0.91 
P=0.003)!
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The large randomised trials evaluating CRT can be viewed in three phases. The earliest trials 
focused on clinical effectiveness as measured using markers of quality of life, exertional 
capacity and exercise tolerance. Once CRT had been demonstrated to have a beneficial effect 
on such endpoints, the emphasis then moved to proving a more prolonged effect on ‘harder’ 
clinical endpoints such as heart failure hospitalisation, cardiovascular hospitalisation, all 
cause mortality and cardiovascular mortality. The results of these trials published in the mid 
2000s, really established CRT as an effective clinical treatment for selected patients with 
symptomatic left ventricular systolic dysfunction and broadened QRS duration on the surface 
electrocardiograms. Since that time point, the question was whether CRT would prove as 
effective for HF populations outside of the established criteria including those with milder 
forms of disease, whether CRT should be combined with a defibrillator, and those with mild 
or moderate LVSD or narrower QRS durations than the guidelines recommendation of 120 
ms. 
 
The earliest randomised trials were the MUSTIC (Multisite Stimulation in Cardiomyopathies) 
study published in 2001 and the PATH-CHF (Pacing Therapies in Congestive Heart Failure) 
Study published in 2002. The two studies do possess similarities but were performed either in 
continental Europe (MUSTIC) or North America (PATH-CHF).(92, 93) 
 
The MUSTIC study had a crossover trial design.(93) Using  67 patients, with NYHA class III, 
LVEF <35 percent, LVEDD =60mm, QRS duration >150 milliseconds, optimal tolerated 
medical therapy and sinus rhythm, CRT was implanted and then investigated with a 
randomised protocol which had a period of 12 weeks during which the patients had their left 
ventricular lead turned off and mode of pacing changed to univentricular with minimal right 
ventricular pacing. The primary endpoint was six minute walk test distance. The results 
demonstrated that CRT within this population increased the 6 MWT distance by 23 percent 
(375 +/- 83 m in the inactive period to 424+/-83m in the active period P<0.004). There were 
also significant improvements in quality of  life score, which improved by 32 percent 
(P<0.001) and peak oxygen uptake which increased by 8 percent (P<0.03).  
 
PATH-CHF (Pacing Therapies in Congestive Heart Failure), was published in 2002.(92) The 
study used a crossover randomised study to investigate whether biventricular pacing was 
superior in comparison to univentricular pacing (right or left ventricular). A series of 41 
patients were recruited who had dilated and severely impaired left ventricular function with 
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underlying aetiologies of either dilated cardiomyopathy or ischaemic heart disease. All were 
in sinus rhythm and had a surface ECG QRS duration of >120 milliseconds. The primary 
endpoints in the study were oxygen uptake at peak exercise and 6MWT distance. Secondary 
endpoints within the study were quality of life assessment using the Minnesota Quality of 
Life for Heart failure Questionnaire and NYHA classification. Cardiac resynchronisation 
therapy improved exertional capacity and peak oxygen uptake and there was also significantly 
improved NYHA functional class and quality of life score. (From 12.57 +/-0.63 at baseline to 
15.63 +/- 0.86 at one year - peak oxygen uptake - P<0.001). Due to the trial structure there 
was one crossover period after 4 weeks followed by an open label phase. Due to this structure 
some patients received univentricular pacing twice and were noted to have decreased 
exertional ability as measured by the parameters above.  
 
The next three studies, which were published, were the MIRACLE study in 2002, CONTAK-
CD study published in 2003 and the MIRACLE-ICD study in 2004. These studies collectively 
investigated the same endpoints as before on a much larger scale but also collected data on 
clinical endpoints.  
 
The MIRACLE (Multicentre In Sync Randomised Clinical Evaluation) recruited 571 patients 
predominately from American centres over a time period between November 1998 and 
December 2000.(7) Several patients had to be withdrawn with 47 patients unable to have a 
CRT device implanted, two patients becoming clinically unstable and two patients requiring 
emergency cardiac pacing. A pilot study was also performed which recruited the initial 71 
patients and therefore the study cohort described in the manuscript is actually 453 patients. 
The cohort was randomised to CRT (228 patients) and a control group (225 patients). The 
trial inclusion criteria were NYHA class III or ambulatory IV heart failure, LVEF below 35 
percent with an LVEDD of greater than 55mm, a QRS duration of >130 milliseconds and a 6 
MWT distance of less than 450m. All patients were on optimal tolerated HF medication 
including diuretics, ACEI, beta blockers and digoxin. The primary endpoints of the study 
were NYHA class, quality of life score assessed by Minnesota Quality of Life Score and 6 
MWT distance. Secondary endpoints were a clinical composite score, severity of mitral 
regurgitation, duration of QRS and end diastolic dimension. Clinical data was also collected 
on all-cause mortality, heart failure progression and hospitalisation. CRT was effective at 
improving all primary endpoints, with an improvement in 6MWT (P=0.005), QOL (P=0.001) 
and NYHA class (P<0.001). The effect was also replicated on secondary endpoints with 
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improvements in left ventricular ejection fraction, end diastolic dimensions, area of mitral 
regurgitant jet and duration of QRS interval (P<0.001). It also improved markers of exercise 
performance (total exercise time P=0.001) and peak oxygen consumption (P=0.009). During 
the six months of follow up there was also a reduction in heart failure hospitalisations 
(P=0.02). The effectiveness of CRT had been evaluated within a randomised format for the 
first time and demonstrated to have effectiveness over a six month follow up period on 
symptomatic, mechanical and also clinical endpoints.  
 
As technology advanced it became possible to combine cardiac resynchronisation therapy 
with a implantable cardioverting defibrillator (CRT-D). The next two summarised trials were 
specifically conceived to evaluate the effects of CRT-D within patients who fulfilled other 
criteria for CRT.  
 
CONTAK-CD was published in 2003.(94)  It recruited 490 patients from North American 
centres and randomised the group to CRT-D and conventional medical therapy and ICD only 
on a 1:1 basis. All patients had to be in NYHA II-IV heart failure, with LVEF <35 percent, 
QRS duration >120 milliseconds and had conventional indications for implantation of an 
ICD. Due to the necessity of implanting an ICD, the steering committee proposed a period of 
30 days after device implantation where no device therapy was active. This allowed 
pharmacotherapy optimisation following device implantation. The study design was initially a 
randomised crossover design with three month observational periods however following 
concerns about morbidity and mortality associated with CRT and with sponsor interference 
(Boston Scientific) the study was amended into a parallel randomised CRT-D vs medical 
therapy and ICD only. The initial endpoints selected by the steering committee were similar 
to those of previous studies (peak VO2 max, quality of life as assessed by Minnesota Quality 
of Life Questionnaire and 6MWT distance) however following sponsor intervention this was 
changed to a composite endpoint predominately powered by HF progression. The composite 
endpoint was made up of all-cause mortality, heart failure hospitalisation and ventricular 
tachyarrhythmias requiring device therapy.  
 
In the 245 patients randomised to CRT there was a lower event rate with a total event rate of 
79 events (comprised of 11 deaths, 32 patients with HF hospitalisation and 36 patients with a 
ventricular tachycardia/fibrillation episode). This is compared to the non CRT group with a 
total event rate of 94 events (16 deaths, 39 patients with at least one HF hospitalization, and 
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39 patients with at least one VT/VF event). Therefore there was a fifteen percent reduction in 
the composite endpoint, which was not statistically significant (P=0.35).  In terms of the other 
endpoints, CRT-D did improve peak VO2 (0.8 ml/kg/min vs. 0.0 ml/kg/min, P = 0.030) and 
6MWT distance (35m vs 15 m P=0.043), but had a statistically non-significant effect on 
NYHA class (P=0.10) and quality of life as assessed by the Minnesota questionnaire 
(P=0.40). CRT did have a significant effect on markers of left ventricular remodelling with 
improvements documented in both left internal diameters at end systole and diastole. (left 
ventricular internal diameter in diastole = −3.4 mm vs. −0.3 mm, P< 0.001 and left ventricular 
internal diameter in systole = −4.0 mm vs. −0.7 mm, P< 0.001) and improvement in left 
ventricular ejection fraction (5.1 percent vs. 2.8 percent, P = 0.02). The steering group reflect 
in their conclusions that CONTAK-CD was underpowered to detect changes on clinical 
endpoints and hence the result of CRT-D on clinical endpoints was non-significant. They also 
note for those with advanced heart failure (NYHA III-IV), CRT seemed to be effective at all 
of the original primary endpoints, i.e. exertional capacity, NYHA grade and quality of life.  
 
MIRACLE-ICD II (Multicentre InSync ICD Randomized Clinical Evaluation II) was the next 
large randomized trial which published in 2004.(95) Using a smaller cohort patients were 
randomized to conventional medical therapy and an ICD versus CRT-D and medical therapy. 
The investigators deliberately sought to evaluate the effects of CRT –D in a less symptomatic 
population. The inclusion criteria for participation were NYHA class II, a LVEF <35 percent, 
LVEDD>5.5cm and a QRS duration >130 ms and conventional indications for ICD. The trial 
design was a double blinded randomized controlled trial. The primary endpoint was a change 
in VO2 Max over the six month follow up period. The secondary endpoints were similar to 
those of previous studies and included echocardiographic (LVEF, LVEDD), functional 
(6MWT, NYHA class) and quality of life. A total of 186 patients were recruited and 
randomized with 85 patients being randomized to the active arm. Notably, CRT within this 
population had an effect on ventricular volumes, left ventricular ejection fraction and 
ventilatory response (P=0.04, P=0.02 and P=0.01 respectively) but not on the other endpoints. 
This was potentially explained by the study having investigated less symptomatic patients 
who had preserved exercise tolerance. Hence the effect of CRT-D within this population was 
to induce reverse LV remodelling independent of markers of functional status.  
 
 The results of the MIRACLE studies and CONTAK-CD hinted at the longer term effect of 
CRT and particularly on HF hospitalization, morbidity and mortality. However despite having 
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larger numbers of patients within their trial cohorts they were underpowered to evaluate the 
effects of CRT on clinical endpoints. Hence the last two major trials to report around this era 
were the COMPANION trial published in 2004 and CARE-HF in 2005. The two studies are 
viewed as landmark studies within the area due to their evaluation of the effects of CRT on 
clinical endpoints including hospitalisations and mortality.  
 
COMPANION (Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure) 
study was published in 2004.(5) A total of 1520 patients were recruited from American 
centres and were randomised in a 1:2:2 manner to conventional medical therapy only, medical 
therapy and CRT-P and medical therapy and CRT-D. The inclusion criteria were NYHA class 
III-IV heart failure, either ischaemic or non-ischaemic aetiology, a LVEF <35 percent, a QRS 
duration >120ms, a PR interval >150 ms, sinus rhythm and a preceding hospitalisation for 
heart failure in the twelve months preceding enrolment. Patients randomised to CRT 
implantation had commercially available systems implanted and were optimised with a device 
based algorithm which concentrated on atrioventricular delay. The primary endpoint was a 
composite of all-cause mortality and all cause hospitalisation. The secondary endpoint was all 
cause mortality. The study recruitment period ran between January 2000 and November 2002. 
Notably 26 per cent of the medical therapy group withdrew from the original protocol due to 
heart failure events and the need for cardiac devices.  
The rates of the primary end point differed between the medical therapy group and CRT-P 
group (68 per cent in the pharmacological group as compared to 56 per cent in the CRT-P 
group) and 56 per cent in the CRT-D group). The hazard ratios were respectively hazard ratio 
for the primary end point, 0.81; 95 percent confidence interval, 0.69 to 0.96; P = 0.014; 
adjusted P = 0.015 by the log-rank test (medical therapy vs CRT-P) and hazard ratio, 0.80; 95 
percent confidence interval, 0.68 to 0.95; P = 0.010; adjusted P=0.011 (medical therapy vs 
CRT-D). Thus irrespective of defibrillator capacity - CRT reduced the incidence of the 
primary endpoint by approximately twenty percent. There were also a significant reduction  in 
the secondary endpoint (all-cause mortality) with the hazard ratios for medical therapy versus 
CRT-P being (hazard ratio, 0.76; 95 percent confidence interval, 0.58 to 1.01; P = 0.059; 
adjusted P = 0.06) i.e. a trend towards improvement but not statistically significant. This 
compared to CRT-D versus medical therapy (hazard ratio, 0.64; 95 percent confidence 
interval, 0.48 to 0.86; P = 0.003; adjusted P = 0.004) i.e. with the additional defibrillator 
capacity there was a marked reduction in all-cause mortality. The study also had embedded 
prespecified sub group analysis. One of the substudy groups were patients with dilated 
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cardiomyopathy, there was a fifty per cent reduction in all-cause mortality within this 
subgroup hazard ratio(0.50; 95 percent confidence interval, 0.29 to 0.88). This finding is 
noteworthy because prior literature had concentrated on the relationship of ICDs to clinical 
outcomes in patients with prior ischaemic heart disease. 
 
The trial which was last to report from this era is often viewed as the landmark trial - this is 
due to its simplistic design, lack of complexity in terms of intervention and the fact that it has 
periodically released data from its extended follow up period.  
 
CARE-HF (Cardiac Resynchronisation Therapy - Heart Failure), published in 2005, was the 
last study to report and was focused on the clinical effects of CRT without the added issue of 
defibrillators.(6) A series of 813 patients was enrolled from 82 European centres with 
recruitment running from January 2001 and ended in March 2003. The study was not blinded 
- it was run independent of the sponsor. All decisions with regards to trial design, conduct and 
statistical analysis were executed by the steering committee.  
 
Inclusion criteria included a diagnosis of heart failure for at least six weeks preceding 
enrolment, NYHA III-IV heart failure, on optimal tolerated evidence based pharmacotherapy, 
a LVEF <35 percent, a QRS duration of >120 ms and an indexed EDD to height of at least 30 
mm and sinus rhythm. Patients who had a QRS duration between 120 and 149 milliseconds 
had to fulfil two out of three following markers of dyssynchrony (aortic pre-ejection delay 
>140ms, an interventricular delay >40 ms or delayed activation of the posterolateral left 
ventricular wall).  
 
Patients randomised to CRT implantation had a standardised commercially available system 
transvenously implanted. Following successful implantation all devices had 
echocardiographically optimised AV delays. The primary endpoint for the study was a 
composite of all-cause mortality and hospitalisation for a cardiovascular event. The secondary 
endpoints were all-cause mortality, composite of death and unplanned HF hospitalisation, 
NYHA and quality of life scores at 90 days as measured by Minnesota Living with Heart 
Failure Questionnaire and European Quality of Life-5 Dimensions (EuroQOL EQ-5D).  
 
Patients were randomised on a 1:1 basis to medical therapy or CRT-P and medical therapy. 
The median duration of follow up was 29.4 months (range 18 -45 months). By the end of the 
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study the primary end point had been achieved in 224 patients in the medical therapy arm 
versus 159 patients in the CRT-P group. (39 percent vs. 55 percent; hazard ratio, 0.63; 95 
percent confidence interval, 0.51 to 0.77; P<0.001) CRT also reduced the risk of composite 
end point of death and HF hospitalisation (hazard ratio, 0.54; 95 percent confidence interval, 
0.43 to 0.68; P<0.001). (See Figure 7).There was also a universal improvement in patients 
with CRT implants versus medical therapy in LVEF, quality of life scores and NYHA class. 
Hence for the first time CRT-P had been shown to improve functional and symptomatic 
endpoints but also improve morbidity and mortality.  
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Figure 7: Kaplan- Meier Plots for Time to primary outcome and principal secondary outcome -CARE-
HF(6) 
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Following the initial publications of the above trials, CRT became an established clinical 
therapeutic option for patients with symptomatic left ventricular dysfunction and a broad QRS 
duration on optimal tolerated medical therapy and sinus rhythm. However logically the 
scientific community questioned whether CRT would be effective in groups which fell 
outside of the evidence base; this included those with milder forms of heart failure in terms of 
symptoms, those with narrower QRS durations on the surface ECG and those who meet 
current criteria for an ICD and whether this group should receive the additional benefit of a 
left ventricular lead. The most recently published trials evaluating CRT have investigated 
some of these questions. 
 
REVERSE (Resynchronisation reverses remodelling in symptomatic left ventricular 
dysfunction), published in 2008, and evaluated the role of CRT in patients who were either 
asymptomatic or mildly symptomatic (NYHA I-II) heart failure.(96) Potential participants 
had to have a LVEF<40 percent, QRS duration >120 ms and LVEDD >55 mm and in sinus 
rhythm. All patients underwent CRT implantation (some with ICD capacity and some 
without) and were randomised in 2:1 fashion to CRT - ON or CRT-OFF. The European sub 
cohort stayed within their randomised arms for 24 months to evaluate the effect of early CRT 
intervention on heart failure hospitalisations. A total of 601 patients were recruited into the 
study and underwent randomisation. There was no statistically significant effect on the 
primary endpoint between the two groups. (P=0.10) The LVESVI improved (18.4 +/-29.5 
ml/m2) in the CRT-ON group (n = 324) compared with the CRT-OFF group (1.3+/-23.4 
ml/m2; n= 163; P =0.0001). There was no effect from CRT on functional and quality of life 
scores in the study. The authors felt the beneficial effects of CRT on left ventricular 
remodelling were a success and justified the risk of exposing patients to a CRT implant when 
they had no or little symptoms. (16 percent of patients experienced device based 
complications during the study including lead revisions and displacements, atrial arrhythmias, 
cardiac tamponade and diaphragmatic capture). The trial had limited scheduled follow up. 
Hence in terms of data it was the first to contribute to this area of potential expansion of 
indications for CRT but further data are needed to clarify the relationships in this area.  
 
In terms of a narrow QRS duration, there has been a small randomised trial which has 
investigated the area. RethinQ (Cardiac Resynchronisation Therapy in patients with heart 
failure and narrow QRS) published first in 2007.(97) Using a series of patients with either 
ischaemic or a non-ischaemic aetiology and a LVEF <35 percent and a QRS duration 
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<130ms. All patients underwent CRT implantation and were randomised to ICD only or 
CRT-D in a 1:1 manner. The primary endpoint was peak oxygen uptake during 
cardiopulmonary testing at 6 months post baseline. A total of 172 patients were recruited and 
comprised the group on whom statistical analysis was performed. The group receiving CRT 
had a biventricular pacing rate during the study of greater than >85 percent. There was no 
difference between the groups in neither primary endpoint nor echocardiographic or 
functional testing. All results were non-significant.  On prespecified sub group analysis in 
patients with a QRS duration <120 milliseconds there was improvement on peak VO2 
(p=0.02) and NYHA class (p=0.01) with CRT but not in 6 MWT test distance or quality of 
life scores. (p=0.63 and p=0.31 respectively). Hence the trial though not conclusive due to the 
low numbers enrolled into the study is suggestive that CRT is not efficacious in individuals 
without a QRS duration >120 ms.  
 
1.8.4 Patient Selection  
Cardiac Resynchronisation Therapy has now become a clinically established therapeutic 
option for patients with symptomatic left ventricular dysfunction. Guidance has been 
regularly issued in the area by  the European and American bodies.(22, 98) 
 
The current guidelines for CRT in England & Wales are being revised and are due for 
publication. The previous guidance issued by NICE was published in 2007 and hence are now 
outdated, due to the publication of new trial evidence as described above. The current 
guidance was issued by the European Society of Cardiology, with new guidelines released 
this year and a consensus document issued in 2012 as a joint venture between European Heart 
Rhythm Association and Heart Rhythm Society.(99) 
 
Irrespective of which guidelines are consulted, certain criteria are now viewed as fundamental 
for patient selection. The patient should have severe left ventricular dysfunction with a LVEF 
<35 percent, a broad QRS duration >120 ms (preferably in LBBB morphology) and on 
optimal tolerated heart failure medical therapy and in symptomatic NYHA II-IV heart failure.  
 
However, despite the guidelines, the proposition of a patient as a candidate for CRT and the 
implant process of CRT have both been studied in detail. Each step of the process has been 
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analysed to improve ‘response’ rates and the rest of this section is devoted to the discussion of 
these issues.  
	  
1.8.5 Dyssynchrony 
Despite the current selection criteria as recommended by the contemporary guidance, there 
has been much focus on dyssynchrony. This is the quantification into a continuous variable, 
of the degree of in-coordination between septal and posterolateral walls. The purpose of 
quantifying incoordination is to then use the information to predict post CRT implantation 
improvement or even rationalise the use of CRT.  
 
The pre implant measurement of dyssynchrony may be performed with a variety of imaging 
modalities but conventionally has been performed using echocardiography. Initial work 
performed in non-randomised cohorts, with small numbers of patients in single centre studies, 
was able to demonstrate the predictive capacity of such measurements.(100-102) The 
published reproducibility and repeatability coefficients are high and initially indicated that 
these may be able to inform the CRT selection process.  
 
However there have now been three large trials using echocardiographic markers of 
dyssynchrony with no positive findings and the concept of prospective dyssynchrony imaging 
has been challenged by the findings of these studies.  
 
The most famous of the three is the PROSPECT study (Predictors of Response to CRT 
Study). Published by Chung and colleagues in 2008, they evaluated the role of dyssynchrony 
measurement in a prospective cohort.(103) The trial enrolled 498 patients across 53 
worldwide centres and was designed to investigate the sensitivity and specificity of 
echocardiographic markers of dyssynchrony in a multicentre prospective study. The endpoint 
for the study was an improvement in a clinical composite score (based on NYHA class, HF 
hospitalisation and all-cause mortality) and a LV remodelling endpoint of reduction of <15 
percent  in LVESV. The techniques used within the study for identifying dyssynchrony were 
a mixture of conventional echo (M Mode and Pulsed Wave Doppler) and Tissue Doppler 
derived techniques. There were three core echo laboratories which read all echoes for all 
patients, the USA and Hong Kong used the core laboratory based at Emory University, 
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Atlanta, USA. Europe used a core laboratory based in Pavia, Italy and the Hammersmith 
Hospital, London performed Tissue Doppler derived measurement for Europe.  
 
The cohort was followed up for six months and the endpoints recorded. The overall rates of 
clinical improvement (69 percent) and rates of left ventricular remodelling (56 percent) are 
consistent with other published data in the area. However the various echocardiographic 
markers ranged widely for sensitivity and specificity for clinical composite response (6 
percent to 74 percent and specificity ranging from 35 percent to 91 percent) and LV 
remodelling (sensitivity ranged from 9 percent to 77 percent and specificity from 31 percent 
to 93 percent). Notably the reproducibility of the techniques was also variable with volume 
assessments having low variability (CV, 3.8 percent) and Tissue Doppler derived indices had 
both poor intra-observer (CV 15.8 percent) and inter-observer variability (CV 33.7 percent). 
The findings of the study were widely debated due to the surprising result as compared to the 
single centre smaller studies. Potential explanations for these findings offered by the authors 
included heterogeneous CRT implantation criteria (a difference in practice between USA and 
Europe), the poor reproducibility of Tissue Doppler techniques, the use of different echo 
equipment at different core laboratories and whether the LV leads had been implanted to 
reach the actual area of dyssynchrony. The findings of this study however were interpreted by 
those outside of the specialised field of complex echocardiography as removing the need for 
such measurements prior to CRT implantation.  
The Mayo Clinic, Rochester, Minnesota US also investigated this issue and published their 
data in 2010.(104) The study was a prospective study analysing echocardiographic markers in 
131 patients undergoing CRT implantation at the Mayo Clinic from 2005 until 2007. The 
study used fourteen measures including some which had been analysed in PROSPECT but 
had to been found to have poor reproducibility. The measures involved M Mode, tissue 
velocity imaging, tissue Doppler strain, 2D speckle strain, 3D echocardiography and total 
isovolumic time. The study period ran for six months following CRT implantation and used 
the conventional endpoints of clinical response and QOL, 6MWT distance and MVO2 . None 
of the echo measures had strong predictive value only M-mode, tissue Doppler strain, and 
total isovolumic time had a receiver operating characteristic area better than chance but none 
of these were strongly predictive of LV reverse remodelling. (AUC, 0.63 to 0.71). None of the 
indices measured predicted clinical response, 6MWT, improvement in QOL or MVO2.  
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The most recent trial involving dyssynchrony markers was that published in 2013. Echo CRT 
(Cardiac Resynchronisation Therapy in Heart Failure with a Narrow QRS Complex) 
examined the previously documented findings of dyssynchrony in patients with QRS 
durations below 120 milliseconds.(105) This represented an area devoid of previous trial 
evidence and hence outside of the guidelines. The investigators recruited 809 patients on the 
basis of symptomatic LVSD (LVEF <35 percent) and narrow QRS durations (<130 
milliseconds). All patients had to satisfy a dyssynchrony assessment comprised of Tissue 
Doppler imaging and/or radial strain rate imaging. All patients underwent CRT-D 
implantation. Patients were then randomised in a 1:1 fashion to CRT-D or ICD only therapy. 
The primary endpoint was a composite of all-cause mortality and HF hospitalisation. The trial 
was stopped prematurely by the data and monitoring safety committee. This was due to the 
number of deaths in the CRT group. There had been 45 deaths in the CRT group and 26 in the 
control group (11.1 percent vs. 6.4 percent; hazard ratio, 1.81; 95 percent CI, 1.11 to 2.93; 
P=0.02). Hence the authors conclude that CRT within this population does not improve 
clinical endpoints and may even cause an increased rate of mortality.  
 
1.8.6 Electrocardiogram 
Due to the results of the previously discussed randomised trials of dyssynchrony - the 12 lead 
electrocardiogram remains the tool by which candidates for CRT are identified.(22) The 
duration of QRS complex and the cut point of 120 milliseconds arise from the previously 
accrued data. However both the QRS duration and the morphology of the bundle branch block 
have been debated in the literature.  
 
The trials covering CRT implantation in narrow QRS durations (Echo-CRT and RethinQ) 
have been discussed in detail elsewhere in this introductory chapter.(97, 105) Both represent 
large randomised controlled trials with negative outcomes and hence the data currently 
supports the guidelines’ position of CRT should only be considered for those patients where 
QRS duration is >120 ms.  
 
It has been documented from substudy analysis of the randomised controlled trial cohorts, that 
the QRS duration on the pre-implantation ECG correlates with improved clinical response and 
outcomes following CRT implantation.(106-108) However outside of a trial environment the 
effect of more prolonged QRS durations in relation to clinical outcomes following CRT 
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implantation was unknown. There have been recent large datasets released by North 
American groups which indicate that a prolonged QRS duration on the ECG prior to 
implantation is an important predictor of clinical outcomes.  
 
The largest and most recent dataset comes from the Medicare ICD registry with data from 
2006-2009.(109) In total 24,169 patients were surveyed and followed up until December 
2011. All patients received CRT-D implants. The cohort was divided on the basis of QRS 
duration and ECG morphology into three groups; LBBB and QRS >150 ms, LBBB and 
QRS<150 ms and non LBBB (Right Bundle Branch Block (RBBB) and non specific 
intraventricular conduction delay (IVCD)). The endpoint was all cause mortality, 
cardiovascular and heart failure related hospitalisation. The lowest rates of death and 
hospitalisation were for those patients with LBBB and broad QRS duration>150ms as 
compared to the other groups (20.9 percent), compared with LBBB and QRS duration of 120 
to 149 ms (26.5 percent; adjusted hazard ratio [HR], 1.30 [99 percent CI, 1.18-1.42]), no 
LBBB and QRS duration of 150 ms or greater (30.7 percent; HR, 1.34 [99 percent CI, 1.20-
1.49]), and no LBBB and QRS duration of 120 to 149 ms (32.3 percent; HR, 1.52 [99 percent 
CI, 1.38-1.67]). Hence a prolonged QRS duration (>150ms) and LBBB are considered to be 
prognosticators. This position has been quoted within the most recent ESC guidance in the 
area.(22) 
 
Left Bundle Branch Block on a surface electrocardiogram may represent heterogeneous 
electrical activity at a myocardial level. From the original experiments by Sir Thomas Lewis 
in the early 1900s, a recognition of the characteristic pattern emerged and the conventional 
diagnostic criteria were agreed on by an expert panel originally convened in the 1940s.(110, 
111) The advent of CRT has led to further investigational work in the area, due to the 
presence of LBBB being a core part of the selection criteria.  
 
LBBB on a surface electrocardiogram has a distinct phenotypic appearance but comprises 
heterogeneous electrical activation of the right and left ventricles. When mapped using 
invasive electrophysiology, a surface LBBB pattern may conceal complex patterns of 
myocardial activation.(112) Due to the patterns of activation, the scientific community 
questioned whether CRT would have an effect in patients with right bundle branch block. 
However this has now been discredited with recent publications, from substudy analysis of 
the randomised trials, meta analyses and recent registry data.  
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Zareba and colleagues released prespecified substudy data from the MADIT-CRT cohort in 
2011.(108)  Using surface morphology as part of clinical response score, the authors 
demonstrated that QRS morphology was one of several factors when combined into a clinical 
score predicted the degree of left ventricular remodelling at one year.  
 
Sipahi and colleagues released a recent meta-analysis covering all trial participants from the 
CARE-HF, COMPANION, RAFT and MADIT CRT trials.(113) This totalled 5, 356 patients 
and again the cohort was analysed on the basis of QRS duration and morphology. Patients 
with LBBB at baseline, had a highly significant reduction in composite adverse clinical events 
with CRT (RR = 0.64 [95 percent CI (0.52-0.77)], P = .00001). However no such benefit was 
observed for patients with non-LBBB conduction abnormalities (RR = 0.97 [95 percent CI 
(0.82-1.15)], P = 0.75). When examined separately, there was no benefit in patients with right 
bundle branch block (RR = 0.91 [95 percent CI (0.69-1.20)], P = 0.49) or non-specific 
intraventricular conduction delay (RR = 1.19 [95 percent CI (0.87-1.63)], P =0.28). When 
directly compared, the difference in effect of CRT between LBBB versus non-LBBB patients 
was highly statistically significant (P = .0001 by heterogeneity analysis). 
 
Bilchick and colleagues analysed data from the Medicare ICD registry for the period 2005-
2006 and published in 2010.(114) Using the original data and merging with clinical outcomes, 
the authors were able to identify, using Cox regressional analysis techniques, significant 
predictors of mortality within the cohort. The cohort totalled 14,946 patients and all patients 
underwent CRT-D implantation. RBBB was a significant predictor of mortality at both 1 year 
and 3 years. (1-year HR, 1.44; 3-year HR, 1.37; P<0.001). The QRS duration in the context of 
RBBB had no effect on the statistical relationship.  
  
1.8.7 Implantation of CRT devices 
The implantation process of CRT has now become standardised with simplified transvenous 
techniques. The principles of aseptic technique, incision location and peripheral venous 
access are derived from basic pacing. Once the chosen mode of access has been cannulated 
(normally cephalic vein or axillary vein) a right atrial lead (if patient is in sinus rhythm, or 
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likely to return to sinus rhythm), right ventricular lead and left ventricular lead are implanted 
under fluoroscopic guidance. 
 
The implantation of the left ventricular lead is not only a crucial part of the process but is also 
under investigation. Currently a coronary sinus (CS) venogram is obtained with hand 
injections of iodinated contrast (5-10mls) at a time and a delayed acquisition obtained to 
identify the main CS body and all tributaries. A left ventricular lead is then advanced into a 
tributary using ‘lead over wire’ technique and implanted and tested for electrical thresholds, 
capture and stability. The positioning of the left ventricular lead is a vitally important part of 
the process as if it is implanted incorrectly there is risk of LV lead displacement, loss of 
capture and diaphragmatic pacing.  
 
Due to the necessity of functioning LV and RV leads, much attention has been paid to LV 
lead design, position and implantation over the last decade. The challenge for an operator 
using conventional CRT systems is to find a satisfactory stable electromechanical position for  
the LV lead. This is dependent on many factors: the operator’s experience level, the CS 
venous anatomy and the lead design itself. Thus currently LV leads are placed anatomically 
with traditional fluoroscopy rather than targeted LV lead placement.  
 
An early trial published by Aurrichio and colleagues in 2001, demonstrated an adverse 
haemodynamic profile for LV pacing when an anterior position was selected.(115) The best 
haemodynamic profile was induced by positioning the LV lead in the postero-lateral area with 
the postulated benefit being the targeting the area of delayed activation. The discussion has 
been whether the LV lead should attempt to target the area of greatest delayed activation or 
target the segment with the greatest amount of dyssynchrony.  
 
A recent substudy from MADIT-CRT, published in 2011 demonstrated in 799 of the trial 
cohort, that an apical LV lead position was associated with an increased risk of HF 
hospitalisation (hazard ratio=1.72; 95 percent confidence interval, 1.09 to 2.71; P=0.019) and 
death.(116) (Hazard ratio=2.91; 95 percent confidence interval, 1.42 to 5.97; P=0.004) An 
alternative substudy from the REVERSE randomised trial documented similar findings with 
LV leads in the apical versus non apical position.(117) The time taken to achieve death or HF 
hospitalisation was quicker in the LV lead apically paced population.(HR 0.27; 95 percent CI 
0.11-0.63; P= 0.001) 
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The explanation for these findings from both groups is that a LV lead positioned at the apex 
may be in close proximity to RV depolarisation from the RV lead and therefore there is not 
much separation between the two areas of depolarisation. Secondly LBBB is associated with 
delayed activation of the lateral and postero-lateral LV wall. Thus by pacing from an apical 
segment, there is the possibility that the area of interest is not being reached by the 
depolarisation of the LV lead and also that it may also be inducing further dyssynchrony.  
 
A further consideration which relates to LV lead position is the positioning in relation to the 
area of latest activation. A tailored approach is dependent on both the operator being able to 
reach such an area of delayed activation and also suitable venous anatomy. Apart from 
selective targeting of the area of maximal dyssynchrony, the other factor which is postulated 
to govern delivery of  LV pacing is the avoidance of myocardial scar or fibrosis.  
 
Khan and colleagues published a randomised controlled trial in 2012, looking at selective LV 
lead placement.(118) The TARGET (Targeted Left Ventricular Lead Placement to Guide 
Cardiac Resynchronization Therapy) study randomised patients to a  conventional CRT 
implant or a speckle tracking two dimensional radial strain guided approach to avoid 
myocardial scar. The LV lead in the active arm was implanted at the latest site of peak 
contraction with an amplitude of >10 percent which indicated absence of scar. The primary 
endpoint was a reduction in LVESV >15 percent with secondary endpoints being clinical 
response, all-cause mortality and combined all-cause mortality and heart failure 
hospitalisation. The targeted CRT implant group had higher rates of LV remodelling at 6 
months (P=0.031) and improved clinical response. (P=0.003)  
 
 Another potential imaging technique to visualise macroscopic myocardial scar is a cardiac 
magnetic resonance study with gadolinium contrast. The delayed phase of such a study would 
represent late gadolinium enhancement (LGE) which represents defects in the myocardial 
extracellular matrix and therefore depending on clinical context may represent myocardial 
scar or fibrosis. These patterns of LGE carry an adverse prognosis in a variety of 
cardiovascular disease states. Little is known about the distribution of myocardial scar and 
application of CRT and particularly LV pacing. Though there is a lack of data within this 
area, intuitively pacing regions of myocardial scar and fibrosis may prevent the delivery of 
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successful pacing, may lead to localised exit block and may even be pro-arrhythmic.(119, 
120) 
 
The data in the area is limited and should be viewed as hypothesis generating. Ypenburg and 
colleagues in 2007 demonstrated in 34 patients with severe LVSD with prior ischaemic heart 
disease, that large amounts of late gadolinium enhancement, when treated as a dichotomous 
variable, was associated with a failure to undergo LV remodelling. (P<0.05)(121)  
 
The data acquisition from a CMR study is currently done ‘offline’ i.e. separate to the catheter 
laboratory, and the data therefore is not accessible to the current methods of fluoroscopic 
guided CRT implantation. Duckett and colleagues published a pilot study in 20 patients 
undergoing CRT implantation with CMR enhanced fluoroscopy in 2011. (122) Using a 
conventional fluoroscopy image in the catheter laboratory, regions of CMR measured 
dyssynchrony were overlaid with different colour schemes to indicate areas of maximal 
dyssynchrony. At six months 92 percent of the cohort paced with a CMR assisted protocol 
had developed significant reduction in LV volumes as compared to the control group. 
(P=0.04) 
 
The principle issue which underpins all further attempts at LV lead position is coronary 
venous anatomy. Despite the possibility of tailoring the LV lead position to target areas of 
dysynchrony, the operator is limited by the anatomy. A couple of methods have been 
suggested: firstly multisite pacing has been investigated in small numbers. It has been 
demonstrated to be successful in pilot studies on acute haemodynamics but needs larger 
amounts of data before proceeding to a randomised controlled trial. The alternative, which 
started off as a research prospect but is now clinically established, is a multi-polar LV lead. St 
Jude Corporation (St. Paul, Minnesota, US) and Medtronic Inc (Minneapolis, Minnesota, US) 
have released quadripolar leads onto the market and these can permit a much larger number of 
configurations via vectors than normal unipolar or bipolar LV leads. 
 
1.8.8 Optimisation 
Following successful CRT implantation there has been much focus on the process of 
‘optimisation’ or more specifically device based optimisation. This is the adjustment of 
atrioventricular and ventriculo-ventricular delay under some method of assessing 
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haemodynamics which results in the optimal AV and VV delay to ensure optimal left 
ventricular filling. Though the process of device based optimisation has had numerous studies 
published within the area it remains an area of contention and hence in the most recent ESC 
guidance it is now reserved for those patients who fail to respond following CRT 
implantation.(22) One other area of ‘optimisation’ which is lacking in terms of data and 
evidence is the medical optimisation of such patients - this is the process of uptitrating and 
initiating evidence based pharmacotherapies. The two facets of optimisation are not mutually 
exclusive and the recent consensus document issued by the European Heart Rhythm 
Association and the Heart Rhythm Society US suggests that both should be taking place 
simultaneously.(99) 
 
1.8.9 Device Based Optimisation 
Device based optimisation should be considered as a separate entity to medical optimisation 
and is the adjustment of the AV and VV intervals for maximal haemodynamic benefit, 
improvement in cardiac output, reduction in pre-systolic mitral regurgitation and optimal left 
ventricular filling.(22) The process of device optimisation may of course indirectly influence 
and aid the uptitration of medical therapies by improving cardiac performance, work and 
indirectly systolic blood pressure.  The field of device optimisation is associated with a high 
level of debate due to the fact that prior literature is inconsistent and that no definitive longer 
term association has been proved for clinical outcomes. Several potential techniques and 
methods have been investigated but the lack of consistent findings means the current position 
in the recent joint Consensus statement released from a panel of US and European experts 
states that it should be reserved for patients not experiencing the desired clinical benefit 
following CRT implantation.(99) This viewpoint is further supported by the recent ESC 
guidelines in the area, published this year which state a similar role for device based 
optimisation.(22) 
 
The historical basis for optimisation of intervals within CRT devices comes from experience 
within dual chamber pacing systems and the large randomised clinical trials of CRT which 
have been previously described.  
 
The original studies using dual chamber pacemakers in heart failure published in the 1990s 
have been summarised and discussed above. Though performed with earlier generations of 
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pacing systems, they did possess the ability to have an adjusted AV delay via programming. 
Brecker and colleagues investigated this in 1992, and found that in a population of patients 
with dilated cardiomyopathy, the best haemodynamic profile was induced by a much 
shortened AV delay as compared to manufacturer settings.(88) There were significant 
reductions in pre systolic mitral and tricuspid regurgitation.  
 
Other groups investigated this relationship around this timepoint. Hayes and colleagues 
analysed these findings using invasive catheters which generated pressure volume loops.(123) 
Taking two groups of patients with severe LVSD but differing degrees of conduction delay 
the authors were able to demonstrate in those who had conduction abnormalities (PR interval 
>200ms on surface electrocardiogram) that cardiac output was increased with adjustment of 
the AV delay. However in the seven individuals with normal surface electrocardiograms, 
variation in AV delay resulted in a deterioration in cardiac output. 
 
The non-uniform findings behind AV delay optimisation in basic pacing was further 
complicated by work by Mehta and colleagues, published in 1989 who demonstrated in a 
pacing dependent population (n=9) with preserved LV systolic function that the optimal AV 
delay at rest of 140 to 150 milliseconds was reduced on exercise with an optimal AV delay of 
75-80ms.(124) The field was divided as to whether device based optimisation would be 
something beyond a research interest.  
 
The first generations of CRT devices had fixed AV delays which were preset by the 
manufacturer with no option of varying the AV delay via programming. As time progressed, 
further generations of CRT devices began to have the ability of variable AV delays and 
eventually VV delays. These second generation CRT devices were the ones tested within the 
large randomised controlled trials. The most recent studies from the era 2000 to 2005 
incorporated device based optimisation within them and it is this start point which led to their 
inclusion within guidelines on CRT. The two studies focused on mortality and clinical 
endpoints, (CARE-HF published in 2005)(6) and COMPANION in 2004(5)) both had device 
optimisation protocols embedded within the trial structure. CARE-HF had echocardiographic 
optimisation of the AV delay using Doppler traces of the transmitral flow with the optimal 
AV delay in the study being the one with greatest E and A wave separation. COMPANION 
contained different methodology using a device based algorithm which automatically 
 77 
calculated optimal AV delay from intrinsic PR interval, intrinsic QRS duration and the intra-
cardiac AV interval at time of implantation.  
 
These methods and the positive results of the trials led to the inclusion of device based 
optimisation within the contemporary ESC guidelines of the time.(125) However as the field 
has expanded, and with more publications and data, the viewpoint on device based 
optimisation has become divided. Some groups view it as an essential part of the overall CRT 
care process whereas others view it as an inappropriate technique with misallocation of 
healthcare resources. The consensus document issued jointly by an intercontinental panel of 
experts in 2012, suggests that AV and VV optimisation may be considered and certainly 
should be offered to patients who fail to respond following CRT implantation.(99) The major 
difficulties in offering clear guidelines in the area is the differences in available techniques, 
the publication of small datasets predominately from centres with non-randomised studies and 
the lack of longer term clinical data on patients who have undergone device based 
optimisation.  
 
The rest of this section will discuss each potential methodology of performing device based 
optimisation.  
 
1.8.10 Algorithms for CRT device AV and VV delay optimisation 
As technology has progressed, CRT leads and generators have become more sophisticated 
with potential ability to offer remote monitoring, intra-thoracic impedance measurement and 
measures of volume status. In conjunction with these, all major manufacturers have 
considered whether a dedicated device incorporated algorithm would improve the process of 
optimisation. The rationale being that due to constant beat to beat monitoring via atrial and 
ventricular leads, the CRT device would be able to use intrinsic and paced delays to self-
adjust AV and VV delays to improve a preset cardiac haemodynamic variable.  
 
These algorithms have been tested in large randomised studies which thus far have not shown 
any significant superiority over other methods of optimisation.  
 
 78 
The SMART-AV (The SmartDelay Determined AV Optimization: A Comparison to Other 
AV Delay Methods Used in Cardiac Resynchronization Therapy) Study was the first 
algorithmic based clinical trial to publish in 2010.(126) The study recruited a cohort of 1014 
patients and randomised them to one of three arms following implantation with a CRT-D 
device. The population fulfilled modern criteria for CRT implantation and were randomised 
to either a fixed AV delay of 120 ms, SMART-AV™ delay optimisation or an 
echocardiographic guided optimisation using the iterative technique and transmitral Doppler 
flows. The SMART AV delay was a programme based on detection of paced and intrinsic AV 
delays and resulting self-adjustment.  The primary end point was a change in left ventricular 
end systolic volume. The usual collection of secondary endpoints comprising NYHA class, 
quality of life scores and 6MWT test distance were used within the study. The findings 
demonstrated no statistical significance between any of the three arms (SMART AV delay as 
compared to echocardiography P=0.52 and fixed delay P=0.66) in terms of left ventricular 
volume changes. The follow up period ran for six months following enrolment into the study. 
There was also no positive effect on any of the secondary endpoints.  
 
Alternative studies have been performed or are underway from rival manufacturers and 
different algorithms to investigate the area, further. The FREEDOM (Frequent Optimization 
Study Using the QuickOpt Method) study was performed using the Quick Opt algorithm from 
St Jude.(127) Again a large number of patients (n=1580 patients) were recruited into the study 
and randomised either to a one off echocardiographic optimisation following CRT 
implantation or algorithmic optimisation 'QuickOpt™'. Further attempts at echocardiography 
guided optimisation could be considered but were completely up to the investigator on site. If 
the patient whilst in this arm had symptomatic deterioration the trial structure encouraged a 
review and further attempt at optimisation of the AV and VV intervals. The other group were 
subjected to algorithm guided frequent optimisation of AV and VV intervals. The primary and 
secondary endpoints were clinical and focussed on clinical response, all-cause mortality and 
hospitalisation with heart failure. The trial completed recruitment in 2010 but thus far there 
has been no publication of data. Both Quick Opt and Smart AV relied on intra-cardiac 
electrocardiograms to calculate the optimal AV and VV delays. 
 
Sorin had a different algorithm, the SonR™ algorithm which works by calculating myocardial 
contractility from VV delay and then finding the ideal AV delay from the figures derived 
from the above, the process being termed peak endocardial acceleration. SonR was then tested 
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in the pilot randomised trial, the CLEAR (Clinical evaluation on advanced resynchronisation) 
study which evaluated its performance as compared to traditional echocardiographic guided 
optimisation.(128) Slightly differently as compared to other modern CRT trials, the steering 
group decided on inclusion criteria which replicated those of CARE-HF.(6) This was a more 
severe group of patients with NYHA III/IV heart failure with QRS durations above 120 ms 
(and evidence of mechanical dyssynchrony if in the 120-149 ms bracket - using echo 
measures as per CARE-HF protocol). The primary endpoint was a clinical composite made up 
of improvement in NYHA class, quality of life, HF hospitalisations and all-cause mortality. A 
total of 238 patients were recruited and randomised to frequent device based optimisation or 
conventional echocardiographic measurement on a 1:1 basis. Each patient was followed up 
for one year and the SonR optimised group had significant improvement in functional class 
(P=0.002) and which drove a significant improvement in the primary endpoint as compared to 
those with conventional optimisation. (P=0.03) 
 
The most recent data was published from the Adaptive-CRT study in 2012.(129) This was a 
study designed to evaluate the Medtronic Adaptive™ algorithm which offered dynamic 
ambulatory optimisation of AV and VV intervals. The trial was designed as a non-inferiority 
trial. A total of 522 patients were randomised in a 2:1 fashion to the Adaptive optimisation 
versus conventional echocardiographic optimisation. Patients were reviewed at one, three and 
six months following enrolment. The study successfully proved on the non-inferiority basis 
that the proportion of clinical improvement between the two arms was the same. (73.6 per 
cent vs 72.5 percent, with a non-inferiority margin of 12 percent; P = .0007). Evaluating the 
haemodynamic profiles using measured aortic velocity time integral between the two groups 
demonstrated high rates of correlation. (Concordance correlation coefficient = 0.93; 95 
percent confidence interval 0.91-0.94) and at 6-month post randomisation (Concordance 
correlation coefficient = 0.90; 95 percent confidence interval 0.87-0.92). There were no 
significant differences between the arms with respect to heart failure events or ventricular 
arrhythmia episodes.  
 
 The DECREASE-HF (The Device Evaluation of CONTAK RENEWAL 2 and EASYTRAK 
2: Assessment of Safety and Effectiveness in Heart Failure) study was a study focused on VV 
optimisation via a device based algorithm.(130)  The Expert-Ease™ algorithm was based on 
the measurement of intrinsic VV interval with data derived from the PATH-CHF studies.(92) 
The trial randomised 306 patients in a 1:1:1 fashion to sequential and simultaneous 
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biventricular pacing and left ventricular pacing only. Echocardiography was performed at 
baseline, 3 and 6 months. There were uniform reductions in LV end systolic and diastolic 
dimensions. (P<0.001). The simultaneous VV pacing group had the greatest reduction in LV 
end systolic dimensions (P<0.007). Stroke volume and ejection fraction improved in all three 
groups. (P<0.001). 
 
1.8.11 Echocardiography Guided Optimisation 
The most widespread and established technique of device based optimisation are those 
derived from transthoracic echocardiography. The ease of access to transthoracic 
echocardiography and its portability and ability to measure haemodynamics quickly have all 
meant that the first optimisation studies were based on this methodology. Amongst the 
echocardiographic literature there is data which supports AV and VV optimisation, with the 
majority of the data being devoted to AV delay adjustment. As previously discussed the 
subject of AV delay was first investigated using dual chamber pacing in heart failure 
populations and once CRT was clinically established, further studies were performed within 
this area.  
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Figure 8: Demonstrate the effect of shortened and prolonged atrioventricular delay on ventricular filling.  
 
It is reported that atrial contraction contributes 20-30% of stroke volume at rest, which may 
increase on exercise.(131) A prolonged AV delay would result in late ventricular contraction 
and interrupted diastole with impaired ventricular filling. (See Figure 8) This is further 
compounded by the presence of pre-systolic mitral regurgitation. Correct AV programming 
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can abolish diastolic MR and improve the timing of the cardiac cycle to further enhance left 
ventricular filling.  
 
A shortened AV delay causes early ventricular contraction and premature onset of ventricular 
contraction and early mitral valve closure. This also may have negative effects in ventricular 
filling times. Therefore the role of optimisation is to ensure maximal E and A wave separation 
and to complete diastolic filling prior to the onset of ventricular contraction. 
 
The criticisms of echocardiographic optimisation are several. Firstly the historical basis on 
which optimisation was founded was based on small single centre studies, which were often 
not randomised and had limited follow up periods.(131-133) The range of echocardiographic 
techniques means that direct comparison of different studies and data are difficult. The other 
area of difficulty is that the majority of studies did not contain a control group in whom a 
fixed AV interval was delivered. Without such control groups it is hard to characterise the 
effect of AV and VV delay adjustment on endpoints. Another major limitation of optimisation 
is that most previous studies have optimised a patient whilst lying on the couch at rest. This 
may not be ideal for younger, fitter patients and does not necessarily replicate the findings re 
AV delay on exercise. Due to these limitations, the field is still widely debated and further 
work is ongoing in the area.  
 
A number of transthoracic echo techniques exist, the major ones will be discussed below but 
others do exist albeit in smaller studies with limited data.  
 
The Ritter method is based on methods derived from the early experience with regards to AV 
delay adjustment in dual chamber pacing in heart failure.(134) A long AV delay and very 
short AV delay are programmed and the optimal AV duration identified by the application of 
a complex equation. Due to the calculation of the optimal A wave without testing serial 
measurements it gives a result quicker than the iterative technique. The technique has not 
been tested in a large study and when compared to other techniques in a cohort of 28 patients 
was least likely to predict the optimal AV delay as compared to invasive haemodynamic 
monitoring.(135) 
 
The mitral valve inflow velocity time integral equates to the left ventricular filling volume, 
providing the mitral valve has a constant area. The AV delay in this technique is tested at 
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multiple intervals to ascertain the delay which correlates with the maximal mitral valve inflow 
VTI. In a small prospective study of 40 patients undergoing CRT, aortic and transmitral VTI 
were increased by either method. There was no correlation between the two methods 
(r=0.03).(136) 
 
The iterative method uses pulse wave Doppler through the mitral valve. The filling time is 
measured from the start of the E wave until the end of the A wave. A long AV delay is 
programmed and altered in 20 ms increments until the physician observes truncation of the A 
wave.  Once this is observed the AV delay is increased in 10 ms intervals until no truncation 
of the A wave is observed.(131) 
 
A recent study by Shanmugam and colleagues, published in 2013 investigated the effect of 
iterative optimisation on left ventricular end systolic volumes and also B type natriuretic 
peptide levels.(137) Using the Iterative method and a cohort of 72 patients, the authors 
demonstrated a marked improvement in NT-proBNP levels one week following optimisation. 
(P=0.00001). On further analysis of the cohort, which was divided into two groups - (Group I 
- no change in implant settings & Group II - A change in implant settings) it was found that 
the greatest reduction in circulating NT-proBNP levels was in the non-responder population 
(defined as those patients who demonstrated a <15 percent reduction in LV end systolic 
volumes). Seventy-three per cent of non-responders demonstrated a fall of 474 pg/mL in NT-
proBNP post-AV optimisation. These results support a positive haemodynamic effect but the 
longer term clinical progress for such patients is unknown.  
 
The longer term effects of echocardiography guided AV optimisation are mostly unknown. 
There is very limited data in this area. A retrospective observational study has previously 
been performed by a group from the Cleveland Clinic which published in 2006.(138) Using a 
series of patients who had undergone CRT implantation between 1999 and 2003, those who 
had received AV delay optimisation were compared to those who had not. AV delay 
optimisation was performed within thirty days of CRT implantation Though the optimal AV 
delay was different to the manufacturer preset interval (P=0.0001) there was a longer term 
effect over the mean follow up period of 23 months on NYHA class and LVEF. However 
what is unknown from the results of the study is what happened to the other 285 patients in 
whom CRT was implanted at the institution over the same time period. Therefore without the 
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results of a control group it is unknown as to whether the acute effects of the optimisation 
translated into longer term clinical benefit.  
 
These three techniques are the major three techniques either incorporated into the randomised 
controlled trials or supported within the guidelines. Other echocardiographic techniques do 
exist for AV delay optimisation but with lesser degrees of data, and hence have not been 
discussed.  
 
The predominant clinical and research focus in echocardiographic optimisation studies has 
been on atrioventricular delay - however there have been a few studies performed looking at 
ventriculo-ventricular delay. This period correlates with the delay in ventricular 
depolarisation and systole between right and left ventricles. CRT offers the possibility of 
restoring atrio-ventricular pacing but also synchronous biventricular pacing. However 
whereas the role of AV delay optimisation has been evaluated in historical cohorts with basic 
pacing and such methodology incorporated into clinical trials, VV delay adjustment has not 
been studied in either context.  
 
Again the main methods which have been studied have been echocardiographic. Other 
potential methods do exist and are described elsewhere in this introductory chapter. By using 
Pulsed wave Doppler at the level below the aortic valve cusps gives the left ventricular 
outflow tract velocity time integral (LVOT VTI). By multiplying this number against the 
cross sectional surface area it is possible to calculate stroke volume. Some small pilot studies 
which were non randomised and contained small numbers of patients have been 
performed.(139-141) 
 
The InSync III study investigated the role of VV optimisation in a larger trial format, and 
reported in 2005.(139) Using InSync III devices, it investigated whether VV optimisation 
resulted in improved functional and haemodynamic variables. A series of 422 patients was 
enrolled into a non-randomised prospective study with all participants followed up for six 
months. The results for this study were compared to the control group from the MIRACLE 
trial.  
 
InSync III patients experienced greater improvement in 6MWT, NYHA functional class, and 
QoL at six months compared to control (all P< 0.0001). Optimization of the sequential pacing 
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increased (median 7.3 percent) stroke volume in 77 percent of patients. Though there was an 
improvement in stroke volume in the optimised cohort there were no changes in functional 
status or QOL.  
 
Another clinical trial performed within the area has been the Rhythm ICD II trial (The 
Resynchronization for the HemodYnamic Treatment for Heart Failure Management II 
implantable cardioverter defibrillator study).(142) A total of 121 patients were recruited and 
randomised in a 1:3 ratio to simultaneous biventricular pacing or optimised biventricular 
pacing. All patients had CRT-D systems implanted and trial was performed as a prospective 
randomised study with the endpoints of NYHA class, 6 MWT distance and improvement in 
QOL. There was no difference between the two groups in any endpoint (p=non-significant for 
all endpoints).  
 
1.8.12 Invasive Optimisation 
Some of the initial CRT studies used invasive methods of CRT optimisation. By using on 
table catheters which could measure intra-cardiac pressures, the investigator is able to 
generate values for myocardial work. These can then be analysed to give the invasive dP/dt 
which reflects myocardial contractility but may be influenced by preload, afterload and heart 
rate. The PATH-CHF studies used this methodology to optimise CRT devices.(92) The 
benefits of this technique being a direct measure of intra-cardiac haemodynamics and can be 
performed as part of the implant procedure. 
 
However the invasive nature means that the clinical use of such techniques is limited due to 
the added risk of performing measurements and also prolonging the implantation time. Since 
the publication of the initial studies as described above, there have been some small single 
centre studies with limited numbers of patients with no longer term outcome data.(143, 144)  
From a clinical perspective such techniques currently remain impractical and research 
orientated.  
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1.8.13 Impedance Cardiography 
Impedance Cardiography is the non-invasive method of deriving cardiac haemodynamic 
measurement by the application of a small amount of pulsed alternating current through the 
surface electrodes (conventionally four electrodes). Electrical current seeks the path of least 
resistance and hence will travel through the blood filled aorta. Beat to beat variation exists 
and the technology measures a series of consecutive beats to give an averaged result.(132) 
 
Early studies demonstrated some efficacy on early endpoints such as NYHA and LVEF.(145) 
Bioreactance measurement is a derivative of ICG. Bioreactance systems calculate CO by 
measuring real-time changes in the phase of the received voltage signal relative to the applied 
current signal. Thus rather than using the absolute values the technology relies on the phase 
shift i.e. the rate of change of electrical resistance and inductive properties.  
 
There are several ICG and bioreactance systems available commercially but fundamentally all 
operate on the basis discussed above.  
 
Khan and colleagues, in 2009, firstly documented the efficacy of the NICOM device 
(Bioreactance measurement) in the optimisation of CRT recipients.(145) Using a series of 47 
patients and a primary endpoint of reduction in left ventricular end systolic volume (LVESV) 
by >15 percent, the group were able to establish the effectiveness of the equipment. In all 
patients, cardiac output (CO) increased significantly at optimized settings compared with 
baseline (5.66 ± 1.4 vs. 4.35 ± 1.1 L/min, P < 0.001). Importantly the reproducibility of 
measures derived from NICOM correlated well with transthoracic echocardiography for both 
AV and VV delays. 40 of 47 patients (85%, r = 0.89, P < 0.01) and for VV delay in 39 of 47 
patients (83 percent, r = 0.89, P < 0.01). 
 
Having established reproducibility and repeatability of the technique- the same group then 
investigated the effects of such NICOM based optimisation on AV and VV delays in a 
prospective study.(146) The results of this study were published in 2011. A total of 203 
patients were randomised to fixed standard settings (n=54 (AV delay=120ms, VV delay =0 
ms) or NICOM based optimisation. All were followed up for six months following enrolment 
and measured endpoints were LVEF, NYHA and 6 MWT.  After six months the optimisation 
group had improved QOL (35 ± 18 vs 42 ± 20, P = 0.045) and NYHA class (2.1 ± 0.8 vs 2.4 
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± 0.8, P = 0.048) which correlated with improvements in left ventricular end systolic volumes 
and ejection fraction (108 ± 51 vs 126 ± 60 mL, P = 0.048) and (30 ± 7 vs 27 ± 8, P = 0.01) 
respectively.  However there was no difference between the groups in 6MWT test distance. 
(P=0.81) 
 
1.8.14 Finger Photoplethysmography 
A conventional pulse oximeter uses a photo detector to detect arterial pulsation. From these 
recordings it is possible to deduce systolic blood pressure, pulse pressure and mean arterial 
pressure. The use of this technique is aided by its high degree of reproducibility and 
portability. However the waveforms are limited by peripheral arterial system and autonomic 
tone affecting the peripheral vascular resistance.  
 
It has been shown to be highly reproducible with positive effects documented on acute 
haemodynamics.(147) Again longer term clinical data has not been published using this 
technique.  
 
1.8.15 Overview  
The varieties of techniques presented within this section suffer from similar limitations. Early 
work has documented acute effects on haemodynamics with positive effects on systolic blood 
pressure, stroke volume and cardiac output. However the longer term effects on the whole are 
unknown. One area of optimisation which has been explored in large numbers with 
randomised trials has been algorithmic based optimisation. The data that has been published 
from these trials to date has been disappointing with no longer term effects documented on 
clinical endpoints. However the field contains several smaller, single centre studies using 
variety of techniques and follow up periods. The heterogeneous literature makes direct 
comparison difficult and only allows limited conclusions to be made.  
 
The limitations of the field have been heavily discussed in recent document issued by the 
ESC, EHRA and HRS.(99) The joint consensus document published in 2012 suggests a 
cautious approach to device optimisation with the process being reserved for those patients 
deemed non-responders. The ESC guidelines published this year, 2013, go further and suggest 
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routine device based optimisation should not be performed but due to the evidence accrued 
from the studies described above, device optimisation should be considered for those with 
pre-existent ischaemic heart disease, those patients who fail to derive clinical benefit 
following CRT implantation and those who receive inadequate degrees of atrio-biventricular 
pacing.(22) 
 
1.8.16  Medical Optimisation 
The process of uptitrating and initiating evidence based pharmacotherapies following CRT for 
the purposes of this thesis will be referred to as medical optimisation. There are two major 
issues which surround this option but both lack data. Firstly the question of what is the best 
model to facilitate medical optimisation is unanswered; there is limited American evidence 
for such specialised clinics but little from the European literature. Secondly the comment with 
regards to medical optimisation is whether it is feasible and more importantly translates into 
improved clinical outcomes and higher rates of symptomatic benefit for the patient.  
 
1.8.17 Optimisation Clinics 
The process of ‘optimisation’ may be carried out in dedicated heart failure pacing clinics. 
However the data available to support the creation and maintenance of such a service is 
limited. Generally throughout the western world there are multiple different models of 
healthcare for patients undergoing CRT implantation, partly this relies on financial 
reimbursement, structure of the overall health service and ownership of the patient between 
primary, secondary and possibly tertiary care. Hence it is not uncommon for an interventional 
electrophysiologist to implant CRT and to hand back the patient’s ongoing care to a general 
physician, cardiologist or primary care practitioner. This model of healthcare is the status quo 
in many parts of the United Kingdom and Western Europe. What is currently unknown with 
this ad hoc pattern of service is what is happening to the patients following discharge and 
what is happening to their medical therapies. There is a real need for such data and the 
existing registry data from Britain, Europe and the US does not cover this period.  
 
The only  limited information that reflects on current healthcare models is the extended follow 
up data released from the European CRT Survey.(148) A total of 2111 patients were tracked 
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for one year (range of follow up 9 to 15 months) out of the original cohort of 2438 patients 
(87 percent). The data demonstrates significant rates of morbidity with 346 (16 percent) 
patients being hospitalised for HF over this time period and 207 (10 percent) patients dying. 
When looking at the characteristics of the patients who suffered clinical events (death or HF 
hospitalisation) there are significant differences in the levels of beta blocker use (p<0.0001) 
and a trend toward significance in angiotensin II receptor blockade (p=0.08). The data is not 
sufficiently detailed to investigate this relationship further. The patients who suffered clinical 
events may have had efforts to uptitrate or commence beta blockade but this information is 
lacking within the dataset. Nevertheless the difference between the two groups is striking and 
on absolute numbers, statistically significant.  
 
Dedicated heart failure pacing clinics have been suggested more recently but the data which 
supports their existence has not been forthcoming. The necessary data is predominately 
American which reflects a different healthcare infrastructure and system. The first publication 
in the field was by Mullens and colleagues who described the initial experience of 75 patients 
following CRT implantation assessed in a structured clinical protocol format at the Cleveland 
Clinic, USA, published in 2009.(149) The protocol involved a heart failure physician, a heart 
failure specialist nurse, physiologist, echocardiographer and electrophysiologist (i.e. heart 
failure and device multidisciplinary team). In this group of patients who were not deriving the 
anticipated clinical benefit, a range of findings were documented: inadequate device settings 
(47 percent), suboptimal medical treatment (32 percent), arrhythmias (32 percent), and 
inappropriate lead position (21 percent). The majority of the patients were also uptitrated or 
initiated on evidence based pharmacotherapy (74 percent) and hence were on suboptimal 
medical therapy at the time of clinic attendance.  
 
More recently there has been a publication from the group at Massachusetts General, Boston, 
USA published in 2012.(150) Here patients following CRT implantation were randomised to 
conventional care or a structured clinical protocol. The study consisted of 254 patients 
randomised to the clinical protocol arm and 173 patients in the conventional care arm. 
Patients were comparable in clinical characteristics and were reviewed by the 
multidisciplinary team at 1,3, and 6 months following CRT implantation. The patients' 
outcomes were then measured over the following two years with a primary endpoint of heart 
failure hospitalization, cardiac transplantation, or all-cause mortality. The event-free survival 
was significantly higher in the clinical protocol group versus the traditional care (P = 0.0015). 
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A significant reduction in clinical events was noted between those patients randomised to 
more intensive monitoring and intervention by the multidisciplinary team. (hazard ratio: 0.62, 
95 percent CI: 0.46-0.83, P = 0.001). 
 
1.8.18 Medical Therapy Following CRT Implantation 
The period following CRT implantation may be characterised by an increased systolic blood 
pressure, the removal of bradycardia and, potentially, an improvement in the glomerular 
filtration rate.(22) All of these beneficial aspects mean that there is a window of opportunity 
to review HF medication. Hence the time period following CRT implantation may lead to 
increased doses of proven prognostically beneficial neurohormonal antagonists. 
 
However, this period has not been adequately studied and there is limited data in this area.  
One group of drugs in particular that may be started following CRT implantation is beta 
adrenoceptor antagonists. This is due to the removal of the risk of bradycardia as a side effect 
and potential reason for the discontinuation for the drug. A study which focussed on beta 
blocker doses following CRT implantation was the CARIBE-HF trial (Beta blocker in 
advanced heart failure trial) published by Grosu and colleagues in 2011.(151)  Using a 
prospective observational study design, 106 patients were identified and had their dose of 
carvedilol uptitrated towards target dose. This was Phase I of the study. Those then eligible 
for CRT based on standard selection criteria had CRT implanted. Following a second phase of 
the study the carvedilol dose was higher in the CRT group than the non CRT group.(+20.0 +/- 
19.8 mg vs. -0.3 +/- 20.5 mg; P = 0.015). These changes were also associated with an 
improvement in NYHA class and LVEF. (P=0.011 and P=0.018 respectively).  
However the actual numbers of patients in the CRT and non CRT groups were extremely 
small by the end of the seven year follow up period. This is a recurrent theme in the available 
data and needs to be investigated with a larger dataset.  
 
Another group from Cardiff, Wales also documented significant improvements in 74 patients 
undergoing CRT implantation.(152) The group followed up such patients in a nurse led 
medical optimisation clinic and found that in the six months following CRT implantation 
there was a significant improvement in beta blocker dose and use. (P<0.01) and similar 
findings were demonstrated with ACE inhibitors. (P=0.02)  
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The scientific consensus is that uptitration and initiation of evidence based pharmacotherapies 
following CRT should translate into improved clinical outcomes. However again there is a 
lack of appropriate data to investigate this relationship. Adlbrecht and colleagues published 
on this subject in 2009.(153) Using a retrospective observational study design the authors 
described the progress of a cohort who had undergone CRT-P or CRT-D implantation. 
Following a mean duration of follow up of 16.8+/-12.4 months, there were 83 patients who 
suffered events (death or heart failure related hospitalisation). Sub optimal heart failure 
medical therapy following Cox regressional analysis was a significant predictor of adverse 
clinical outcomes (For CRT-P (HR = 2.080 (1.166-3.710), P = 0.013 and for CRT-D (HR = 
2.504 (1.550-4.045), P < 0.001)).  
 
Hence limited data exists within the area, but, when directly compared to other areas of 
clinical research allied to cardiac resynchronisation therapy, there is a significant lack of 
published data and investigation and further work is much needed in this area.  
 
1.9 Response 
 
The clinical effectiveness of cardiac resynchronisation therapy has been previously 
documented in the large randomised clinical trials.(5, 6) However, when CRT became 
established as a clinically available therapeutic option, it was soon recognised that some 
patients derived clinical benefit and some did not. This dichotomy has been labelled as 
response.  
 
The origins of the term are unknown, it is unclear from the literature but as soon as the first 
randomised controlled trials were published, editorials from leading experts in the field 
included the term. A small clinical trial was published by Haissaguerre and colleagues in 
2002 which specifically investigated the issue of response after CRT implantation.(154) A 
cohort of 102 patients receiving second generation CRT devices was followed up for a year. 
Response within the study was defined as improvement in NYHA class at one year. The non-
responder rate within the cohort was 18 percent (n=18). According to the small dataset the 
predictors of the response endpoint were prior history of ischaemic heart disease, minimal 
mitral regurgitation and low cardiac output. 
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Following this initial work, the term has become widely accepted. The limitation of the term 
is that it is felt to represent the clinical improvement a patient may have following CRT 
implantation. Heart failure is a complex clinical syndrome with many potential methods of 
assessing endpoints within such patients. Previously used endpoints have included functional 
(NYHA classification, 6MWT distance, MVO2), symptomatic (QOL scores) and mechanical 
(LVEF, End diastolic and systolic diameters and end systolic volumes). The problem with 
response as a term is the lack of consensus either in the guidance or scientific literature. In the 
absence of an agreed definition, discussion and comparison of published literature is difficult.  
 
The term ‘response’ also induces other problems. Firstly, by using a cut point, it can be 
viewed as a dichotomous variable and therefore patients fall into a response or non-response 
category. However when it comes to symptomatic improvement, the clinical effect may be 
subtle and hence incorrectly labeled as non-response. With certain heart failure 
characteristics, it may be that CRT induces a graded response and hence should not be viewed 
as a categorical variable.  
 
Another issue is that the application of CRT to a patient in heart failure may modify the 
natural course of the disease but this is unknown in contemporary heart failure care. The large 
randomised controlled trials recruited patients from an era of evolving evidence for optimal 
heart failure pharmacological treatment. Hence the quantitative effect of CRT as compared to 
modern HF therapy is unknown. It is also now unethical to deny CRT to a population who 
qualify for it in order to carry out a longitudinal epidemiological study to document the 
natural history of a directly comparable population with and without CRT. 
 
The implantation of a CRT device is also a minimally invasive procedure which takes 
between one and two hours. However, due to the emphasis of patient selection, patients may 
experience a placebo effect following CRT implantation similar to other medical procedures. 
To date there has been no data in this area which has analysed this.  
 
The actions of CRT have been previously documented. However,  little is known in terms of 
exact cellular and sub cellular mechanisms of action. This may differ according to different 
aetiologies of left ventricular systolic dysfunction. Though poorly characterised, sub study 
analysis from previous randomised controlled trials has demonstrated increased levels of 
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remodelling in non ischaemic dilated cardiomyopathy.(22) Again this raises the possibility 
that CRT is exerting a different effect in different populations.  
 
Initially, CRT was implanted into patients with severe symptoms and marked limitation of 
functional capacity. However it is now advocated for patients with milder forms of disease, 
due to the publication of successful randomised trials in such cohorts.(96) The two groups of 
patients may view response differently, with patients with marked severe symptoms expecting 
a reduction in their symptoms; whereas patients with milder symptoms may expect a 
reduction in hospitalisation and mortality. Apart from patients, the attendant cardiologist or 
electrophysiologist may also share such viewpoints.  
 
Lastly, response, though a heavily debated topic within the field, needs urgent clarification. It 
is only when a consensual definition has been agreed on and released that accurate scientific 
investigation may occur. Though now an established term, response as a concept is not used 
as a marker of clinical benefit in other treatments e.g. medical therapy. Therefore response 
has become a subject of great interest. By dividing populations who undergo CRT into a 
responder and non-responder group, the question arises as to what should be done for such 
non-responding individuals. Current ESC guidance suggests they should be carefully 
reevaluated with a process of device and medical optimisation, review of programming and 
the addressing of co-morbidities.(99) The suggested location for such care to occur is a 
dedicated specialised multidisciplinary clinic.  
 
Limited data does exist for such clinical structure but comes from North America and has 
been presented and discussed elsewhere in the introduction. Hence the increasing numbers of 
patients who fail to derive the anticipated clinical benefit still need further investigation. The 
processes of device optimisation and medical optimisation have little published data and it is 
this subject which has formed the basis of this thesis. The recognition of this pool of patients 
means that appropriate healthcare infrastructure should be created to allow a systematic 
examination of any potential causes of ‘non-response’.  
 
The endpoints most often used to adjudicate on response are those allied to reverse 
remodelling, e.g. LVEF or left ventricular end systolic volumes. Others endpoints have 
focussed on more functional assessments e.g. NYHA class improvement. Whichever is the 
chosen endpoint on which to base improvement leads to different quoted rates of response. A 
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non- response rate of 20-30 percent is often quoted but when using symptomatic endpoints 
may be more like 40-50 percent. Though a variety of endpoints exist, the most discussed are 
those relating to left ventricular volumes and NYHA improvement.  
 
1.9.1 LV Remodelling - ‘reverse’ remodelling 
The effect of CRT on reverse remodelling has been documented in several studies. The rate 
varies from study to study depending on endpoints. The major questions when using reverse 
remodelling as a marker of response are whether it correlates with clinical improvement, 
whether it is persistent and if observed then whether it is an indicator of longer term clinical 
course and prognosis.  
 
An early study which demonstrated the potential for LV remodelling following the 
application of CRT was performed by Yu and colleagues and published in 2002.(101) Using a 
series of 25 patients, with LVEF <35 percent, QRS duration > 140 milliseconds, the authors 
demonstrated a significant reduction in end systolic and diastolic volumes at 3 months 
following CRT implantation. (205+/-68 versus 168+/-67 mL, P<0.01) and end-systolic 
volume (162+/-54 versus 122+/-42 mL, P<0.01) On withholding biventricular pacing, it was 
observed that there was a deterioration in left ventricular systolic function. Others 
subsequently replicated these findings in their own small, non-randomised cohorts with 
varying degrees of follow up.  
 
However a natural question was whether reverse remodelling correlates with clinical 
improvement. Bleeker and colleagues investigated this issue and published results in 
2006.(102) A cohort of 144 patients were analysed (all of whom fulfilled standard CRT 
selection criteria). Response was measured as a reduction in left ventricular end systolic 
volumes >15 percent at six months. A significant reduction in end systolic volumes was 
documented (P<0.0001). However the actual follow up period was heterogeneous and some 
patients were followed up for only three months. A clinical response rate (defined as 
improvement by NYHA grade of one or above) of 70 percent was observed at 3-6 months of 
follow up. There was an echocardiographic response rate of 56 percent. A total of 51 percent 
of patients had both a clinical and echocardiographic response (n=74). Clinical improvement 
without LV remodelling was observed in n=27 (19 percent) and n=7 (5 percent) demonstrated 
 95 
LV remodelling without symptomatic improvement. When using a cut point of LV end 
diastolic volume reduction >15 percent, there was disagreement in n =47 (32 percent).  The 
lack of correlation between the two measures was not explained by the authors but 
documented. One explanation is that there may be a placebo effect following CRT 
implantation which represents cardiac intervention. Another is that heterogeneous heart 
failure aetiologies and follow up periods with a limited number of study participants means 
that the actual effect beyond observation was not fully characterised. Hence the study should 
be viewed as observational. 
 
However the longer term question was whether a patient who underwent reverse remodelling 
was more likely to have a better clinical outcome. Data has now been produced both from the 
randomised trial cohorts and original prospective studies 
 
The CARE-HF study has been previously described, but the rates of remodelling were charted 
in 790 of its participants (90 percent of cohort).(155) All individuals whether randomised to 
CRT or not had repeat echocardiograms at 3, 9 and 18 months with a mean follow up period 
of 29 months. After 18 months of follow up there was a significant improvement in LV 
reverse remodelling in the CRT arm as compared to the medical therapy group. (49.2 percent 
versus 18.6 percent P<0.001) The substudy authors note that LV remodelling took time to 
occur, but when it did so after anything up to nine months, it persisted for up to three years. 
There were slight differences between the ischaemic and non-ischaemic cohort with CRT.  
 
Verhaert and colleagues also analysed this relationship in 2010, charting the effect of CRT on 
left ventricular end systolic volumes in a prospective study.(156) The effect of reverse 
remodelling was then correlated against a composite clinical endpoint of all-cause mortality, 
heart transplantation and implantation of a left ventricular assist device.  
 
Patients with the highest rates of survival had lower baseline LVESVi (Change=8.6 ml/m2, 
SE= 4.6 ml/m2, P < 0.0001). These patients with higher LVESVi decreased LVESVi by -0.11 
ml/m2/day during the first six months following CRT implantation, whereas the LVESVi 
remained unchanged in patients with adverse events (P< 0.0001). Within this study, six 
months represented a time point at which reverse remodelling becomes less prominent. 
Predictors of reverse remodelling were non-ischaemic aetiology, female sex, and a wider QRS 
duration (P <0.0001, P =0.014, and P=0.001, respectively). Hence the conclusions from the 
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data obtained from this study were that patients who experience clinical benefit had higher 
rates of reverse remodelling.  
 
A more recent publication by Bertini and colleagues takes this analysis a step further.(157) 
The results were published in 2013. Using a cohort of patients undergoing CRT implantation 
(n=679) all with pre implantation echocardiograms and clinical assessments, the rates of 
response using the previously discussed definitions (<NYHA grade I improvement and 
LVESV reduction >15 percent) were measured at six months. At six months 77 percent 
(n=510) showed a clinical response and 62 percent (n=410) showed an echocardiographic 
response. After a mean follow up period of 37+/-22 months, 21 percent of the cohort had 
died. On multivariable Cox-regression analysis only echocardiographic response to CRT was 
independently associated with superior survival (hazard ratio: 0.38; 95 percent CI: 0.27-0.50; 
P < 0.001).  
 
Hence the overall impression is that CRT in certain individuals may facilitate reverse 
remodelling, which may be long lasting. The exact mechanisms for this phenomenon are 
currently unknown. The rates of echocardiographic response lie between 50 and 60 percent. It 
still remains unknown as to predictors of reverse remodelling, and some patients experience 
this and others do not. Logically the application of CRT to an area of myocardial scar 
following prior ischaemic insult may not induce remodelling but other mechanisms which 
improve the overall survival of the patient.  
 
1.9.2 Symptomatic Improvement following CRT 
As already stated the most widespread measure of this in the literature is the improvement in 
NYHA grade by >1. However beyond such grading systems, other potential endpoints used to 
support a symptomatic improvement following CRT include 6MWT distance  and maximal 
oxygen demand.  
 
However little is known about the effect of CRT on these endpoints beyond the randomised 
controlled trials which have been presented above. Six minute walk test distance has been 
used as a prognosticator in CRT populations. However what is less characterised is the effect 
of CRT on such endpoints. A recent pilot study by Sherry and colleagues published this year 
demonstrates in 21 subjects an improvement in 6MWT at three months following CRT 
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(P<0.0001).(158)  However such findings need to be fully investigated in much larger 
randomised cohorts.  
 
The literature is similar for MVO2 with early randomised trials using it as a primary endpoint. 
Subsequently there has been little investigative work with a pilot study published this year 
(2013) by Larsen and colleagues who investigated with cardiopulmonary testing the effect of 
CRT within 21 patients at six months.(159) CRT induced a positive improvement in peak 
Vo2 (P=0.07). Again this was in a non-randomised pilot cohort. A much larger dedicated 
cohort would be needed to re-evaluate these findings.  
 
1.9.3 Overview 
Though response remains a debated element of post CRT implant care, there is now a wide 
body of literature which covers both functional and mechanical endpoints. Hence as a concept 
it has become established but, due to the lack of a consensual definition, still remains a 
difficult concept to analyse scientifically. Notably Fornwalt and colleagues in 2010, analysed 
the published response criteria up to that point in time in a landmark study.(160) Using the 
top fifty publications up until that point in time they extracted 17 different criteria which had 
been used as markers of response. See Table 3. 
 
 
Response criteria Echocardiographic 
 
1. ↑LVEF ≥5% (absolute) 
 
2. ↑LVEF ≥15% 
 
3. ↓LVESV ≥10% and did not die of progressive HF within 6 months 
 
4. ↓LVESV >15% 
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5. LVESV <115% of baseline 
 
6. ↓LVESVI >15% 
 
7. ↓LVEDV >15% 
 
8. ↑Stroke volume ≥15% 
 
Clinical 
 
9. ↓NYHA ≥1 
 
10. ↓NYHA ≥1 and did not die of progressive HF within 6 months 
 
11. ↓NYHA ≥1 and ↑6MWD ≥25% 
 
12. ↓NYHA ≥1 and ↑6MWD ≥25% and did not die of progressive HF within 6 months 
 
13. ↓6MWD >10%, no heart transplant, did not die of progressive HF within 6 months 
 
14. (↓NYHA  ≥1 or ↑V˙ O2max >10% or ↑6MWD >10%) and alive, no hospitalization for 
decompensated HF 
 
15. Two of 3: ↓NYHA ≥1 ↑6MWD ≥50 m ↓QOL≥15 
 
16. Clinical composite score improved  
 
Combined 
 
17. (↑LVEF ≥5% [absolute] or ↑6MWD ≥30 m) and (↓NYHA ≥1 or 
↓QOL ≥10) 
 
 99 
Table 3: Lists seventeen different response criteria.↑indicates increase; LVEF, left ventricular ejection 
fraction; ↓, decrease; HF; heart failure; LVESV ; left ventricular end systolic volume; LVESVI, LVESV 
indexed by body surface area; LVEDV left ventricular end-diastolic volume; NYHA, New York Heart 
Association functional class; 6MWD, 6 minute walk distance; VO2max oxygen consumption at peak 
exercise; QOL, quality of life score (160) 
 
 
The list comprised clinical and echocardiographic criteria. The Cohen correlation coefficient 
was used to statistically analyse the relationship between differing methodologies. The criteria 
showed poor correlation, with a mean kappa of 0.22+/- 0.24.  
 
The authors then extrapolated their results to the PROSPECT study cohort.(103) When 
applied to the cohort, the response rate varied between 32 percent and 91 percent with 99 
percent  of the cohort being classified as responders when criteria were applied and 94 percent 
classified as non-responders when alternative criteria were applied. The group highlights the 
problems with response and the inconsistency of the data.  
 
Further work is needed and, once a consensual definition has been agreed on, this would lead 
to more robust scientific discussion and investigation. For the purposes of this thesis where 
applicable, the studies have used both functional and mechanical endpoints similar to those in 
the published literature as described above. 
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Figure 9: Demonstrates the spectrum of response to the application of cardiac resynchronisation therapy, 
those with the highest degree of response at the top. From the European Society of Cardiology Guidelines 
for Cardiac Resynchronisation Therapy 2013(22) 
 
 
1.10 Mechanisms of CRT  
 
Cardiac resynchronisation therapy is now an established treatment option for selected 
patients. However despite the clinical effectiveness in several large randomised controlled 
trials, its effects are not wholly understood.  
 
The concept of response and non-response has been discussed elsewhere in this chapter but 
CRT probably exerts its effects on a multifactorial level. Currently with modern imaging 
techniques much is known and has been documented with macroscopic disease, what is less 
well characterised is the cellular, metabolic and effect on intracellular pathways that CRT 
may have. A non-responder is, according to the latest guidance, a patient who fails to develop 
symptomatic, mechanical, functional or neurohormonal benefit following CRT 
implantation.(22) The pathophysiology behind why some individuals experience this is 
unknown. Certain factors not currently included in selection criteria may have some impact 
on the overall effect and outcome of the patient, but their exact relationship with CRT is 
unknown. e.g. right ventricular dysfunction, renal impairment and anaemia.  
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1.10.1 Left Ventricular Remodelling and Functional Mitral Regurgitation 
Macroscopically as previously stated, CRT may induce reverse remodelling. There may also 
be a reduction in functional mitral regurgitation (due to annular dilatation) and correction of 
dyssynchrony. With modern sophisticated cardiac imaging techniques, these positive effects 
of CRT have been previously documented. However CRT may also have effects at a sub 
cellular level, for which there is limited knowledge. The correction of electromechanical 
dyssynchrony is well understood, but what is less understood is the direct mechanism for the 
reduction in arrhythmias (independent of defibrillator capacity). Hence CRT may be viewed 
as having documented macroscopic effects, and poorly characterised and understood cellular, 
sub cellular and electrical effects.  
 
LV remodelling following CRT has been investigated. One of the first investigative studies of 
CRT on mitral regurgitation (MR) intensity was performed by Breithardt and colleagues and 
published in 2003.(161) A series of 24 consecutive patients was studied after CRT 
implantation. The investigators then analysed the mitral regurgitation using the proximal 
isovelocity surface area (PISA) technique to calculate the effective regurgitant orifice area 
(EROA). The estimated maximal rate of left ventricular systolic pressure rise was also 
recorded. (dP/DTmax). Patients underwent CRT implants and then had them turned off and 
with CRT turned back on again. Effective regurgitant orifice area decreased from 25 +/- 19 
mm2 (OFF) to 13+/- 8 mm2 (CRT). The change in EROA was directly related to the increase 
in LV dP/DTmax (r= -0.83, p <0.001).  
 
This was a short term haemodynamic assessment of mitral regurgitation; longer term evidence 
for the effect of CRT on functional MR comes from van Bommel and colleagues in 
2010.(162) A total of 98 patients who had high operative risk and moderate to severe 
functional mitral regurgitation were studied. Two thirds of the cohort had an ischaemic 
aetiology and the mean QRS duration was 166 +/-29ms. After a follow up period of six 
months, 13 patients had died, but the ones who had survived had an improvement in NYHA 
class, 6 MWT distance and reductions in ventricular volumes and mitral regurgitation. 
(P<0.0001)  
The cohort was then followed up for an extended period (median 32 months range 6-116 
months) and death rates recorded. There was significant improvement in survival in the MR 
improvers as compared to the MR non-improvers (P<0.001).  
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1.10.2 Neuroendocrine effects and renal function 
CRT may also exert its effects on other macroscopic systems which may be quantifiable. 
Neuroendocrine dysfunction is a characteristic of the heart failure syndrome and hence both 
renal function and B type natriuretic peptide may be easily measured using serum assays.  
 
The relationship between CRT and renal function has been investigated but needs further 
data. The limitation is that renal impairment was a contraindication to participation in the 
some of the larger randomised controlled trials. Hence a lot of the work within the area comes 
from substudy analysis from the randomised studies. The substudy from the MIRACLE group 
was published in 2008. The cohort was divided into three groups on the basis of renal 
function at baseline (EGFR (estimated glomerular filtration rate)>90 mls/min –  
preserved renal function; eGFR 60-90mls/min- mildly impaired and eGFR 30-60mls/min - 
moderately impaired. CRT improved eGFR in the most impaired group but had no effect in 
the other groups on renal function. (-2.4 +/- 1.2 vs. +2.7 +/- 1.2 mL/min per 1.73 m2; P = 
0.003)(163)  
 
Baseline renal function prior to CRT also seems to have some importance. The Mayo Clinic, 
published the results from their own registry data in 2011, with 482 patients stratified by renal 
function.(164) The rates of survival were higher in those patients with normal or mild renal 
dysfunction as compared to those with established chronic renal impairment. (72 vs. 57 
percent at 3 years, P < 0.01). Chronic renal impairment remained a prognosticator in 
multivariable analysis.  
 
A recent meta-analysis of 18 studies, published in 2012 demonstrated a modest improvement 
in eGFR following CRT implantation and also a slight improvement in left ventricular 
ejection fraction.(165) (Mean difference 6.24 percent; 95 percent confidence interval, 3.46 to 
9.07). The authors reviewed a collection of studies dating back to the 1990s and suggest that 
more data within the area is needed.  
 
The exact mechanism for an improvement in renal function following CRT implantation is 
unknown. Postulated theories are a reduction in central venous pressure and hence enhanced 
perfusion across the renal bed due to reduction in local renal venous pressure, an increase in 
systemic arterial blood pressure and increased renal arterial blood supply.(166) Further work 
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is needed to characterise the precise mechanism and interaction between renal function and 
CRT but it remains a potential prognosticator in populations undergoing CRT implants.  
 
B type natriuretic peptide as discussed elsewhere in the introduction is a marker of 
neurohormonal activation. It has been previously been shown to be a prognostic marker in 
patients with systolic heart failure.(167) Hence logically, the levels of circulating BNP prior 
to or after CRT implantation may reflect a level of disease which is refractory to the effects of 
CRT.  
 
There is a shortage of published data in this area, and the largest sets of data come from 
substudy analysis from the CARE-HF and MADIT-CRT studies. Brenyo and others released 
their data in 2013 and analysed BNP levels at baseline and one year after CRT 
implantation.(168) An elevated baseline BNP was a predictor of death in patients receiving 
either CRT-D (p=0.007 (68%)) or ICD (p-0.02 (58%)). At one year there was a greater 
reduction in BNP levels in the CRT-D recipients (26%) versus ICD recipients (8%) (p= 
0.005). The one year BNP level was both a predictor of death and left ventricular reverse 
remodelling.  
 
The CARE-HF substudy was published much earlier by Fruhwald and colleagues in 
2007.(169) Embedded within the trial structure all participants had serum analysed at 3 and 
18 months. NT pro-BNP was measured and the difference between the medians in the CRT 
group and medical group was highly significant at both 3 months (537pg/mL; P<0.0001) and 
18 months (567 pg/mL; P<0.0001). The findings were independent of changes in 
pharmacotherapy and renal function, but were associated with improvement in ventricular 
volumes and renal function.  
 
Hence BNP appears to be a prognostic marker in cohorts undergoing CRT implantation. 
However the relationship needs further characterisation and evaluation. Within this context it 
appears to be a surrogate for neurohormonal and sympathetic activation, which is readily 
available and quantifiable. However further work is needed to understand the relationships of 
circulating levels with clinical outcomes and important subgroups e.g. patients with prior 
ischaemic disease versus those with dilated cardiomyopathy.  
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1.10.3 Cardiac Haemodynamics  
Prior work as summarised elsewhere in the introduction has illustrated the potential effect on 
acute haemodynamics of CRT. Initial enthusiasm for these observational studies was 
tempered by the need for pressure/volume conductance catheters, dedicated catheter 
laboratory time and the acknowledgement of an extension in procedural time and potential 
risk to the individual patient.  
 
A recent example of such a study was that performed by Duckett and colleagues in 
2011.(170) Using a consecutive series of 33 patients undergoing CRT implantation all had on 
table dP/dt generated by using a pressure wire and the data used to guide the LV lead position. 
There was a significant improvement in left ventricular dP/dT max (P=0.001) and left 
ventricular end systolic volume (P=0.001). There was an association between reverse 
remodelling and acute improvement in haemodynamics (P<0.001).  
 
Hence CRT may induce a positive short term haemodynamic improvement which seems to be 
linked to longer term reverse remodelling. Whether this is reliably associated with clinical 
outcomes is unknown, longer term correlation of clinical endpoints with short term 
haemodynamic data is needed but this question should be analysed in a much larger format.  
 
1.10.4 Systemic Blood Pressure  
Cardiac resynchronisation therapy may exert some effect on systemic arterial blood pressure. 
However the evidence for such effects is limited and needs further investigative work. 
 
Ather and colleagues performed a meta-analysis of observational study and randomised 
controlled study data, publishing in 2011.(171) The initial analysis of non randomised data 
demonstrated an increase (from baseline) in systolic blood pressure by 4.4 mm Hg (95% 
confidence interval [CI] 0.8 to 8.0, P = 0.02), no change in diastolic blood pressure (P = 0.21). 
Results from CARE-HF and COMPANION were concordant with an increase in systolic 
blood pressure by 3.9 mm Hg (95 percent CI 1.1 to 6.8, P = 0.007), no effect on diastolic 
blood pressure (P = 0.40), and an increase in pulse pressure by 4.3 mm Hg (95 percent CI 4.1 
to 4.5, P <0.001) compared to medical therapy. (5,6) Hence CRT may have some limited 
effect on systemic blood pressure.  
 105 
 
An alternative effect of CRT linked to optimisation has been documented by Whinnett and 
colleagues in 2006.(147) Using finger plethysmography and by adjusting AV delay in twelve 
patients, it was noted that AV delay adjustment also resulted in changes to systemic blood 
pressure. Altering the AV delay had a more pronounced effect on BP (average range of 
SBP=17.4 mmHg) compared with resting rates (average range of SBP=6.5 mmHg), 
P<0.0001. 
 
1.10.5 Sympathetic activation and arrhythmias 
One of the widely discussed potential benefits of CRT is its ability to prevent and treat 
ventricular tachyarrhythmias this is particularly of interest in the ischaemic population.  
 
The previous randomised trials have been discussed and the clinical question of whether to 
implant an ICD or CRT-D has also been covered via presentation and discussion of the large 
randomised trials.  
 
However beyond the trial format, some have advocated that CRT may by LV pacing mediate 
a reduction in arrhythmias. Others suggest that the application of an electrode contiguous to 
an area of myocardial scar or fibrosis may be pro-arrhythmic.(119) The exact cellular 
mechanism is unknown. Clinical observational studies performed in smaller cohorts generate 
different findings and hence the field is under active investigation.  
 
Lin and colleagues analysed this issue from the Mayo Clinic dataset, in 2008.(172) Using 52 
patients who underwent upgrade to CRT-D from dual chamber ICD, the frequency of 
ventricular arrhythmias was observed pre and post upgrade. There was no significant 
reduction in non-sustained ventricular tachycardia, sustained ventricular tachycardia and 
ventricular fibrillation with the upgrade to CRT. (P=non-significant for all measures) The 
authors found in this study this effect was unrelated to left ventricular remodelling.  
 
However Thissjen and coworkers released a study in 2011, refuting the findings of the 
previous study(173)  using a consecutive series of 115 patients, and documenting ventricular 
arrhythmia burden and left ventricular remodelling (<15 percent reduction in LVESV at 6 
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months). The group was able to demonstrate in those who remodelled (70 percent), there was 
a trend towards significant reduction in arrhythmic burden. (P=0.052) Those patients who 
failed to experience reverse remodelling had a higher rate of arrhythmias following CRT 
upgrade. (P=0.014)  
 
Hence the data which reflects observational practice is conflicting and needs some 
clarification. Little is known about the anti-arrhythmic effect within ischaemic and non 
ischaemic populations following CRT implantation.  
 
The actual mechanisms for such electrical effects are unknown. However apart from cellular 
level change and signalling pathway upregulation, an alternative explanation is offered by the 
use of radionuclide imaging.  
 
Iodine-123 metaiodobenzylguanidine (123-MIBG) is a radioisotope of iodine which is taken 
up by adrenergic receptors. It therefore when used with scintigraphy can visually demonstrate 
the current sympathetic activity within an organ system. It has been validated in heart failure 
cohorts and has been shown to be a prognosticator.(174) 
 
Marshall and colleagues in 2012, evaluated the role of 123-MIBG in a cohort undergoing ICD 
implantation at a tertiary centre in the United Kingdom.(175) A series of 27 patients was 
studied with a mixture of CRT-D (n=19) and ICD (n=7). By using 123-MIBG and single 
photon emission computed tomography (SPECT) the authors were able to correlate levels of 
sympathetic activity with the occurrence of ventricular arrhythmias. However in such a small 
cohort none of the cut points were robust enough to base clinical decisions upon.  
 
Alternative data comes from Cha and colleagues, who published in 2008.(176) Using a series 
of 16 patients and documenting 123-MIBG washout rates, plasma noradrenaline levels and 
heart rate variability, the authors were able to show that in individuals who experienced 
reverse remodelling, CRT led to improved markers of sympathetic activity. The improvement 
in NYHA after CRT was significantly associated with baseline (123)I-MIBG washout rate (r 
= 0.65, P = 0.03). The improvement in LVESV index was associated with baseline (123)I-
MIBG delayed ratio (r =-0.67, P = 0.02) and washout rate (r = 0.65, P = 0.03). 
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1.10.6 Metabolic Effects 
Left Bundle Branch Block has been demonstrated to induce regional myocardial metabolic 
variation between septal and lateral walls. In the presence of LBBB, prior work has 
documented a low uptake of glucose within the septal wall with a compensatory response in 
the lateral wall of the left ventricle. (41) 
 
The use of positron emission tomography (PET) scanning and radiolabelled glucose permits 
the analysis of metabolism. Ukkonen and colleagues released the first data in this area with an 
observational study performed in eight patients published in 2003.(41) Septal uptake of 
glucose was increased following CRT implantation (P=0.04) and the septal/lateral wall ratio 
also improved (P=0.01), hence this initial pilot study demonstrated that regional discrepancies 
of metabolism had been corrected by CRT.  
 
Lindner and co-workers investigated this further in 2005, by analysing a myocardial oxygen 
demand and blood flow in a cohort undergoing CRT implantation.(177) A total of 42 patients 
(31 DCM and 11 dilated cardiomyopathy with prior history of ischaemic heart disease) 
undergoing CRT were studied using 11C-acetate-PET at baseline and four months following 
CRT implantation. Following CRT, the rate of blood flow and oxygen demand decreased in 
the lateral wall (P=0.045) and increased in the septum (P=0.045) in the non ischaemic DCM 
group. Similar observations were documented in the ischaemic group with no significance. 
Hence the authors suggest that on the basis of this study, CRT may have been more effective 
in patients with non ischaemic aetiologies.  
 
More recent studies have investigated this and found similar findings, but once again with 
small numbers of patients.(178) Though of interest, the field needs a larger prospective study 
to correlate short term metabolic effects with longer term clinical outcomes. The apparent 
differences between ischaemic and non ischaemic aetiologies also requires further analysis as 
this may be a potential explanation of the mechanism of CRT in the two different groups and 
explain the increased rates of reverse remodelling observed in the non ischaemic aetiologies.  
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1.10.7 Cellular Effects and Signalling Pathways  
With the application of CRT and the advent of sophisticated modern cardiac imaging, the 
effects described above may be directly observed with reproducible and established 
techniques. e.g. echocardiography.  
 
However beyond the macroscopic level, what remains unknown is the effect of CRT at a 
cellular level both directly on individual myocytes and intracellular signalling pathways. The 
field of basic science allied to CRT is small and has followed the large clinical publications. 
However the desire to understand some of the observed phenomenon following CRT 
implantation has led to increased interest in this field. Particularly the phenomenon of reverse 
remodelling following the application of a depolarising electrode is not understood.   The 
longer term aim of such investigation would be to guide patient selection, refine CRT itself 
and potentially even extrapolate such proteins and intracellular signals to the pharmacological 
arena to permit the development of future agents.  
 
Due to the lack of knowledge in the area several cellular mechanisms are being studied. 
Recent publications in the area have included the following studies.  
 
Pezzali and colleagues published this year (2013) on a cohort of CRT recipients (n=101) who 
had been evaluated for beta adrenoceptor polymorphisms.(179) The group investigated the 
beta-1 Arg389Gly, beta-2 Arg16Gly, and beta-2 Gln27Glu ARs gene polymorphisms. The 
endpoint was the magnitude of left ventricular remodelling and correlations with appropriate 
ICD shocks. The Gln27Glu ARs gene polymorphism had higher rates of LV remodelling 
(P=0.0018). Gln27 homozygotes had a higher incidence of appropriate shocks for both 
ventricular fibrillation and tachycardia.  
 
Clinical observational studies have documented certain patients experience reverse 
remodelling. Hence logically CRT in some individuals may have some effect on extracellular 
matrix turnover and the physiological pathways involved with this. 
 
Marfella and colleagues analysed this and published in 2013.(180) Micro RNAs are non-
coding RNAs which are linked to the regulation of cardiac structure and function. Due to the 
adverse cardiac remodelling, there may be dysregulation of the expression of micro RNAs. 
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The authors investigated the relationship between micro RNA expression, and LV reverse 
remodelling following CRT implantation.  
 
A total of 81 patients made up the cohort. Micro RNA levels were measured in a healthy 
control group, age matched and disease matched (not for heart failure) and a heart failure 
population. At baseline, the HF population had a lower rate of expression of micro RNAs as 
compared to the healthy control group. (P<0.04). At 12 months 68 percent of the HF cohort 
(n=55) were classified as responders based on echocardiographic parameters. The levels of 
expression of certain micro RNAs were different between the responders and non-responders. 
The responders were characterised by higher expression of five miRNAs 
(MiRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p; P , 
0.01 for all) as compared with non-responders. These micro RNAs have been linked to 
cardiac fibrosis and hypertrophy.  
 
Hessel and co-workers investigated the effect of CRT on tissue matrix metalloproteinases, 
with particular attention to MMP-9.(181) This specific matrix metalloproteinase is felt to 
govern apoptosis and previously been found to be expressed in high levels in pathological 
disease states e.g. abdominal aortic aneurysms.  
 
A series of 64 patients was followed up for six months and 72% of the cohort had LV 
remodelling. (>10 percent LVESV) This group had a significant reduction in circulating 
levels of MMP-9 (P=<0.01) and hence the suggestion is that reverse remodelling may be 
associated with an increased rate of extracellular matrix turnover.  
 
Beyond the effect of specific pathways, CRT’s effects have also been investigated on 
intracellular signalling.  
 
It has been previously observed by Spragg and colleagues in 2003, that there was an 
imbalance between the expression of selective cardiac handling proteins and mitogen 
activated protein kinase.(182) The same group investigated this further in 2008, with the lead 
author being Chakir.(183) In the context of dyssynchronous contraction represented by LBBB 
on the surface electrocardiogram, the lateral wall showed an increase in p38 MAPK and Ca2+-
Calmodulin Kinase II activation and increased TNF-alpha which were both reversed with 
CRT.  
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Electrically myocytes when isolated from failing hearts suffer from prolonged action 
potentials.(184) This has been noted particularly in the lateral wall of the left ventricle, 
irrespective of aetiology.(185) CRT may shorten action potential duration in the lateral wall 
and therefore diminish the effect of prolonged action potentials in the lateral wall.  
 
Another important mechanism noted in failing hearts is the abnormalities associated with 
calcium handling. Myocytes isolated from patients with heart failure demonstrate delays in 
the movement of intracellular calcium and altered intracellular kinetics. Beat to beat variation 
in calcium handling is influenced by both intracellular channels (L type Ca2+ currents) and 
large scale Ca 2+ release through the sarcoplasmic reticulum by the phospholamban regulated 
SR Ca2+- ATPase. (SERCA 2A) CRT may restore normality to intracellular calcium 
movement and had some effect on regional variation.(186) However like most of the 
molecular field allied to the effects of CRT, the data is limited and the effect is not wholly 
understood nor characterised.  
 
The effect on beta adrenoceptors has been discussed above, however beyond the cellular 
surface, abnormalities of G protein signalling allied to such receptors has also been 
documented.(187, 188) Analysis of adenylyl cyclase activity (cAMP) shows a reduction in 
patients with heart failure, CRT has been shown to upregulate cAMP levels.(186) Additional 
effects on G protein signalling have also been demonstrated with patients with CRT implants. 
G-proteins are inhibitory on the effects of beta adrenoceptor signalling. Pertussis toxin is 
inhibitory of G protein signalling, but when administered to myocytes following the 
application of CRT, had no effect.  
 
The molecular, sub cellular and signalling fields with respect to CRT have been historically 
overlooked, but more attention is being paid to these mechanisms which underpin the 
macroscopic processes observed in some patients following CRT implantation. Further work 
is underway and much needed both in vivo studies and ex vivo with robust animal models 
which replicate human physiology. With the data thus far which has been published, it is clear 
that CRT does influence certain cellular pathways and expression of proteins.  
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1.11 Implementation of CRT 
 
The body of evidence collected from the large randomised studies summarised above led to 
the rapid uptake of CRT within clinical guidelines in the UK, Europe and the United 
States.(22, 98)  
 
All recommend CRT on the basis of the accrued evidence and suggest the consideration of 
implantation when the established selection criteria have been met. (LVEF <35 percent, QRS 
duration >120 milliseconds, optimal tolerated medical therapy and NYHA class II to IV 
therapy). However trial evidence does not reflect ‘real-world’ practice due to the inclusion 
criteria which often stipulate lack of co morbidity and younger age. Hence contemporary 
subgroups which are often clinically encountered are not represented in the literature e.g. the 
elderly, patients of female gender, those with co-morbidities (renal dysfunction, anaemia and 
diabetes mellitus) and those who have deteriorating left ventricular systolic function and have 
pre-existent pacing systems in situ. Hence since the uptake of CRT into the guidelines, several 
publications have released data from registries which actually reflect clinical practice. i.e. 
‘real world’ practice. 
 
British data is represented by the national audit of cardiac rhythm devices run by Heart 
Rhythm, United Kingdom (UK).(189) The most recent data is that from 2011 and primarily 
reflects number of CRT implants. The overall view is that CRT implantation rates have 
markedly increased from 2001 to 2011 but with significant country variation. See Figure  10. 
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Figure 10: Depicting rate of CRT implantation across the four individual countries which make up United 
Kingdom (England, Wales, Scotland and Northern Ireland). From UK National Audit of Heart Rhythm 
Devices(189) 
 
England has shown the largest increase in CRT implantation whereas the overall rate in 
Scotland has not increased over the same time period. The figures released by cardiac 
networks also demonstrate widespread geographical variability. The CRT implant rate varies 
in England from 70 per million in the North Trent Cardiac Network to a 180 per million in the 
Dorset Network. The mean is a 113 CRT implants per million (which is still under the target 
figure set by the British Society of Heart Failure and Heart Rhythm UK of 130 per million).  
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Figure 11: Demonstrates geographical 
variation in CRT implant rates across 
England and Wales .From UK 
National Audit of Heart Rhythm 
Devices. Highest rates of implantation 
are represented by the darkest 
colours 
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The increased numbers of CRT implants however have led to the UK becoming the 8th 
country in the European league table for CRT implantation. This was as compared to previous 
data which demonstrated the rate of CRT implant in the UK was lower than most of the rest 
of the Europe. In terms of indications, the data demonstrates that the majority (approximately 
80 per cent) of implants fulfils criteria for CRT implantation and has prolonged QRS 
duration, reduced LVEF and are symptomatic. However there is a notable issue within the 
audit with regards to lack of data capture and there are significant amounts of missing data 
with regards to indications; with a rate of absent data of up to 60 percent. Hence conclusions 
regarding the validity of CRT implantations have to be interpreted cautiously.  
 
The European experience with CRT has been documented by the European CRT survey 
chaired by Professor Dickstein and coordinated as a joint venture between the Heart Failure 
Association and European Heart Rhythm Association.(190) This was first published in 2009 
and hence reflects the initial experience with CRT across the member countries of the 
European Society of Cardiology.  
 
A total of 140 centres across 13 countries contributed data on 2638 patients. The median age 
of patients was 70 years of age (Interquartile range 62-76 years of age) and nearly a third (31 
percent) of the cohort were aged >75 years of age. Prior to CRT implantation the mean LVEF 
was 27+/- 8 percent and the mean QRS duration was 157+/-32 milliseconds. The QRS 
duration was below 120 milliseconds in only 9 percent of cases. Approximately a quarter (26 
percent) of the cohort underwent an upgrade of a preexistent pacing or ICD system to CRT 
capacity and 23 percent of the population had atrial fibrillation. Male patients of younger age 
with a prior ischaemic history were more likely to receive a CRT-D rather than CRT-P 
implant. The survey highlights regional variation in clinical practice and that the clinical use 
of CRT extended into areas with a paucity of literature e.g. the elderly, patients undergoing 
upgrade procedures with the addition of a LV lead and those with concomitant atrial 
fibrillation. All of these sub groups are under further investigation and require further 
clarification of the effects of CRT within these populations.  
 
American data come from the ' Get with the Guidelines Programme’ - a dedicated cardiac 
network of several hundred institutions spread across the continental United States. The 
programme was originally devised and supervised by the American Heart Association. The 
particular emphasis of the programme is to improve cardiovascular care via several 
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mechanisms, including guidelines, suggested clinical care bundles, recommendations, 
education and ongoing clinical audit.  
 
Piccini and colleagues published on the most recent set of data in 2008 whereby they had 
analysed 33,898 patients from a period of 2005 to 2007.(191) 4201 patients were discharged 
with a CRT device in situ with 811 having received them as new implants on that admission. 
10 percent of patients who received a CRT implant had a LVEF >35 percent. The survey 
documented widespread geographical variation and due to the structure of the American 
healthcare system patients attending tertiary academic centres were more likely to receive a 
CRT implant on that admission. The data also demonstrated significant rates of co morbidities 
- 10% of this cohort had a creatinine clearance of less than 35mls/min and 20% of patients 
had chronic obstructive pulmonary disease. Similar to other registry data described above, the 
American data indicates the extension of the application of CRT to other groups beyond those 
represented in the clinical trials.  
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2.1 Aims 
 
The following aims will be tested within the four study chapters described later in the thesis.  
1. To present the initial experience of a dedicated specialist heart failure pacing clinic.  
2. To investigate whether the passage of patient with a CRT implant through a dedicated 
specialist heart failure pacing clinic results in higher rates of initiated and uptitrated evidence 
based therapies 
3. Whether impedance cardiography is comparable to conventional echocardiographic 
methods of CRT device based optimisation 
4. Whether impedance cardiography has sufficient reproducibility and reliability when 
compared to other methods of cardiac output monitoring in an intensive care/high dependency 
care setting.  
5. Whether right ventricular dysfunction as assessed on cardiac magnetic resonance imaging 
prior to CRT implantation predicts clinical outcomes  
6. Whether right ventricular dysfunction as assessed by cardiac magnetic resonance imaging 
prior to CRT implantation predicts left ventricular remodelling 
 
2.2 Hypotheses 
 
The following hypotheses will be tested within the study chapters and are presented below: 
1. A dedicated specialised heart failure pacing clinic does result in increased doses of 
evidence based heart failure pharmacotherapies - 'Medical Optimisation'  
2. Impedance Cardiography is comparable to conventional echocardiography for the 
adjustment of device based atrioventricular and ventriculo-ventricular delays - 'Device 
Optimisation'  
3. Impedance Cardiography is a reproducible and reliable technique when assessing changes 
in haemodynamics in patients in intensive care following cardiac surgery  
4. Right ventricular function as assessed by cardiac magnetic resonance imaging does predict 
clinical outcomes in patients undergoing cardiac resynchronisation therapy implantation 
5. Right ventricular function as assessed by cardiac magnetic resonance imaging does predict 
the degree of left ventricular remodelling in patients undergoing cardiac resynchronisation 
therapy implantation 
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General Methods 
 
Within this thesis, the patients underwent a series of tests and questionnaires to ascertain their 
severity of HF. These included NYHA classification, Minnesota living with HF score, 
echocardiography, 6 minute walk test distance and venous blood sampling for serum uric acid 
levels and B-type natriuretic peptide. (BNP)  
 
3.1 New York Heart Association Classification 
 
The NYHA classification was devised to assess the patient’s functional status.(192) Using a 
categorical system, the patient’s ability to perform differing levels of physical activity is 
graded, usually by a physician. The symptoms have been previously been shown to correlate 
with the degree of LVSD and prognosis.(193, 194) 
 
The grading system is described below: 
NYHA I: No limitation in physical activity. 
NYHA II: Slight limitation in physical activity 
NYHA III: Marked limitation in physical activity 
NYHA IV: Unable to carry out physical activity without discomfort. Symptoms at rest.   
 
Minnesota Living with Heart Failure Questionnaire (MLHFQ) 
 
This is a 21 item questionnaire devised to assess physical symptoms of heart failure, 
psychological status and social aspects of a patient with heart failure.(195, 196) Each question 
is scored on a Likert scale from 0-5 and the total score is thus 105. A higher score indicates 
more symptoms and psychometric disturbance.(197) Conventionally it is used as a tool for 
documenting change in patient psychometric status over time. It has been used in several 
large randomised clinical trials involving drugs and cardiac pacing (including univentricular 
and bi ventricular systems).(198, 199) The original questionnaire was devised and validated 
within the United States, but has subsequently been validated and translated into several 
languages worldwide. Within the United Kingdom (UK), limited data are available but it has 
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been used as an assessment tool within several studies based within heart failure populations 
in the UK.(200, 201)  
 
A copy of this questionnaire is included within the Appendix.  
 
Trans-Thoracic Echocardiography 
 
Left Ventricular function was assessed by trans-thoracic echocardiography. (TTE) As 
described in the introduction, TTE has become a key part of the diagnostic and follow up 
process for patients with heart failure.  
 
Its ease of use and widespread availability has meant that it is a routine examination for 
patients with heart failure. Using ultrasonic waves generated via a piezoelectric crystal, it is 
able to offer the ability to image the heart in real time. It does not involve radiation, nor 
invasive testing and is safe. It has been previously been demonstrated to be reproducible and 
enables the visualisation of intra-cardiac structures such as valves and chambers.  
 
All echocardiography for this thesis was carried out by accredited trained professionals 
working in the Derek Gibson echocardiography laboratory at the Royal Brompton Hospital, 
London. All images were acquired either on Vivid 7 (General Electric, Andover, 
Massachusetts, US) or on iE33 (Phillips, Amsterdam, The Netherlands) with a multi-
frequency transducer. The echocardiographer was blinded to the results of the other end point 
measures.  
 
As per the American Society of Echocardiography guidelines, all LVEF measurements were 
calculated using the Biplane Simpson’s technique.(202) This measured LVEF using a 
standardised format in the four chamber view and two chamber view. The accuracy of the 
measurement of LVEF is enhanced by choosing two planes which are perpendicular to each 
other. The measurement of LVEF via this technique is the suggested gold standard, however 
it is also recognised that there may be a reproducibility error with repeated measurement of 
such views.(203) Additionally, the echocardiographer also measured and recorded the left 
ventricular end systolic and end diastolic diameters. These were measured at rest, from the 
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cross sectional M- Mode recordings of the LV minor axis using the left parasternal long-axis 
view with the cursor at the tips of the mitral valve leaflets. The LV dimensions were taken at 
end-diastole and at end systole. The left atrial diameter was measured from the M-Mode 
recording from the left parasternal view at the level of the aortic valve.  
 
During the routine echocardiographic study, co existent valvular disease was assessed. If 
mitral regurgitation was present, its severity was documented by using the colour Doppler of 
the regurgitant jet width at the level of the mitral valve. The regurgitant fraction was 
quantified using the recommendations from the American Society of Echocardiography for 
the assessment of valvular regurgitation.(204) Peak pulmonary artery pressure (PAP) was also 
recorded where possible. The technique was reliant on the patient having a degree of tricuspid 
regurgitation. 
 
3.2 Six Minute Walk Test 
 
The symptoms of heart failure are usually more severe on exertion. Symptoms such as 
shortness of breath and fatigue may not be prominent at rest or on minimal exertion but may 
be more apparent on mild – moderate exertion.  
 
Exercise testing for patients with heart failure has been described over the past four decades. 
One option is to establish the patient’s maximal oxygen (MvO2) consumption via treadmill or 
ergonometric bicycle testing. Though it is a reproducible and reliable measure which is 
predictive of prognosis and the need for cardiac transplantation; it requires the use of trained 
personnel and complex equipment.  
 
An alternative method which tests the patient’s sub-maximal exercise tolerance in a 
standardised format is a six minute walk test. This was initially described in patients with 
respiratory disease; however two subsequent studies then described its application in patients 
with heart failure.(205-207) It was shown to be reproducible and reliable.(207) 
 
It is also a prognostic marker in heart failure cohorts, and for patients undergoing 
implantation of cardiac resynchronisation therapy (CRT).(208-210) The 6 minute walk test 
has also been demonstrated to be able to predict long term mortality following CRT 
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implantation.(211) The data from Brugada’s group indicates a pre CRT implantation six 
minute walking distance of 225m predicts long term mortality. 
Within this thesis where used, the 6 MWT was performed according to one of its initial 
descriptions in patients with heart failure.(207) It was administered by two experienced 
observers familiar with the protocol. No encouragement was given to the patient during the 6 
minutes. A walking track of twenty metres was marked out and the patients walked 
continuously from the start to the finish during the test period. Patients completed the course 
at their own pace. All tests were performed at least 2 hours after the administration of heart 
failure medication.  
 
3.3 B-Type Natriuretic Peptide (BNP) 
 
Previously described within the introduction, natriuretic peptides are released in response to 
myocardial stress. BNP is released by myocytes in response to raised ventricular filling 
pressures and volume overload. It should be noted that though BNP is specific for excluding 
heart failure, it has a limited sensitivity. BNP carries prognostic information for all aetiologies 
of heart failure and has been shown to be associated with adverse outcomes in patients 
undergoing CRT implantation.(212-214) 
 
All BNP results quoted within this thesis, were collected and then subsequently analysed by 
the Department of Biochemistry, Royal Brompton Hospital, Royal Brompton & Harefield 
NHS Foundation Trust. A standardised assay was used for all samples. (Alere Triage BNP 
Assay, Alere Corporation, San Diego, California, US) All samples were processed on the 
same immunoassay system. (Beckman-Coulter Incorporated, Brea, California, US). The 
normal reference range for serum BNP for the duration of the studies performed within this 
thesis was <4 pmol/Litre.  
 
3.4 Statistics 
 
Statistical analysis was performed using SPSS version 19.0 for Microsoft Windows. 
(Chicago, IL) Continuous variables were expressed as a mean ± standard deviation (SD) and 
categorical variables were expressed as a percentage. Normally and non-normal distributed 
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variables were analysed with the appropriate statistical test depending on the statistical 
relationship under investigation. More complex statistics were performed under the 
supervision of a senior statistician. A p value <0.05 was deemed to be of statistical 
significance for all analyses. 
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pacing clinic facilitates medical 
therapy optimisation in patients 
following Cardiac Resynchronisation 
Therapy  
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4.1 Introduction 
 
Cardiac resynchronisation therapy (CRT) is a proven treatment in patients with symptomatic 
left ventricular systolic dysfunction (LVSD), on optimal tolerated medical therapy and a 
broad QRS duration.(22) It improves both morbidity and mortality in such patients.  
 
Optimal medical therapy was an inclusion criterion for all trials with CRT. However there is a 
paucity of data in terms of medical therapy following CRT implantation. CRT, once 
implanted successfully, may improve haemodynamics,  reduce central venous pressure, 
prevent symptomatic bradycardia and improve renal function.(99) All of these characteristics 
suggest that medical therapy following CRT implantation should be revisited. 
 
Currently there are increasing numbers of CRT implants both in Europe and the United 
Kingdom (UK).(190) Due to limitations within healthcare infrastructure there is widespread 
geographical variation in the care of such patients following CRT implantation. The 
responsibility for uptitration or initiation of evidence based medical therapies may be 
devolved to a local general cardiologist, physician or primary care practitioner.  
 
The aim of the present study was to present the initial experience of a dedicated specialist 
heart failure pacing clinic. We hypothesise that a dedicated service for these patients would 
lead to the improvement in both the initiation and uptitration of evidence based medical 
therapies for patients with heart failure.  
 
4.2 Methods 
4.2.1  Patient Selection & Management 
A consecutive series of 148 patients who fulfilled standard criteria for implantation of CRT 
(Left Ventricular Ejection Fraction (LVEF) ≤ 35 percent, QRS duration >120ms in Left 
Bundle Branch Block Morphology (LBBB), NYHA Class III/IV or (II if they had a preceding 
decompensation episode in the last 12 months) were identified from the specialist heart failure 
pacing clinic at the Royal Brompton Hospital, London.(215) Prior to the consideration of 
CRT implantation, all patients had had efforts made for the uptitration of evidence based 
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pharmacotherapies. Patients were evaluated at baseline, one and six months post CRT 
implantation (Figure 12). Data were retrieved from hospital records, electronic, 
echocardiographic systems and the pacing records.  
 
4.2.2  Medical Therapy 
At every clinic visit, the patients’ medication status was recorded. As per current guidance 
wherever possible; evidence based pharmacotherapy was uptitrated to target doses with 
monitoring of renal function and blood pressure.(10) Following CRT implantation, 
pharmacotherapies were reconsidered for initiation and where appropriate were started.   
 
 
 
 
 
 
 
 127 
 
 
	  
 
	  
	  Patients with HF r efer red to clinic for  assessment for  CRT eligibility	  
	  
	  History:	  NYHA	  class	  III/IV	  &Physical	  examination.	  
ECG:	  QRS	  ≥	  120ms.	  	  
Echocardiography:	  EF	  ≤	  35	  percent	  
Blood	  tests*	  
Medical	  therapy:	  adjustment	  if	  not	  optimal	  
	  Detailed	  discussion	  with	  the	  patient	  and	  relatives	  
on	  available	  therapies	  for	  HF,	  aim	  of	  CRT,	  
probability	  of	  improvement,	  possible	  
complications	  
Obtain	  consent	  
	  
	  Elective CRT implantation	  
	  
 
	  
Access	  to	  specialist	  heart	  failure	  nurses	  via	  
telephone	  and	  outpatient	  visits	  	  
	  
 One month visit	  
History	  /NYHA	  class	  -­‐Physical	  examination	  
Blood	  tests*/Device	  
interrogation/Echocardiography	  
AV	  /	  VV	  delay	  optimization	  of	  device	  
	  
 Six month visit	  
History	  /NYHA	  class	  -­‐Physical	  examination	  
Blood	  tests*/	  Device	  Interrogation	  
	  
	  
 Access	  to	  specialist	  heart	  failure	  nurses	  via	  
telephone	  and	  outpatient	  visits	  	  
	  
	  
	   General HF Clinic Follow Up 
History/NYHA	  Class	  
Device	  Interrogation	  
	  
Figure 12: Demonstrating Patient 
Pathway through the clinical protocol 
at baseline, 1 month and 6 month 
intervals. * Blood Tests = Venous 
blood sampling for full blood count, 
renal function and electrolytes and B-
type natriuretic peptide. 
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4.2.3  Device Implantation 
All CRT implants were performed in a standardised manner. The left ventricular epicardial 
lead was implanted using established techniques into a lateral or postero-lateral branch of the 
coronary sinus. Right atrial and ventricular leads were implanted as per usual techniques. The 
type of CRT device implanted (i.e. CRT-P or CRT-D) was determined by the patient’s 
clinical characteristics. The final lead position was confirmed by peri-procedural fluoroscopy 
and chest radiography 24 hours post procedure.  
 
4.2.4  Echocardiography 
All patients underwent transthoracic echocardiography at baseline, one and six month’s clinic 
visits.  
Echocardiography was performed by accredited cardiac physiologists using either GE (Vivid 
7,GE Vingmed Ultrasound AS, Horten, Norway) or Philips (iE33; Philips Ultrasound, 
Bothell, WA) systems.  
Standardised 2D and Doppler echocardiography were performed on each individual at 
baseline, one and six month visits. Cardiac dimensions, the presence of valvular pathology 
and left atrial size were all recorded. LVEF was calculated using Biplane Simpson’s 
technique. At the one month visit, all patients underwent atrio-ventricular (AV) and 
ventriculo-ventricular (VV) optimisation using previously reported methodologies.(135) 
 
4.2.5  Patient Education 
Specialist heart failure nurses (HFSN) provided patient education with regards to aetiology, 
medical and device based therapy and psychosocial support. Between clinical visits, patients 
were encouraged to contact the HFSN team to discuss further physical or psychosocial issues.  
 
4.2.6  Ethics 
The study was ethically approved by the hospital ethics committee. (05/Q0404/121) The 
study complied with the principles of the Declaration of Helsinki.  
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4.2.7  Statistical Analysis 
Statistical analysis was performed using SPSS version 19.0 for Microsoft Windows. 
(Chicago, IL) Continuous variables were expressed as a mean ± standard deviation (SD) and 
categorical variables were expressed as a percentage. Differences in variables at months 1 and 
6 as compared to baseline were tested by Student’s paired t-test for normally distributed 
variables or by Wilcoxon sign test for non-normally distributed ones. Differences between 
different groups were tested either by the Student’s t-test or the Mann-Whitney test for 
normally and non-normally distributed variables, respectively. Chi-square test was used for 
comparison between categorical variables. Related categorical variables were compared using 
the McNemar test. A p value <0.05 was deemed to be of statistical significance for all 
analyses. Data were censored in the case of absence of follow up data or death or heart failure 
hospitalisation prior to the scheduled clinic visits.  
 
4.3 Results 
4.3.1  Demographics 
The baseline demographics for the cohort are described in Table 3. Mean age at CRT 
implantation was 67 ± 13 years, with n= 42 (28 percent) of the cohort aged greater than 75 
years old. The majority of the cohort were male; n=118 (79 percent) and received CRT-D 
implants n=114 (76 percent).  Prior to CRT implantation the mean QRS duration was 164±29 
milliseconds, mean LVEF 25± 7 percent and mean NYHA classification 2.9 ± 0.6.  
 
4.3.2  Medical Therapy  
Heart failure pharmacotherapy rates are described in Table 4. The rate of beta blocker (BB) 
prescription rose from 69 percent at baseline to 83 percent at 6 months (p=0.004). The 
numbers of patients on ≥50 percent of target dose (TD) rose from 32 percent to 61 percent at 
six months (p<0.0001). Angiotensin-converting enzyme inhibitors/ angiotensin II receptor 
blockers (ACEI/ARB) prescription rose from 91 percent at baseline, to 96 percent at one 
month following CRT implantation and 98 percent at six months following implantation. 
(p=0.06) There was a reduction in the prescription rate of loop diuretics and digoxin from 82 
percent to 77 percent (p=0.42) and 18 percent to 13 percent (p=0.77). The rate of 
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anticoagulation with warfarin rose over the 6 month period from 30 percent at baseline to 42 
percent at six months (p=0.001).  
 
4.3.3  Change in clinical and echocardiographic variables 
Changes in clinical and echocardiographic variables are demonstrated in Table 4. NYHA 
class improved both as a continuous and categorical variable. Initial mean NYHA class was 
2.9±0.6 which improved to 1.9±0.8 at six months (p<0.0001). LVEF also rose significantly 
over the six months from 25±7 percent to 33±12 percent (p<0.0001). All patients had levels 
of >92 percent of biventricular pacing at initial follow up. 
 
4.3.4  Follow Up 
The series included 148 patients at baseline, however a total of 126 (85 percent) patients 
attended one month and 136 (92 percent) attended six month appointments respectively. All 
bar a solitary patient survived to the six month clinic appointment. All patients were followed 
up in general heart failure clinics following discharge from the structured CRT clinic 
protocol. Following a median follow up period of 41.8 months (Interquartile range 20 months 
to 58.1 months), 36 (24 percent) of the cohort had died.  
 
4.4   Discussion 
This study demonstrates that a structured heart failure pacing clinic model can facilitate the 
initiation and uptitration of evidence based pharmacotherapies. The rates of ACEI/ARB, BB 
and warfarin prescription rose during the initial six months following CRT implantation.  
 
Current national and international guidance recommend CRT is only considered in 
symptomatic individuals with a broad QRS duration who are on optimal medical therapy.(11, 
22) However there are very limited data available in the post implant cohorts. A recent 
document issued by the European Heart Rhythm Association (EHRA) and the American 
Heart Rhythm Society (HRS) suggests that heart failure pharmacotherapies should be 
uptitrated in the post CRT implant. However this is a consensus view agreed upon by leading 
cardiologists and electrophysiologists in the field. The consensus statement points out that 
 131 
there is lack of data in this area and the need for further investigation.(99) Prior to 
implantation the rates of BB and ACEI/ARB usage were 72 percent and 85 percent 
respectively in CARE-HF, 68 percent and 89 percent in COMPANION and 96 percent for 
both in REVERSE.(5, 6, 96) However registry data demonstrate a lower rate of prescription. 
The European CRT survey describes clinical practice in relation to 2438 implants across 
thirteen European countries. The data showed that 84 percent of the cohort were on BB and 
91 percent were on ACEI/ARB at the time of discharge. US data shows similar trends with a 
rate of ACEI/ARB usage in the IMPROVE-HF cohort of 79 percent.(216) 
 
 The reasons behind suboptimal levels of heart failure pharmacotherapies are varied. These 
include adverse physiological effects; beta antagonist mediated symptomatic bradycardia, 
ACEi/ARB mediated deterioration in renal function and orthostatic hypotension. These 
potential effects on physiology may be addressed by CRT. A functioning bi-ventricular 
system will prevent symptomatic bradycardia. CRT may also improve renal function in some 
patients. The exact mechanisms for this remain unclear but may be due either to an increase in 
renal perfusion or a reduction in central venous pressure.(217) Ultimately the potential effects 
of CRT mean that a previously trialled medication which was not tolerated should be 
reconsidered following successful CRT implantation.  
 
This study adds to the currently limited data which exist for medical therapies following CRT 
implantation. Within this study which focussed on a specialist heart failure pacing clinic 
model, supervised by consultant cardiologists with expertise in heart failure and device 
management, the rates of evidence based therapies rose at 6 months following CRT 
implantation. The rate of absolute BB usage rose from 69 percent to 83 percent at 6 months. 
(See Figure 13) (p=0.004) The amount of patients on greater than 50 percent of target dose 
also rose over the same time period from 32 percent to 61 percent (p<0.0001). Though non-
significant the rates of ACEI/ARB usage also rose over the six month period; from 91 percent 
to 98 percent. The lack of significance reflects the high rate of ACEI/ARB usage at baseline. 
The rates of digoxin and loop diuretics initially fell (p<0.001) but then rose subsequently by 
six months. This may be explained by an initial beneficial effect of CRT in terms of 
symptomatic response. However six months following CRT implantation it may be that the  
initial positive effects have receded or higher rates of atrial fibrillation have been detected.  
The rate of warfarin usage also rose significantly within the cohort over six months from 30 
percent to 42 percent (p=0.001). Left ventricular systolic dysfunction is an established risk 
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factor for thrombo-embolic stroke within patients with atrial fibrillation.(218) Modern CRT 
devices are sophisticated and are capable of storing prolonged periods of rhythm data. Hence 
following implantation an active CRT device with accompanying device interrogation may 
detect higher rates of atrial arrhythmias. Once documented, patients should be considered for 
anticoagulation to minimise their thrombo-embolic risk.(219) 
 
Limited data exists with patients in the post CRT period and medical therapy. Mullens and 
colleagues have presented the experience in 75 patients via a dedicated CRT clinic.(149) 
Using a structured clinical protocol, the authors identified 24 percent of patients at the time of 
implantation were not on evidence based pharmacotherapies. Altman and colleagues describe 
the experiences of a differing clinical protocol located within another tertiary centre in the 
United States.(150) Within this observational study, a potential area of identifiable 
improvement was the prescription of HF pharmacotherapies.  
 
Current guidance suggests that uptitration of pharmacotherapies should be performed in all 
patients with LVSD. This includes patients undergoing CRT implantation, particularly as they 
are both symptomatic and have severe levels of LVSD. The studies performed with these 
agents suggest that patients should be uptitrated to target doses. Limited trial data exists for 
such suggestions, but clinical data are more suggestive that those patients who remain on 
suboptimal doses, especially those at less than <50 percent target dose have adverse clinical 
outcomes.(220)  Due to these statistical relationships and as per current guidelines, HF 
therapies were uptitrated to target doses in this population.  
 
4.5 Limitations 
 
This study represents the initial experience of a specialist heart failure pacing clinic model 
located within a tertiary centre within the United Kingdom. Hence the referrals for 
consideration for device therapy were from secondary care and not primary care. This may 
have led to referral bias. However the demographics of the cohort are consistent with other 
clinical registry data within the field.  
 
It is a single centre study with relatively low numbers of patients. The study is retrospective in 
design and hence the data utilised within it reflects that of a clinical service. In terms of 
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echocardiography, a number of accredited professionals carried out imaging studies and hence 
no appropriate measures of variance can be performed. Although the doses of prescribed HF 
pharmacotherapies were recorded, there were no measures of concordance. Hence it is 
assumed patients were compliant with the recommendations for concordance.  
 
This study is a cohort study with no control group, but without a structured protocol and 
clinical recovery it is more unlikely that primary care follow up would have achieved an 
uptitration in pharmacotherapies.  
 
The study lacked an un-paced control group, the study of whom is no longer possible with the 
approved guidelines for the implementation of CRT exist. Such a group would offer a control 
group in which to compare effect.  
 
4.6 Conclusion 
 
This study describes a dedicated heart failure pacing clinic protocol for the uptitration of 
evidence based HF pharmacotherapy following CRT implantation. The initial results 
presented within the study are suggestive that such an approach with subsequent uptitration 
and initiation of pharmacotherapies may represent one model of care for such patients this as 
compared to the tendency to maintain current dosages in conventional practice. Further 
prospective work needs to be carried out in this area to determine whether uptitration of 
pharmacotherapies in patients following CRT translates into improved clinical outcomes.  
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 Patients n=148 
Age (years) 
Age >75 years (%) 
67±13 
42(28) 
Gender (M/F) (%) 118(79)/30(21) 
Left ventricular ejection fraction (%) 25±7 
NYHA class (mean +/- SD) 
NYHA II (%) 
NYHA III (%) 
NYHA IV (%) 
2.9±0.6 
26(17) 
94(64) 
28(19) 
Ischemic aetiology (%)  75(50) 
CRT-D/P (%) 114(76)/36(24) 
Diabetes mellitus (%) 34(23) 
Hypertension (%) 35(23) 
Baseline rhythm (%) 
Sinus rhythm 
Atrial fibrillation/atrial flutter 
Paced 
Complete heart block 
 
98(67) 
37(25) 
5(3) 
8(5) 
QRS duration (ms) (Mean +/- SD) 164±29 
Systolic BP (mmHg) (Mean+/- SD) 117±19 
Diastolic BP (mmHg) (Mean +/-SD) 70±15 
 
Table 4:Baseline demographics; NYHA; New York Heart Association Classification; CRT-D; Cardiac 
Resynchronisation Therapy and Defibrillator; CRT-P; Cardiac Resynchronisation Therapy and 
Pacemaker; BP; Blood Pressure 
 
 
 135 
 Baseline Month 1  
P value* 
Month 6  
P value* 
NYHA class 2.9±0.6 2.0±0.6 <0.0001 1.9±0.8 <0.0001 
LVEF % 25±7.0 31±12 <0.0001 33±12 <0.0001 
LVEDD (cm) 6.7±1.0 6.4±1.0 0.042 6.6±1.1 0.380 
Systolic BP (mmHg) 117±19 118±22 0.421 116±19 0.896 
Diastolic BP (mmHg) 69±12 72±10 0.133 70±11 0.526 
Haemoglobin (mg/dL) 13.0±1.6 13.1±1.4 0.499 13.2±1.4 0.303 
Urea (mmol/L) 10.2±5.7 10.4±6.1 0.886 10.4±5.1 0.878 
Creatinine (µmol/L) 122±47 118±45.7      0.529 119±39 0.701  
BNP (pmol/L) 135±150 112±151 0.301 110±92 0.091 
AV delay (ms) 128±25 124±36 0.302 126±28 0.570 
Β blockers % 
≥50% TD  
69 
32 
79 
37 
0.078 
0.180 
83 
61 
0.004 
<0.001 
ACEi/ARBs % 
≥50% TD 
91 
71 
96 
76 
0.344 
0.263 
98 
82 
0.065 
0.185 
Aldosterone antagonist % 60 65 1.000 66 0.824 
Digoxin % 18 4 <0.001 13 0.424 
Loop diuretic % 82 35 <0.001 77 0.774 
Thiazide % 8 4 0.289 11 0.18 
Warfarin % 30 34 0.454 42 0.001 
 
Table 5:Changes in echocardiographic and clinical variables over 6 months. NYHA (New York Heart 
Association); LVEF (Left Ventricular Ejection fraction); LVEDD (Left-Ventricular End-diastolic 
Diameter); BP (Blood Pressure); BNP (B type Natriuretic Peptide); AV (Atrio-ventricular); TD (Target 
Dose)* p values represent paired T tests comparing values at follow up with baseline 
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Figure 13:Demonstrates changes in heart failure pharmacotherapies within the cohort over the 6 month 
period. 
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5.1 Introduction 
 
Cardiac Resynchronisation Therapy (CRT) is an established device based treatment for 
patients with symptomatic left ventricular systolic dysfunction, a broad QRS duration and on 
optimal tolerated medical therapy.(10) Despite documented beneficial effects upon morbidity 
and mortality, a minority of recipients do not derive the anticipated clinical benefit. 
 
Previous explanations for such lack of benefit have included left ventricular dyssynchrony, 
position of left ventricular lead, age, impairment of renal function and the extent and 
distribution of myocardial scar.(121, 212, 221) The most recent guidance in the area is from 
the European Society of Cardiology, published in 2013. This suggests that all patients who 
fail to improve clinically following CRT implantation should be considered for device based 
optimisation i.e. adjustment of the atrioventricular (AV) and ventriculo-ventricular (VV) 
intervals.(22)  
 
Both the rationale behind adjustment of AV and VV intervals and potential methods of 
optimisation have been covered in depth in Chapter I- Introduction. Amongst the non invasive 
techniques, impedance cardiography has been previously studied. Tse and colleagues in 2003, 
evaluated the role of impedance cardiography (ICG) in six individuals. ICG was used to 
optimise the AV delay, the results were then compared to those derived from transthoracic 
echocardiography. A range of values was evaluated and the optimal AV interval was identical 
in 5/6 patients (83 percent) (222) Braun and colleagues analysed data from a larger series 
published in 2005.  Using 24 patients, the optimal AV delay was again evaluated using ICG 
and conventional echocardiographic methods. In terms of the identification of optimal AV 
delay there was a degree of positive correlation between the two methods. (r=0.74; 
p<0.001).(223) Heinroth, in 2007, also evaluated the performance of ICG in the optimisation 
of AV and VV intervals in 46 patients undergoing CRT implantation. Mean cardiac output 
rose from baseline following ICG optimised AV and VV intervals to 4.86+ 1.1L/min 
(P=0.05).(224) This pilot study was devised to compare non-invasive cardiac output 
monitoring (NICCOMO) based optimisation versus echocardiographic techniques on non-
subjective symptomatic endpoints including 6 minute walk test distance, B type natriuretic 
peptide and quality of life scores in a non-inferiority trial design.(225) 
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5.2 Methods 
5.2.1  Setting and Patient Population 
Between January 2010 and April 2012, 44 patients were assessed for inclusion within this 
study. All potential participants within the study were identified from the dedicated heart 
failure pacing clinic within the institution. The institution was a tertiary university teaching 
hospital within London, United Kingdom.  
All patients fulfilled contemporary guidance for the implantation of CRT.(215) This included 
optimal tolerated heart failure pharmacotherapy, broad QRS duration on surface 
electrocardiogram (>120 milliseconds, preferably in left bundle branch block morphology 
(LBBB)), a left ventricular ejection fraction (LVEF) of <35 percent and the presence of 
symptoms (New York Heart Association (NYHA) grade II-IV).   
The study gained ethical approval from the local ethics committee (05/Q0404/121). The study 
protocol complied with the Declaration of Helsinki and all participants gave fully informed 
written consent.  
	  
5.2.2  Study Protocol 
Paired data was collected for all study participants. Patients were optimised either via 
echocardiographic techniques (trans-mitral velocity time integral (VTI) and left ventricular 
outflow tract VTI) or by optimisation with the NICCOMO device. CRT devices were 
optimised at one month and paired data was collected at one and three months on clinical, 
echocardiographic, biochemical and functional indices. The study CONSORT diagram is 
demonstrated in Figure 14.  
 
The primary endpoint for the study was a comparison of 6 minute walk test (6MWT) 
difference; secondary endpoints were NYHA class, Minnesota living with Heart Failure 
(MHLHFQ) scores, B-type natriuretic peptide levels and LVEF. 
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Figure 14: CONSORT trial flow diagram depicting recruitment and patient pathway through the study 
 
5.2.3  Cardiac Resynchronisation Therapy Implantation 
All patients received CRT implants in a standardised manner by a single experienced 
consultant operator (Dr Rakesh Sharma, Consultant Cardiologist and MD Supervisor). A 
selection of leads and generator boxes were used from the major manufacturers of CRT 
devices. All permitted alteration of both AV and VV intervals. A lateral or postero-lateral 
venous tributary of the greater cardiac vein was selected wherever possible. The final left 
ventricular lead position was confirmed in the catheter laboratory in multiple planes using 
fluoroscopy. Chest radiography was performed the following day in both posterior-anterior 
44 Patients Identified  
2 patients declined 
42 Patients enrolled into 
study - intention to treat 
analysis 
19 Patients randomised to 
Impedance Cardiographic 
Optimisation 
23 Patients randomised to 
Echocardiographic 
Optimisation  
Follow Up Visit – 3 Months 
	  
End	  of	  Study	  Participation	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and lateral views. All left ventricular leads were implanted successfully and there were no 
lead displacements within this cohort.  
 
5.2.4  NICOMMO Device 
The commercially available NICOMMO device (Medis, GmbH Ilmenau, Germany) was used 
to perform biosensor mediated impedance cardiography (ICG). Four surface electrodes were 
placed in the configuration demonstrated in Figure 15. Following the administration of small 
amounts of alternating current and using the algorithmic interpretation of Ohm’s law, ICG can 
calculate bioreactive impedance using the pulsed blood volume in the ascending aorta. 
The NICCOMO device can calculate cardiac output, cardiac index, stroke volume and 
systemic vascular resistance over a twenty beat cycle and has been previously validated.(226) 
 
 
Figure 15: Demonstrates the configuration of surface electrodes for a recording using the NICCOMO 
device 
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5.2.5  Optimisation Procedure 
Patients were randomised to either echocardiographic or NICCOMO based optimisation via a 
randomisation protocol. Due to physical limitations, patients and the investigator  could not 
be blinded to the method of optimisation and hence the study was performed as a randomised 
non blinded study.  
 
For both forms of optimisation, a range of AV delays was assessed (80 milliseconds to 200 
milliseconds) and a range of VV delays also tested. (Right Ventricle Pre-Excited +60 
milliseconds to Left Ventricle Pre-Excited +60 milliseconds). Prior to recording any 
measurements, a minute was allowed to elapse. All recordings took place in a quietened room 
with the patient recumbent. For patients in atrial fibrillation only the VV delay was optimised. 
For all patients wherever possible AV delay was performed first. The pacing mode for all 
participants was placed in DDD mode at 70 beats per minute except for those patients in atrial 
fibrillation who were placed in VVI mode at 70 beats per minute.  
 
5.2.6  Echocardiography Optimisation 
To guide the adjustment of AV and VV delays the previously described techniques of 
transmitral VTI and LVOT VTI were used.(135, 227) The ideal AV delay was identified by 
the maximal transmitral VTI and E/A wave morphology. The A wave was reviewed for 
potential truncation and encroachment into diastole. The ideal VV delay was identified by the 
maximal LVOT VTI.  
 
5.2.7 NICOMMO (Impedance Cardiography) Optimisation 
All patients receiving an ICG optimisation did so after a period of rest within the room for 10 
minutes. This was to minimise any external stimuli which may have induced sympathetic 
activation.  
After each change in pacing mode, the ICG module would self analyse 20 consecutive beats 
and calculate a mean cardiac output. The ideal AV and VV delays were those with the 
maximal cardiac output. No further echocardiography was performed within these patients to 
optimise their pacing systems.  
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5.2.8 Echocardiography 
Routine 2-D and Doppler echocardiography were performed on all study participants at one 
month and three month intervals. All echocardiography was performed with commercially 
available systems (Vivid 7, General Electric Healthcare, Milwaukee, WA, US or ie33 Philips 
Medical Systems, Bothell, WA, US). Left ventricular measurements including dimensions, 
volumes and ejection fraction were all recorded as per the American Society of 
Echocardiography guidelines.(202) The Biplane Simpson’s technique was used to calculate 
all LVEF. 
 
5.2.9  Statistical Analysis 
All statistical analysis was performed using SPSS version 20 (Integrated Business Machines 
Corporation, Armont, NY, US). Continuous variables are expressed as mean ± standard 
deviation. Categorical variables are expressed as a number and percentage.  
 
Differences in continuous variables were tested by the Student’s paired t –test for normally 
distributed variables. Differences between groups were tested by the Student's t-test or the 
Mann-Whitney U test for normally and non-normally distributed variables respectively. 
Fisher's exact test was used for comparisons between categorical variables. For all analysis a 
p value <0.05 was deemed statistically significant.  
 
5.2.10  Power Calculation 
From a previous dataset of patients who have undergone CRT through the dedicated heart 
failure pacing clinic the mean 6MWT was 242m with a standard deviation of 82m.  To detect 
a clinically significant difference of  twenty five percent  between the two groups with a 
power of 80 percent and a significance level of 5 percent we would require a sample size of 
41 patients in each group. This number of patients would also be sufficient to demonstrate  
that the ICG method of optimisation is non inferior to that of echocardiographic optimisation.  
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5.3 Results 
5.3.1  Baseline Demographics 
A total of 44 patients were approached to participate in the study; 2 patients declined 
participation due to geographical distance from the institution. Hence 42 patients were 
enrolled. A solitary patient declined to return for follow up but was included in analysis on an 
intention to treat basis.  
 
Pre- CRT implantation characteristics are demonstrated in Table 5. Study baseline 
characteristics are demonstrated in Table 6. The population prior to CRT implantation had a 
mean LVEF of 27.7 ± 7.8  percent, with a mean QRS duration of 156.5 ± 24.5 milliseconds. 
The rate of medical therapy in the cohort prior to CRT implantation was 33 (79 percent) on 
ACEI/ARB, 24 (57 percent) on beta blocker and 19 (45 percent) on an aldosterone antagonist.  
 
At baseline there were no significant differences between the group of patients who 
underwent echocardiographic and impedance cardiographic optimisation save for uric acid 
levels.  
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8 Characteristic 9 All Patients (n=42) 
10 NYHA  11 2.6 ± 0.8 
12 ACEI/ARB n (%) 13 33 (79%) 
14 >50% TD ACEI/ARB n (%) 15 18 (43%) 
16 β-Blockers 17 24 (57%) 
18 >50%TD β- Blockers n (%) 19 10 (24%) 
20 Aldosterone Antagonists n (%) 21 19 (45%) 
22 Loop Diuretics n (%) 23 31 (73%) 
24 Systolic Blood Pressure (mmHg) 25 117.3 ± 21.8 
26 Diastolic Blood Pressure (mmHg) 27 69.2 ± 11.7 
28 Left Ventricular Ejection Fraction (%) 29 27.7 ± 7.8 
30 Left Ventricular End Diastolic Diameter (centimetres) 31 6.3 ± 0.8 
32 QRS duration 33 156.5 ± 24.3  
 
Table 6: Pre implantation baseline characteristics of the optCRT study population 
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34 Characteristic 35 All Patients 
(n=42) 
36 TTE Optimisation 
(n=23) 
37 ICG Optimisation 
(n=19) 
38 Age (Years) 39 66.7±12 40 66.4 ± 10.4 41 67.3 ± 14.1 
42 NYHA  43 1.8 ± 0.6 44 2.0 ± 0.6 45 1.7 ± 0.7 
46 ACEI/ARB n (%) 47 40 (95) 48 23 (100) 49 18 (95) 
50 >50% TD ACEI/ARB n (%) 51 26 (62) 52 17 (74) 53 12 (63) 
54 β-Blockers 55 37 (88) 56 21 (91) 57 16 (84) 
58 >50%TD β- Blockers n (%) 59 14 (33) 60 6 (26) 61 7 (39) 
62 Aldosterone Antagonists n (%) 63 24 (57) 64 16 (70) 65 8 (42) 
66 Loop Diuretics n (%) 67 29 (69) 68 16 (70) 69 13 (68) 
70 Dilated Cardiomyopathy n (%) 71 24 (57) 72 12 (52) 73 12 (61) 
74 Ischaemic Cardiomyopathy n (%) 75 18 (43) 76 11 (48) 77 7 (39) 
78 Diabetes Mellitus n (%) 79 9 (21) 80 7 (30) 81 2 (10) 
82 Hypertension n (%) 83 7 (17) 84 5 (22) 85 2 (10) 
86 Sinus Rhythm n (%) 87 31 (74) 88 18 (78) 89 13 (69) 
90 Atrial Fibrillation n (%) 91 11 (26) 92 5 (22) 93 6 (32) 
94 Systolic Blood Pressure (mmHg) 95 117.1 ± 18.5 96 113.2 ± 16.5 97 121.4 ± 20.7 
98 Diastolic Blood Pressure (mmHg) 99 71.9 ± 12.5 100 72.7 ± 12.2 101 70.1 ± 12.8 
102 Haemoglobin (g/Dl) 103 12.6 ±1.7 104 12.4 ± 1.9 105 12.8 ± 1.3 
106 Urea (mmol/L) 107 9.4± 4.6 108 9.6 ± 3.9 109 9.2 ± 5.4 
110 Creatinine (mmol/L) 111 105.2 ± 40.0 112 104.6 ± 31.5 113 106.8 ± 50 
114 B-Type Natriuretic Peptide (ρmol/L) 115 105.9 ± 119.3 116 127.8 ± 114.8 117 85.6 ± 125.4 
118 Uric Acid (µmol/L) 119 427.6 ± 136.5 120 472.9 ± 114.1 121 380.6 ± 148.4 
122 6 Minute Walk Test (Metres) 123 307.6 ± 106.3 124 304.7 ± 114.3 125 310.1 ± 99.7  
126 Left Ventricular Ejection Fraction (%) 127 33.6 ± 10.1 128 31.9 ± 9.6 129 35.2 ± 10.9 
130 Left Ventricular End Diastolic Diameter 
(centimetres) 
131 6.1 ± 0.9 132 6.2 ± 0.9 133 6.0 ± 0.9 
 
Table 7: Baseline Entry of Study Characteristics (1 Month following implantation of cardiac 
resynchronisation therapy); TTE; Trans thoracic echocardiogram; ICG; Impedance Cardiography; 
NYHA; New York Heart Association; TD; Target Dose 
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Table 8: Demonstrates the study endpoints for patients undergoing echo and impedance cardiography 
guided optimisation of the CRT device, BNP; B-Type Natriuretic Peptide; 6MWT; 6 Minute Walk Test; 
NYHA; New York Heart Association; LVEF; Left Ventricular Ejection Fraction; LVEDD; Left 
Ventricular End –Diastolic Dimension; LVESD; Left Ventricular End Systolic Dimension; MLHFQ; 
Minnesota Living with Heart Failure Questionnaire 
 
 
5.3.2  Optimal AV and VV delays 
Within the cohort, 28 (90 percent) of eligible patients (i.e. those not in atrial fibrillation) had a 
change in AV delay from baseline. In 10 patients (32 percent) the optimal delay was 120 
milliseconds For VV delay 26 (66 percent) of patients had an adjustment of their delay with 
the majority resulting in the optimal delay of simultaneous depolarisation. These are 
demonstrated in Figure 16: Demonstrate spread of atrioventricular and ventriculo-ventricular 
delays within the optCRT cohort using either echocardiographic or impedance cardiography 
methods of optimisation. 
 
134 Variable 135 TTE Baseline 136 TTE FU 137 P Value 138 ICG Baseline 139 ICG FU 140 P Value 
141 BNP (ρmol/L) 142 127.8 ± 114.8 143 120.7 ± 162.3 144 P=0.95 145 85.6 ± 125.4 146 55.2 ± 54.3 147 P=0.27 
148 6 MWT 
(metres) 
149 304.7 ± 114.3 150 349.2 ± 101.2 151 P=0.23 152 310.1 ± 99.7 153 365.2 ± 100.4  15 P=0.15 
155 NYHA 156 2.0 ± 0.6 157 1.9 ± 0.7 158 P=0.49 159 1.7 ± 0.7 160 1.7 ± 0.6 161 P=0.57 
162 LVEF (%) 163 31.9 ± 9.6 164 32.7 ± 10.5 165 P=0.56 166 35.2 ± 10.9 167 39.1 ± 11.8 168 P=0.14 
169 LVEDD (cm) 170 6.2 ± 0.9 171 6.2 ± 0.9 172 P=0.98 173 6.0 ± 0.9 174 5.9 ± 1.0 175 P=0.62 
176 LVESD (cm) 177 5.2 ± 1.0 178 5.3 ± 0.9 179 P=0.78 180 4.9 ± 1.1 181 4.9 ± 1.2 182 P=0.77 
183 MLHFQ 184 44.2 ± 25.3 185 37.4 ± 19.2 186 P=0.23 187 28.4 ± 23.3 188 28.9 ± 29.5 189 P=0.96 
190 Urate (µmol/L) 191 472.9 ± 114.1 192 462.8 ± 115.7 193 P=0.87 194 380.6 ± 148.4 195 394.7 ± 102.7 196 P=0.72 
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Figure 16: Demonstrate spread of atrioventricular and ventriculo-ventricular delays within the optCRT 
cohort using either echocardiographic or impedance cardiography methods of optimisation 
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5.4 Discussion 
 
The study does not demonstrate a significant difference between an echocardiographic 
optimisation process as compared to using impedance cardiography. This relationship was 
confirmed for both primary and secondary endpoints i.e. functional (6MWT distance), 
mechanical (LVEF), neurohormonal markers (BNP, Urate) and symptomatic assessments. 
(NYHA, MQLHF) 
 
The reasons behind these findings are varied. The study was originally conceived as a pilot 
study with a randomised, non blinded non inferiority study. However due to difficulties with 
patient recruitment and the initial purchase of the equipment, the study is underpowered. In 
terms of trial design the study had follow up visits at three months. However it is recognised 
within the literature that CRT may take up to six months to exert its effects on functional and 
mechanistic endpoints.(22) Though others have documented a rapid response in terms of 
symptoms, the other beneficial effects of CRT seem to take longer to become apparent. Hence 
if the study was repeated with larger numbers of individuals, it may be worthwhile to extend 
the follow up period to that over six months.  
 
The population enrolled within the study were all recruited from the institution’s dedicated 
heart failure pacing clinic. The institution is a tertiary university teaching hospital based in 
London and hence its patient load reflects a mixture of referrals from primary or secondary 
care. The majority (53 percent) of the population within this study had a non-ischaemic 
aetiology.  All patients had CRT implanted on the basis of current guidance.(215) At their 
enrolement visit i.e. one month following CRT implantation, the rates of medical therapy 
were comparable to that of other studies with CRT and registry data. (ACEI/ARB -90 percent, 
β-Blocker -88 percent, Mineralocorticoid Receptor Antagonists -57 percent).(190) Following 
whichever method of optimisation that was performed (See Figure 16) there was a wide range 
of AV delays and VV delays identified as the optimal settings. The majority of patients had a 
change in their AV delay as compared to factory settings. (90 percent) and two thirds (66 
percent) of patients had changes in their VV delays as compared to implantation intervals.  
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The study was equivocal in terms of endpoints. The primary pre-specified endpoint was the 6 
minute walk test distance. Though the mean 6 MWT distance rose in both arms (349.2 ± 
101.2, 365.2 ± 100.4 (echocardiographic and ICG respectively), none of these results 
demonstrated statistical significance. There was also a reduction in both groups in NYHA 
class and plasma BNP concentrations. Again these did not achieve statistical significance. 
Interestingly there was also little improvement neither in mechanical variables including 
LVEF, LVEDD nor in symptom score questionnaires. (Minnesota Living with Heart Failure 
Questionnaire) 
 
There are several potential explanations for these results. Firstly the study is underpowered 
and this due to problems with recruitment. Though Figure 5 demonstrates high rates of 
agreement to participate in the study, there was a delay in securing ethical approval, 
purchasing the NICOMMO device and subsequent technical issues. All of this reduced study 
recruitment. A number of single centre studies have published data which demonstrates CRT 
may take anything up to 6 months to fully exert its beneficial effects.(102, 228) Hence this 
may explain the lack of positive remodelling in patients included within this study. Previous 
work has demonstrated that measures of left ventricular systolic function e.g. LVEF do not 
necessarily correlate with symptoms.(229) This is supported by a reduction in symptomatic 
classification as compared to lack of improvement in mechanical endpoints. 
 
The introductory chapter summarises potential methods of optimisation – however the 
commonest methods of optimisation are echocardiographic based. This requires intensive 
labour, appropriate levels of skill and technology and therefore incurs significant cost. The 
other major criticism of echocardiographic measures is that raised by PROSPECT in terms of 
reproducibility and repeatability of complex echocardiographic methodology. PROSPECT 
evaluated numerous complex echocardiographic markers of dyssynchrony on a mass scale (all 
of which had been proven in smaller single centre studies) and demonstrated poor 
reproducibility.(103) Another issue is that resting echocardiographic alteration of the CRT 
device intervals does not take into account day to day variability of loading conditions, nor 
the effect of physical exertion on transmitral flow and subsequent left ventricular physiology. 
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Previous groups have therefore looked at device based algorithms for device ‘self-
optimisation’. The belief was that device based algorithms would monitor intrathoracic 
impedance or other biometric data and then adjust AV intervals accordingly. Two studies 
have published using device based protocols for optimisation. SMART-AV™ evaluated a 
three armed randomised, non-blinded study in 1014 participants randomised to a fixed AV 
delay of 120 milliseconds, SMART-AV CRT based adjustment of AV delay or 
echocardiographic adjustment of AV delay.(126) The study used the Smart Delay ™ sensing 
algorithm which was embedded in the CRT device as manufactured by Boston Scientific 
Corporation. (Natick, MA, US). Alternatively quickOPT™ is another device based algorithm 
in a different manufacturer which evaluated frequent optimisation versus echocardiography 
(FREEDOM Study).(127) In this study, 1580 patients were studied and the primary endpoint 
was a worsening in a heart failure composite endpoint. Secondary endpoints included 
cardiovascular hospitalisation and all-cause mortality. The results were equivocal and did not 
demonstrate any clear superiority in terms of clinical endpoints nor outcome.  
 
With the lack of consensus derived from the literature with regards to echocardiography and 
device based methods of optimisation, others proposed impedance cardiography as an 
alternative. There is a paucity of literature within this area and few trials to date have been 
published evaluating optimisation via ICG techniques and clinical endpoints. Khan and 
colleagues in 2011 demonstrated in 203 patients, that ICG based optimisation was superior to 
standardised factory settings at six months in terms of symptoms (lower NYHA class), quality 
of life scores and echocardiographic setting.(146) However this study made a direct 
comparison to a randomised arm with no device optimisation and ICG optimisation. There 
was no comparison between ICG and echocardiographic methods of optimisation.  
 
Another major critique of optimisation however it is performed is the lack of longer term 
clinical endpoints including heart failure hospitalisation and mortality. Though studies are 
underway to investigate this relationship there is no published evidence in either observational 
or randomised formats.  
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5.5 Limitations 
 
This was a small non randomised observational study performed in a tertiary centre within the 
United Kingdom. Hence caution has to be exercised in terms of extrapolating the results to 
other populations and also in interpretation of its findings. As stated within the methods 
section, the study utilised resting measures of cardiac output and transmitral and trans aortic 
flow these may not correlate with those obtained following exertion and would represent 
another area of investigation. As per the institutional protocol and previous published 
literature AV delay was optimised followed by VV delay. This may not be correct and further 
work needs to be done to investigate whether this methodology is correct in terms of interval 
adjustment.  
 
All patients were reviewed and recruited to the study, four weeks after CRT implantation. 
This differs to other studies of optimisation. This represents institutional policy and that the 
left ventricular lead is both functional and embedded with no changes in thresholds and 
impedances. However the differing time frames denoted within this study may not have been 
sufficient to capture a positive effect from CRT implantation and optimisation. The study is 
underpowered and thus statistical relationships obtained from this protocol require a correctly 
powered study to formally investigate the hypothesis in more robust fashion.  
 
Lastly the study did not contain a control arm, with patients who had undergone CRT 
implantation and received no device optimisation. To truly evaluate the clinical effects of any 
optimisation intervention this would be necessary to evaluate the added effect of the change.  
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5.6 Conclusions 
 
This study on the basis of its recruitment demonstrated no difference between an 
echocardiographic based or impedance cardiographic based method of optimisation on 
functional, symptomatic and mechanical endpoints over a follow up period of three months. 
Despite its limitations, it is one of only a few studies which compares two different methods 
of optimisation. Clearly a larger study is needed to further clarify this relationship and the 
current study’s findings. It is noteworthy though that the population within this study had 
higher rates of heart failure pharmacotherapy as compared to baseline and that whichever 
method of optimisation was selected resulted in significant changes in AV and VV delay.   
 
A larger multi-centre robust study is needed with multiple comparative methodologies with 
prespecified hard clinical endpoints which reflect the course of heart failure patients e.g. heart 
failure decompensation, major arrhythmic occurrence and death. It is only with such data and 
rigorous scientific evaluation that the community will be able to draw more formative 
conclusions.  
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Chapter VI: Right Ventricular 
Dysfunction and its clinical 
importance in patients with Cardiac 
Resynchronisation Therapy 
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6.1 Introduction 
 
Cardiac Resynchronisation Therapy (CRT) has become an established therapy for selected 
patients with symptomatic left ventricular systolic dysfunction.(22) However a number of 
patients as described in Chapter I do not obtain a symptomatic benefit. This is despite the 
current well recognised recommendations for patient selection for CRT devices. Furthermore 
this means that a number of patients are undergoing device implantation without acute clinical 
improvement, though as previously discussed there may be longer term effects on heart 
failure hospitalisation, progression of disease and mortality.  
 
The definition of CRT response has been discussed in the introductory chapter. This remains 
controversial with no consensus.  From a mechanical standpoint; studies have demonstrated 
that CRT may invoke left ventricular (LV) remodelling in certain patients, following 
implantation.(230) 
 
Previous studies evaluating right ventricular (RV) function in such circumstances have used 
echocardiography and radionuclide imaging.(231-233) However the RV is anatomically 
complex and its structural geometry poses major challenges for cardiac imaging.(234) Cardiac 
Magnetic Resonance Imaging (CMR) has the ability to image the right ventricle throughout 
the cardiac cycle leading to a more robust and validated assessment of RV function.(23) The 
inter-observer variability in a validatory study performed in healthy subjects was 6.3 percent 
for end diastolic volumes (EDV), 8.6 percent for end systolic volumes (ESV), 7 percent for 
stroke volume (SV), 4.4 percent for ejection fraction (EF), and 7.8 percent for right 
ventricular mass (RVM). Intra-observer variability was 3.6 percent for EDV, 6.5 percent for 
ESV, 5.9 percent for SV, 4 percent for EF, and 5.7 percent for RVM. 
 
The aim of this study was to investigate the impact of RV function, as assessed by CMR 
within patients undergoing CRT on clinical outcomes.  
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6.2 Methods 
6.2.1 Study Population 
A consecutive series of 60 patients was identified from the specialist heart failure pacing 
clinic at the Royal Brompton Hospital, London. All participants fulfilled contemporary 
criteria for CRT implantation.(215) 1. New York Heart Association Class III –IV, 2. QRSd 
>120 ms on surface electrocardiogram (ECG), 3. LVEF ≤ 35 percent by trans thoracic 
echocardiography) and on optimal tolerated evidence based medical therapy. Additionally all 
study participants had had a CMR study at most 3 months prior to CRT implantation.  
 
The study period ran between January 2005 and March 2010.  
 
Prior to CRT implantation, baseline demographical data was recorded, including aetiology of 
heart failure, symptomatic status, medication use, ECG data (including QRSd and rhythm). 
The data was obtained from the patient’s medical records and electronic records.  
 
The study involved a local review of patient medical records, therefore individual consent was 
not deemed necessary by the hospital Ethics Committee who approved  the study.  
 
6.2.2 Imaging 
Cardiovascular magnetic resonance studies were performed in 1.5T Sonata or Avanto 
scanners (Siemens, Erlangen, Germany). A short-axis stack from atrio-ventricular level to the 
apex was acquired using a steady-state free-precession cine sequence (echo time 1.6 ms, 
repetition time 3.2 ms, flip angle 60°, slice thickness 7 mm with a 3 mm gap, acquisition time 
of 8-12 cardiac cycles) to quantify left and right ventricular volumes. Long-axis cines were 
also acquired to define the valve plane throughout the cardiac cycle. An inversion recovery 
gradient echo sequence was used 10 minutes after gadolinium injection (Magnevist® or 
Gadovist®, 0.1 mmol/kg) to assess myocardial scar. Inversion times were set to null the 
normal myocardium with images repeated in two stacks of identical short-axis planes but 
separate phase-encoding directions to exclude artefacts. 
Left and right ventricular volumes were calculated using semi-automated software (CMR 
tools, Cardiovascular Imaging Solutions, London, UK) as previously described.(23, 24) 
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Epicardial and endocardial borders were traced in all short-axis images and the papillary 
muscles and trabeculations were delineated by thresholding of the blood pool. Tracking of the 
mitral and tricuspid valve was used to correct left and right ventricular volumes during 
systole. The resulting values were then indexed to body surface area and compared to 
reference values from a control population. Tricuspid annular plane systolic excursion 
(TAPSE) was measured from the 4-chamber view. RV dysfunction was defined as RVEF < 
0.5 or TAPSE < 15 mm; severe RV dysfunction was defined as RVEF < 0.3 or TAPSE < 10 
mm. Peak RV wall thickness was measured from the short-axis slices. 
 
Valvular regurgitation was graded as mild (n=1), moderate (n=2) or severe (n=3) by blinded 
observers, based on the echocardiographic and CMR findings. LVEF was calculated by 
echocardiography using the Simpson’s method from the 2-chamber and 4-chamber views. 
Pulmonary artery systolic pressure was determined by echocardiography using standard 
methodology.(235) 
 
Assessment of late gadolinium enhancement (LGE) in the left or right ventricle was also 
interpreted by blinded observers. When present, the amount of LGE was quantified in a 16-
segment model based on the “full width at half maximum” technique by customized analysis 
software (MRI-MASS, Medis, Leiden, the Netherlands)(236)  
 
6.2.3 Outcomes  
Every patient was followed up in a specialist heart failure clinic. At these appointments, 
evidence based heart failure pharmacotherapies were adjusted and optimized. No patient was 
lost to follow up.  
 
The primary end point was a composite of all-cause mortality or an unplanned hospital 
admission for a major cardiovascular event. Only the first event was included for analytical 
purposes.  
 
The secondary end point was an improvement in LVEF by ≥ 5 percent, 12 months after CRT 
implantation. This was assessed by trans thoracic echocardiography. (TTE)(237)  
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6.2.4 Statistical analysis 
Results were analysed using SPSS software version 19.0 (SPSS Inc, Chicago, Illinois, US). 
Continuous variables were assessed for normal distribution and if normally distributed 
presented as a mean +/- standard deviation. If they were non normally distributed, they are 
presented as a median +/- interquartile range.  
 
Two-tailed t-test and one-way ANOVA were used to compare normally distributed variables; 
Mann-Whitney test was used to compare non-normally distributed variables. Correlation with 
Pearson’s or Spearman’s methods was used as indicated. 
 
Time-to-event analysis was performed using Cox’s proportional hazard models. Logistic 
regression was used to evaluate the effects of CRT at 12 months. Multivariate analysis was 
performed on parameters that were significant on univariate analysis. A p value <0.05 was 
deemed to be statistically significant.  
 
6.3 Results  
6.3.1 Demographics 
The baseline demographical data are presented in Table 8 . The mean age of the cohort was 
65.3 +/- 12.5 years. The majority of the patients were male (76.7 percent).  The principal 
aetiology within this study was previous ischaemic heart disease (48.3 percent) and the 
majority of patients were in sinus rhythm. (76.7 percent)  
The mean heart rate prior to CRT was 76 +/- 15 beats per minute, the mean QRS duration on 
ECG was 156 +/- 21 ms. 95 percent of patients who had CRT implanted had left bundle 
branch block on their ECG. The median time between CMR study and CRT implantation was 
6 days. Nearly all (93 percent) of the cohort received a biventricular-ICD (CRT-D).  
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Table 9: Data is presented as n (percent), mean ± SD, or median (25th - 75th percentile). 
NYHA = New York Heart Association; ACE = angiotensin-converting enzyme; 
ARB = angiotensin receptor blocker; BNP = B-type natriuretic peptide; EDV = 
End-diastolic volume; ESV = End-systolic volume; EF = Ejection fraction; TAPSE 
= tricuspid annular plane systolic excursion. 
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6.3.2 Right ventricle 
The indexed volumes and RV ejection fraction were non normally distributed. They are 
presented as a median plus interquartile range.  
 
The median end diastolic and end systolic volumes were 82 (65-123) mL/m2 and 38 (27-76) 
mL/m2, respectively. Right ventricular indexed end-diastolic volume was increased in 38 
percent of patients, while the indexed end-systolic volume was increased in 53 percent of 
patients.(22) The median RVEF was 52 percent (IQR 37-62%), with 53 percent of patients 
having a RVEF ≥ 50 percent. 
 
Mean Tricuspid Annular Plane Systolic Excursion (TAPSE) was 13.5 +/- 5.6 mm. If a 
standard echocardiographic definition of a normal TAPSE is applied than 40 percent of the 
population were within normal limits.(235) 
 
The pulmonary artery systolic pressure (PAP) could be measured in 52 patients (87 percent). 
The mean PAP was 38.7 ± 8.7 mmHg, with 37 percent of patients having a PAP > 40 mmHg. 
Tricuspid regurgitation was seen in 57 percent of the patients, and was significant in 14 
percent of patients (12 percent moderate, 2 percent severe). No significant pulmonary 
regurgitation was identified. 
 
There was a moderate correlation of RVEF with TAPSE (r=0.58, p<0.01), and RVEF with 
LVEF (r=0.41, p<0.01). Severity of mitral regurgitation was associated with a higher PAP 
(p=0.01) and a lower RVEF (p<0.01). An inverse correlation was observed between RVEF 
and pulmonary artery pressure (r= -0.37, p<0.01), RV wall thickness (r= -0.28, p=0.03) and 
severity of tricuspid regurgitation (p=0.03). TAPSE was inversely related with RV wall 
thickness (r= -0.29, p=0.03), but not with pulmonary artery pressure (r= -0.15, p=0.28) or 
LVEF (r= 0.09, p=0.48). 
RVEF was similar in patients with an ischaemic and non-ischaemic aetiology (46.9 ± 14.8 
percent vs. 49.5 ± 18.9 percent, p=0.56), and in patients with atrial fibrillation (AF) compared 
to those in sinus rhythm (45.4 ± 14.9 percent vs. 49.2 ± 17.8 percent, p=0.48). 
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6.3.3 Myocardial fibrosis  
All patients received concurrent gadolinium enhanced contrast media at the time of their 
CMR study. LV late gadolinium enhancement (LGE) was present in 66 percent of the group. 
Nineteen  patients (31.7 percent) had subendocardial enhancement suggesting prior 
myocardial infarction, 15 patients (25.0 percent) had mid-wall enhancement pattern indicating 
fibrosis, and the remaining six patients (10.0 percent) had a mixed pattern of myocardial 
infarction and mid-wall fibrosis. Myocardial infarction was therefore present in 25 patients 
(41.7 percent): the septal wall was affected in 11 patients; the inferolateral wall was involved 
in 15 patients.  
 
Right ventricular LGE was present in only five patients (8.3 percent). All these patients had 
coronary artery disease with inferior myocardial infarctions of the LV extending to the 
inferior free wall of the RV.  
 
6.3.4 Follow-up 
There was a median follow up period of 26.1 months (IQR 16.1 -39.3 months) following CRT 
implantation. Eighteen patients reached the primary study end point (13 unplanned 
cardiovascular hospitalisations (All for HF decompensation) and 11 deaths (8 cardiac, 3 non 
cardiac).  
 
Atrial fibrillation and RV dysfunction emerged as the only predictors of the primary 
composite end-point on univariate analysis (See Table 10). Patients in atrial fibrillation or 
flutter had a HR of 2.6 (95 percent CI 1.02-6.84, p=0.047) for the primary end-point. For each 
10 percent decrease in RVEF, the risk of the primary end-point increased by 40 percent (HR 
0.96, 95 percent CI 0.94-0.99, p=0.006); for each 1 mm decrease in TAPSE, the risk of the 
primary end-point increased by 12 percent (HR 0.88, 95 percent CI 0.80-0.96, p=0.006). 
Patients were less likely to undergo LV remodelling if RV function was noted to be poor. 
Significantly impaired RV function, defined as a RVEF < 30 percent or a TAPSE < 10mm, 
was particularly associated with a low rate of LV remodelling with CRT (rates of 18.2 percent 
and 26.7 percent, respectively). 
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6.3.5 Improvement LVEF ≥ 5 Percent 
The majority of patients (n=56 (93%)) completed one year of follow up. 27 (48%) of this sub 
group had an increase of more than 5% in LVEF. Two sets of parameters were associated 
with a failure of LV remodelling (as defined by <5% improvement in LVEF) from CRT on 
univariate analysis: (1) coronary artery disease, associated with myocardial infarction and 
amount of scar (myocardial fibrosis plus infarction), were predictors of a failure of 
remodelling to therapy; (2) right ventricular dysfunction (lower RVEF and TAPSE) and 
hypertrophy (thicker RV free wall). Myocardial infarction (OR 0.90, 95% CI 0.83-0.96, 
p=0.004) and RVEF (OR 1.05, 95% CI 1.01-1.09, p=0.01) were the only variables to remain 
significant on multivariate analysis. (See Table 11 + 12) 
 
Table 10: Univariate Analysis: Primary End Point (time to death from any cause and unplanned 
hospitalisation for a major cardiovascular event)	  Values are n (Percent), mean ± SD, or median (25th - 
75th percentile). HR = hazard ratio; CI = confidence interval. CAD = Coronary artery disease; SBP = 
systolic blood pressure; LGE = late gadolinium enhancement; PAP = Pulmonary artery pressure. 
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Table 11:Univariate Analysis Response to cardiac resynchronisation therapy (LVEF >5 Percent at one 
year). Values are n (Percent) and mean +/- standard deviation, or median +/- interquartile range. OR = 
Odds ratio, CI = Confidence Interval. 
 
 
 
 
 
 
 
 
	  
Table 12 Multivariate Analysis of Response to Cardiac Resynchronisation Therapy (Improvement in 
LVEF >5% at one year) 
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6.4 Discussion 
 
The main findings of this study were that patients with impaired RV systolic function who 
undergo CRT are more likely to have a worse clinical outcome and are less likely to develop 
LV remodelling. RV systolic function has been demonstrated to be a marker of adverse 
prognosis within a range of cardiovascular disease.(238-240) The current study demonstrates 
that impaired RV function demonstrated by CMR imaging is associated with poorer clinical 
outcomes for such patients and less likelihood of LV reverse remodelling.  
 
The study participants fulfilled contemporary criteria for CRT implantation, despite this there 
was a heterogeneous distribution of RV systolic function. This is despite all having decreased 
LV systolic function, which is mandatory for the consideration of CRT implantation. 
The mechanism of RV dysfunction may either be due to a bi-ventricular reduction in intrinsic 
contractility, or raised left ventricular end diastolic pressures and mitral regurgitation.  
 
Poor RV function may reflect more extensive bi ventricular disease or pulmonary 
hypertension, which is less modifiable by CRT. It is notable within this cohort, an RVEF 
<30% indicated a failure to undergo reverse LV remodelling. This relationship needs further 
characterisation and investigation.  
 
6.4.1 Previous work 
Prior work has shown up to 20-40% of RV systolic pressure and volume load is dependent on 
LV contractility.(241) Left Bundle Branch Block (LBBB), may interfere with ventricular 
activation and induce mechanical dyssynchrony. Hence LBBB may have an adverse effect on 
biventricular function. The effects of CRT and right bundle branch block (RBBB) are 
contentious. A proportion of CRT recipients in the randomised controlled trials have had 
RBBB on the surface ECG. An earlier substudy from the MIRACLE trial found that RBBB in 
association with other conduction abnormality (left anterior or posterior fascicular block) did 
not prevent the positive effects of CRT as measured by symptomatic and quality of life 
endpoints.(242) However the more recent MADIT CRT substudy conflicted with this and 
found that RBBB had an increased association with mortality and morbidity.(108)  The 
association between RBBB and adverse outcomes has also been demonstrated in large 
 165 
registry data.  The physiological effects of RBBB have been under investigated and more 
work is needed within the area. RBBB has been shown to induce an activation delay in the 
right ventricular free wall and CRT may improve LV activation but further cause extension of 
the RV free wall delay.(243) However the area has such limited data that more robust 
investigation of physiological mechanisms is needed.  
 
Functional markers of RV function have been previously been evaluated within populations 
undergoing CRT. Field et al investigated RV function in an advanced heart failure population 
consisting of 77 patients. The authors used the Doppler derived myocardial performance 
index (MPI) as a predictor of the composite end point of death, transplantation and left 
ventricular assist devices.(231) A total of 28 patients achieved the primary end point over a 
median follow up period of 21 months. Worse RV function, as demonstrated by a higher RV 
MPI, was seen in those patients who reached the end point compared with those who did not 
(0.83 vs. 0.69, P =0.004). The highest tercile of RV MPI was associated with a 3.3-fold 
increased risk of poor outcome (95% CI 1.3e8.5). Each 0.1 unit increase in RV MPI was 
associated with a 16% increased risk (95% CI 8-26). 
 
A smaller cohort study of 44 patients used echocardiographic indices of RV function (TAPSE 
and RVEF) to assess whether these were associated with LV reverse remodelling at six 
months (defined by >15% increase in LVESV). Severe RV dysfunction was defined as 
TAPSE < or =14 mm and the population was stratified into two groups based on baseline 
TAPSE < or = or > 14 mm. As compared to those with high TAPSE (n = 30), patients with 
low TAPSE (n = 14) were less likely to show LV reverse remodelling after CRT (76% vs 
14%, P < 0.001).(232) Burri and co-workers, using radionuclide imaging also demonstrated 
within a study of 44  patients, that those with a lower RVEF at baseline, were less likely to 
improve in symptomatic status and LVEF following CRT implantation.(233) Following a 
median follow up period of 9 +/- 5 months, a RVEF <35% was associated with a failure in 
improvement in NYHA class (P=0.016) and also had a  non-significant trend towards 
improvement in 6MWT distance and LVEF. (P<0.06).  
 
Longer term data comes from a CARE-HF substudy. Using the original cohort of 813 patients 
enrolled into CARE-HF, 688 had a TAPSE recorded at the recruitment visit.(244) Out of 
these, 345 were randomised to CRT and the median follow up was 748 days (IQR 582 to 950 
days). Patients with lower TAPSE measurements were more likely to have had an ischaemic 
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aetiology and higher rates of mortality. (P<0.001) However when the data was analysed by 
tercile CRT still proved to be effective. TAPSE was a predictor of events irrespective of CRT 
implantation.  
 
6.4.2 Cardiac Magnetic Resonance  
CMR was used as the gold-standard technique within this study. For the purposes of this 
study the reference marker was RVEF. Along with myocardial infarction, RVEF was an 
independent predictor of LV remodelling following CRT. Among an array of established 
prognostic markers in HF, RVEF and TAPSE emerged as the strongest predictors of events. 
 
6.4.3 Tricuspid Annular Plane Systolic Excursion (TAPSE) 
RVEF is a validated prognostic marker in cardio-pulmonary disease. However the right 
ventricle is a complex structure which cannot be modelled with simple geometric 
assumptions. It possesses radial, longitudinal and oblique fibres.(234) Hence measures other 
than EF have been suggested to describe RV systolic function. One such proposed by current 
imaging guidelines, is that of TAPSE.(235) An easily attainable and reproducible marker, it 
has been shown to be a predictor of adverse prognosis which is independent of symptomatic 
status and LV function.(245)  Within this study TAPSE was also predictive of LV 
remodelling and clinical outcomes. Hence this is an alternative measure which may be able to 
be of clinical significance. 
 
In this study, TAPSE not only identified which patients would respond to CRT, but also the 
patients more likely to have major adverse events. Thus, TAPSE may be used by CMR as an 
alternative to RVEF for assessing RV function pre CRT when the latter cannot be estimated. 
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6.4.4 Myocardial fibrosis 
Cardiac magnetic resonance imaging, with the aid of concurrent gadolinium contrast can 
demonstrate myocardial scar or replacement fibrosis.(246) Late gadolinium enhancement has 
been shown to be a prognostic indicator in several disease states.(26, 27) The scar burden, 
location and extent have all been shown to be of clinical importance within populations with 
CRT.(247, 248) This study was not designed to evaluate LGE and CRT. On univariate 
analysis septal and lateral scar was associated with a reduced likelihood of remodelling. (OR 
0.98, 95% CI 0.97-1.00, p=0.01; and OR 0.98, 95% CI 0.97-1.00, p=0.03, respectively), 
however on multivariate analysis the scar burden (determined by percentage of LGE mass) 
did not remain significant. A larger study specifically designed to investigate LGE, extent and 
distribution, is needed to clarify their relationship within patients with CRT. 
 
6.4.5 Atrial fibrillation 
Atrial Fibrillation was the other predictor of clinical outcomes besides RV dysfunction. This 
correlates with the findings of others, where AF has been shown to predict unfavourable 
clinical outcomes.(212)  
 
AF with a fast ventricular rate, may compromise the delivery of biventricular pacing. A low 
level (<90%) of biventricular pacing may interfere with the beneficial effects from CRT.(249, 
250) The rate control of patients within this study was satisfactory (Median 97%, IQR 91-
99%); no patient underwent an atrioventricular nodal ablation.  
 
6.4.6 Left Ventricular Remodelling 
We assessed the role of RV dysfunction on LV remodelling after CRT as a secondary end-
point. In keeping with previous work, response for this study was an improvement in LVEF 
≥5% at 12 months. The remodelling rate observed was 48%, but still in accordance with the 
published literature.(160) Using this criterion, RV dysfunction predicted a failure of LV 
remodelling (RVEF (OR 1.05, 95% CI 1.01- 1.09, p = 0.01) thus supporting previous 
echocardiographic and radionuclide studies.(232, 233) Response to CRT was noted to be 
lower as RV function deteriorated. Poor RV function, defined as a RVEF < 30% or a TAPSE 
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< 10 mm, was associated with a particularly low response to CRT (response rates of 18.2% 
and 26.7%, respectively). 
 
6.5 Limitations 
 
This was a retrospective cohort study with a limited number of patients and events; which 
limits the point of the multivariate analyses.  
 
All patients were scanned and clinically followed up at the Royal Brompton Hospital, 
London. This is a tertiary/quaternary heart failure referral service and hence the study cohort 
may not be representative of less selected heart failure cohorts.  
All CMR scans were performed by the CMR unit on the site; this facilitated consistent CMR 
scanning protocols.  
 
Historically the guidance from device manufacturers has been that CRT generators should not 
be exposed to magnetic resonance imaging this is due to the risk of electromagnetic 
interference. Hence within this study LV remodelling was documented using repeat trans 
thoracic echocardiography.  
 
6.6 Conclusions 
 
This study demonstrates that RV function has potential as a predictor of LV remodelling and 
clinical outcomes in patients following CRT implantation, when assessed by cardiac MR.  
 
Conventional selection criteria focus on left ventricular disease and systolic performance, RV 
function may be a marker which is able to prognosticate adverse clinical outcomes for 
patients following CRT.  
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7.1 Introduction 
 
As described previously, cardiac resynchronisation therapy (CRT) is an established treatment 
for symptomatic left ventricular systolic dysfunction, on optimal tolerated medical therapy 
with a broad QRS duration >120milliseconds on the surface electrocardiogram. One of the 
proposed mechanisms of CRT is to restore coordinated contractility without the expense of 
increased myocardial oxygen consumption.(41) 
 
Within cardiac intensive care (cICU), the use of temporary epicardial pacing systems is 
common in the management of patients in the peri-operative period. Myocardial 
dyssynchrony has been previously demonstrated within patients in the peri-operative 
period.(251) CRT has become an established therapeutic option in the chronic setting; hence 
this has led to a renewed focus on temporary pacing within the intensive care setting. 
Historically this area is underrepresented within the literature.  
 
Cardiac output monitoring within the cICU has been performed conventionally via invasive 
methods. This requires invasive instrumentation in potentially critically ill patients which 
exposes them to the risks of infection or bleeding. Hence alternative methods have been 
investigated for the non-invasive measurement of CO within the intensive care setting.  
 
One such method which has been evaluated is the impedance cardiography (ICG) technique 
which relies on the calculation of intra-thoracic impedance via four surface electrodes and the 
application of a minute amount of direct current to the patient.   
 
Using blood volume passing through the thoracic aorta and the electrical impedance the ICG 
technology is able to calculate various haemodynamic parameters. CO derived from ICG 
measurement has been previously evaluated within ITU patients and has been found to have 
adequate reproducibility and repeatability.(252, 253) One particular sub group in which it 
seemed to have strong correlation with traditional invasive techniques of CO measurement 
was within patients with septic shock which required vasopressors and organ support within 
an ITU setting.(254, 255)  ICG has also been previously been demonstrated to be of clinical 
use in the optimisation of permanent pacing systems. (both dual chamber and biventricular 
types)(146) 
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Utilising the knowledge of previous efficacy both within the field of pacemaker optimisation 
and CO monitoring within an intensive care setting – we proposed a pilot study to validate the 
ICG measure of CO versus those derived from transthoracic echocardiography (TTE) within 
patients in a CICU setting. The hypothesis of the study being that impedance cardiography 
reliably evaluates cardiac output in patients following cardiac surgery as compared to 
transthoracic echocardiography. 
 
7.2  Methods 
 
7.2.1  Patient Selection & Recruitment 
Patients were identified from the pre-operative theatre lists published at the Royal Brompton 
Hospital, London. All potential study participants had to provide written informed consent 
and were given twenty-four hours to consider study participation. Due to the structure of the 
study protocol all potential participants had to have cardiac surgery and potentially temporary 
epicardial right atrial and right ventricular pacing leads connected to the Micro Pace 4580 
temporary pacing box (Pace Medical Inc, Waltham, Massachusetts). Ethical approval was 
provided by the North West London Research Ethics Committee (REC) -1. (Study ID 11-LO-
0131) 
 
7.2.2  Setting  
All study participants were identified prior to adult cardiac surgery and were approached only 
if they fulfilled inclusion criteria. If any exclusion criterion was deemed to apply – the patient 
was not approached. Following cardiac surgery the patients were transferred to the Doverdale 
Adult Intensive Care Unit at the Royal Brompton Hospital, London. All study measurements 
were either performed within the ITU or within the high dependency unit. (HDU). The 
exclusion criteria for the study are listed in Table 11. 
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7.2.3  Methodology 
All participants were haemodynamically stable (defined by no change in ventilatory settings, 
oxygen requirements, change in filling pressures or change in inotrope requirements for > 30 
minutes) prior to the alteration of pacing settings. All patients were also normothermic 
defined as temperature between 35.0 and 37.2 degrees Celsius. Prior to the recording of effect 
of different settings all epicardial leads were tested for electrical stability measured by 
thresholds.  
 
Providing the above conditions had been met the patients then underwent the following 
pacing protocol.  
 
A baseline recording was performed with a ventricular pacing rate set at 80 beats per minute 
(BPM) in the following configurations.  
 
1. Atrial Sensed Pacing (AAI) - This was not performed in patients who had underlying high 
degree atrioventricular block. The patient was paced only from the Right Atrial Lead (RA) 
and a range of heart rates tested from 80 to 120 BPM in 10 beat intervals.  
 
2. AV delay adjustment. The patient was placed in a dual chamber pacing and sensing mode 
(DDD) and the rate preset at 100 BPM. The AV delay was then adjusted between 80 and 200 
milliseconds at 20 millisecond intervals.  
 
3. Ventricular Sensed Pacing (VVI) - Right Ventricular Pacing Only. A range of heart rates 
was tested from 90 beats per minute to 120 beats per minute.  
 
4. Dual Chamber Pacing (DDD) - Right Atrium (RA) to Right Ventricular (RV) pacing with 
fixed atrioventricular (AV) delay of 100 milliseconds. A range of heart rates was tested from 
80 to 120 BPM in 10 BPM increments.  
 
For all adjustments in pacing settings, a period of 30 seconds was allowed prior to the 
recording of cardiac output either via echocardiography or impedance cardiography. An 
average of 20 beats per setting was recorded.  
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7.2.4  Echocardiography 
All transthoracic echocardiography was performed by a single operator with appropriate 
accreditation. All echocardiography was performed using a Philips IE33 system (Phillips 
Corporation, Andover, Massachusetts, US).  
 
The left ventricular outflow tract (LVOT) diameter was measured from the parasternal long 
axis view in systole. The LVOT velocity time integral (VTI) was recorded from the apical 5 
chamber view using pulsed wave Doppler.  
 
Cardiac output was then derived from these settings using the following equation: 
 
Cardiac Output = Heart rate * (π (LVOT diameter/2)2 * LVOT VTI 
 
7.2.5  Impedance Cardiography 
All measurements were recorded using the NICCOMO ICG device (Medis, Medizinische 
Messtechnik GmbH). Four surface electrodes were placed in a standardised configuration as 
recommended by the manufacturer. The device then recorded the cardiac output by analyzing 
20 consecutive beats over each setting.   
 
7.2.6  Statistics 
All analysis was performed using SPSS version 19 (International Business Machines Corp, 
Armonk, NY, US). Continuous variables were expressed as mean ± standard deviation (SD), 
categorical variables are expressed as percentages.  
 
Analysis of the relationships between the two sets of derived variables was guided by an 
experienced statistician and regression equations were generated. A p value <0.05 was 
deemed as statistically significant.  
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7.3 Results 
 
Baseline demographics for the study population are demonstrated in Table 12. In total six 
patients were recruited to the study. All had undergone aortic valve replacement. The majority 
of the cohort (n=4, 67 percent) were male and the baseline left ventricular ejection fraction 
(LVEF) was 57.3 ± 5.5 percent, the mean QRS duration on surface electrocardiogram at 
enrolment was 112 ± 35 milliseconds.  
 
Due to the exclusion criteria all six participants were studied in the HDU setting rather than 
the intensive care setting. Most of the patients were not on any inotropes with a solitary 
patient being on low dose noradrenaline infusion (0.02 mcg/Kg/min).  
 
7.3.1  AAI Pacing Mode  
A full dataset for this pacing mode was only obtained on n=3 (50 percent) of the cohort this 
was due to the patient requesting termination of readings in one case and resting AV block or 
severe sinus bradycardia in the other two cases. Due to the lack of data for this modality 
further statistical evaluation did not proceed.  
 
7.3.2  AV delay adjustment  
A full dataset was captured for this pacing mode in n=5 (83 percent) participants. As 
proposed a range of AV delays was tested with a set heart rate of 100 beats per minute. The 
Bland Altman and Regression Graphs for these settings and the following settings are 
demonstrated in Figures 17 and 18.  
 
7.3.3  VVI Pacing Mode  
A full dataset was captured in this pacing mode for n=5 (83 percent) of participants.  
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7.3.4  DDD Pacing Mode  
A full dataset was captured in all of the study participants in this pacing mode. (n=6, (100 
percent).  
 
7.4 Discussion 
 
The study was conceived as a novel pilot study to evaluate the relationship between 
impedance cardiographic measurement of cardiac output versus a more standardised method 
in this case - transthoracic echocardiography.  
 
Using a very limited number of patients (N=6), a dataset was obtained over different pacing 
configurations and heart rates. Therefore any conclusions drawn from the interpretation of 
such a dataset should be considered with caution. The findings may provoke further 
hypothesis generation for future studies but do not provide definitive conclusions.  
 
Using the data from the VVI, DDD and AV delay pacing groups there is little agreement 
between the two methodologies in terms of recorded cardiac output especially in the VVI and 
DDD pacing groups. There is a tendency for the ICG to generate higher readings especially at 
higher heart rates. There is some degree of correlation in this dataset in terms of AV delay 
adjustment but this as stated above should not be viewed as strong. The scatter of such data 
which is demonstrated in the Bland Altman plots is wide and hence difficult to meaningfully 
interpret. This may reflect individual variability of the patient such as variability in left 
ventricular loading conditions or the technique recording the cardiac output. A Bland Altman 
plot also only demonstrates how well the method under evaluation (in this case ICG) performs 
as compared to the gold standard (again within this study- transthoracic echocardiography). It 
does not demonstrate the ability of ICG to evaluate a change in cardiac output. When 
reviewing the individual values and raw data this is demonstrated within these datasets.  
 
Impedance cardiography calculates cardiac output via the measurement of pulsatile thoracic 
aortic blood flow. It assumes that thoracic fluid is negligible and hence relies on the 
mechanistic changes in aortic dimensions to generate cardiac output. By using the application 
of Ohm's Law to measure changes in voltage and impedance and it is able to translate these 
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into parameters of cardiac function. Several commercial systems are available and have been 
previously evaluated in intensive or critical care settings.(256, 257) 
 
The gold standard of cardiac output monitoring as recommended by international guidelines 
in critical care settings is the thermodilution method using pulmonary artery catheters. Prior 
work has demonstrated that ICG is comparable to pulmonary artery catheters and CO 
measurement in such settings.(257) However this has not been an uniform finding and some 
groups have found poor correlation between the two methods.(258) 
 
Within the critical care setting it has been used to evaluate patients with decompensated heart 
failure, septic shock and hypovolaemia following major insult e.g. trauma. However ICG has 
never been previously used to evaluate cardiac output monitoring in post-operative cardiac 
surgical patients and hence the prior literature is being extrapolated to this context.  
 
With regards to pacemaker optimisation, a few groups have previously compared its 
reproducibility to transthoracic echocardiography in permanent pacing systems and 
atrioventricular delay.(146) However the overall number so patients enrolled into such studies 
is small and though individual studies have demonstrated significant findings a larger 
multicentre study is needed. One of the largest studies recently published was that performed 
by Khan et al who evaluated the NICOM device (Cheetah Medical, Oregon, US) in 47 
patients with cardiac resynchronisation therapy (CRT) implants.(145) Following CRT 
implantation, after a period of fourteen days, the optimal AV and ventriculo-ventricular delay 
was identified using the ICG device. The optimum AV delay determined by NICOM was 
confirmed by echocardiography in 40 of 47 patients (85 percent, r = 0.89, P < 0.01) and for 
VV delay in 39 of 47 patients (83 percent, r = 0.89, P < 0.01). In a longer term study the 
successful identification of AV delay when the NICOM device was used revealed a cohort 
who had higher rates of positive LV remodelling and clinical improvement following CRT 
implantation.(146) 
 
All six patients within this study had undergone aortic valve replacement for aortic stenosis 
and had preserved left ventricular systolic function with a majority also having narrow QRS 
durations. Therefore this is a very different population to that of a patient with left ventricular 
systolic dysfunction and broad QRS duration being considered for CRT. There is no prior 
literature evaluating the physiological effects of temporary pacing in this population. There 
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have been a few limited trials investigating the effects of short term acute biventricular pacing 
in populations with significant levels of systolic dysfunction and dyssynchrony but the overall 
literature is extremely limited.(259, 260) Further work is much needed within this area to 
characterise the effect of pacing in the post operative period and its ability to assist in 
improving cardiac output.  
 
7.5 Study Limitations 
 
The study was conceived as a pilot study and therefore is most limited by its extremely small 
number of participants. All participants had had aortic valve surgery and hence the population 
is certainly not representative of other patients undergoing cardiac surgery e.g. mitral valve 
repair or replacement.  
 
The study did not demonstrate a relationship between impedance cardiography and 
transthoracic echocardiography in terms of cardiac output measurement. However there is 
variation within every patient, to left ventricular systolic function, left ventricular outflow 
tract diameter, biochemistry, loading conditions and electrical conduction. A larger cohort 
would ensure any anomalous outliers in terms of these or other such variables would be 
controlled for.  
 
Due to the exclusion criteria none of the patients were studied in the intensive care unit setting 
directly. Therefore we were unable to compare the relationship between ICG and invasive 
forms of cardiac output monitoring. Another small pilot study under such conditions would be 
necessary to investigate the relationship in this group of patients as compared to invasive 
measurement.  
 
7.6 Conclusions 
 
This small pilot study did not demonstrate a relationship in cardiac output measurement 
between impedance cardiography and transthoracic echocardiography in a cardiac surgical 
post-operative setting.  
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Impedance cardiography within this cohort had a tendency to record a higher cardiac output 
as compared to echocardiography. 
 
Overall alteration of pacing settings and modes within this cohort did result in changes in 
cardiac output. Further work is much needed within this area to further evaluate this effect. A 
larger study is needed to satisfactorily answer whether ICG can reliably assess cardiac output 
in this group of patients.  
 
 
 
 
Persistent Atrial Arrhythmias (Atrial Fibrillation/ Atrial Flutter) 
 
Clinical Deterioration prior to entry into study requiring more than three classes of inotropes 
Serum pH <7.0 
 
Lactate >15 mmol/L 
 
Severe renal dysfunction – (Serum Creatinine >200mmol/L or requiring renal replacement therapy) 
 
The clinical necessity for a Left Ventricular Assist Device (LVAD) prior to recruitment into the 
study 
 
Procedures performed on patients with congenital heart disease and/or involving the right ventricle 
 
 
 
Table 13: Exclusion Criteria for Study 
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197 Variable  198 Mean (Standard Deviation) unless 
specified 
199 Gender 200 Male =4 (67%), Female =2 (33%) 
201 AVR 202 N=6 (100%) 
203 pH 204 7.41 = +/- 0.04 
205 Lactate (mmol/L) 206 1.6+/- 0.9 
207 Haemoglobin (g/dL) 208 9.9 +/- 0.6 
209 Urea (mmol/L) 210 6.6+/- 2.0 
211 Creatinine (mmol/L) 212 101 +/- 23.8 
213 Potassium (mmol/L) 214 4.7+/- 0.5 
215 Sodium (mmol/L) 216 139.5+/-2.9 
217 Magnesium (mmol/L) 218 1.29+/-0.47 
219 QRS duration (ms) 220 112+/-35.4 
221 PR interval (ms) 222 195.6 +/- 97.8 
223 QT corrected (ms) 224 454.6 +/- 46.6 
225 LV Ejection Fraction 
  
226 57.3 +/-5.5 
227 LVEDD (cm) 228 4.5 +/- 0.5 
229 LA Diameter (cm) 230 4.4+/- 0.8 
 
Table 14: Baseline Demographics of cohort; AVR; Aortic Valve Replacement; LVEDD – Left Ventricular 
End Diastolic Diameter; LA – Left Atrial Diameter 
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Figure 17: Bland Altman Plots for the data from 6 paired samples with cardiac output calculated via 
transthoracic echocardiography versus impedance cardiography (NICOMMO device).The three figures 
represent different modes of pacing. 
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Figure 18: Demonstrating the regression equation and Line of best fit.Demonstrates the above 
relationship in variable atrioventricular delays. Demonstrates the above relationship in VVI configuration 
pacing. Demonstrates the above relationship with DDD configuration pacing. 
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Chapter VIII: Discussion, Clinical Implications, 
Ideas for Future Research and Conclusions 
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8.1 Discussion 
 
Cardiac Resynchronisation Therapy (CRT) is an established therapy for patients with 
specified selection criteria and symptomatic left ventricular systolic dysfunction. The 
associated literature within the field of CRT is vast. The thesis has explored some concepts 
within the area and the conclusions drawn are below.  
 
8.1.1 A structured clinical protocol for the care of patients following Cardiac 
Resynchronisation Therapy  
 
Increasing numbers of patients throughout the westernised world and particularly the United 
Kingdom are undergoing CRT implantation.(189, 190) However the systems in terms of local 
and national healthcare infrastructure for the pre and after care of such patients remains 
heterogeneous and non-optimal.  
 
There are limited data from the United States that dedicated heart failure pacing clinics may 
be one such model for patients with CRT implants.(149) The published data suggests that 
such clinics with structured protocols may be able to identify reasons behind the individual 
lack of clinical benefit such as the need for Atrio ventricular (AV) interval and Ventriculo-
ventricular (VV) interval optimisation, the need for addressing co-morbidities such as 
anaemia and the need for review and up titration of concomitant evidence based 
pharmacotherapy. A large proportion of the patients who were not experiencing anticipated 
clinical benefit were on sub optimal evidence based pharmacotherapy.  
 
Using data from the specialised heart failure pacing clinic at the Royal Brompton Hospital, 
London, I was able to demonstrate that a structured clinical approach to the follow up of such 
patients results in improved doses of HF pharmacotherapies.(220) This also agrees with data 
from other groups, whereby the period following CRT implantation may lead to favourable 
physiological conditions where HF therapies may be introduced or uptitrated. The pertinent 
longer term question is as to whether this results in improved outcome for such patients and 
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justifies the added expense of the introduction and maintenance of a specialised clinic. This 
would need further research into the area as described below.  
 
8.1.2. Haemodynamic Optimisation of Cardiac Resynchronisation Therapy Study 
(optCRT)  
 
A consecutive series of 44 patients was recruited prospectively and randomised to either 
echocardiographic guided optimisation or impedance cardiographic (ICG) optimisation. 
Using a primary endpoint of improvement 6MWT distance, both methods were shown to be 
equal. There were no differences on secondary endpoints within either arm.  
 
The trial population was recruited from a single tertiary centre and was small. However the 
study is one of the largest in the field using ICG equipment. Although a larger study is needed 
to evaluate whether ICG is superior as compared to echo guided methods of adjustment of 
AV and VV intervals - it remains a viable alternative on the basis of this study.  
 
Similar to others within studies based around the optimisation process, a notable majority of 
patients had alteration in their AV and VV intervals from the CRT implant baseline settings. 
Though the optimisation process has not been investigated in terms of impact on clinical 
outcomes, the data accrued from this study along with others is suggestive that it should be 
considered for all patients in the post implant period. Another point which was noted within 
this study and links to the findings described in chapter IV is that by evaluating patients 
systematically at preset time points following CRT implantation, this allows the review and 
uptitration of HF evidence based pharmacotherapies.  
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8.1.3  Right Ventricular Dysfunction predicts clinical outcomes in a population 
undergoing CRT 
From analysing the previous literature and my own clinical experience during the research 
period, I noted that several patients seemed to have significant levels of right ventricular (RV) 
dysfunction prior to CRT implantation. Right ventricular dysfunction has long been 
recognised as an adverse prognosticator in populations with heart failure. 
Right ventricular dysfunction has long been recognised as an adverse prognosticator in 
populations with heart failure.(234) Recent observational data from selected groups used 
echocardiography to measure parameters associated with right ventricular dysfunction 
including right ventricular fractional area change, myocardial performance index and 
tricuspid annular plane imaging.(245) Due to its complex geometrical anatomy, the right 
ventricle is difficult to visualise on echocardiography. A certain proportion of patients do not 
possess sufficient acoustic windows to permit accurate visualisation of the right ventricle let 
alone make accurate measurement of structure and function.  
 
Hence using a cohort derived from the heart failure pacing clinic and who had undergone 
cardiac magnetic resonance imaging of their heart prior to CRT implantation, I was able to 
demonstrate that using a cut point of 15 millimetres for Tricuspid Annular Plane Systolic 
Excursion distance (TAPSE) and 50 % for Right Ventricular Ejection Fraction (RVEF) was 
associated with adverse clinical outcomes defined as a composite endpoint of heart failure 
hospitalisation and all cause mortality. A couple of further points of interest emerged from 
this study. Firstly there was a wide spread heterogeneity in RV function despite all patients 
fulfilling the necessity to possess a LVEF <35% for CRT implantation. Since the publication 
of the study included in this thesis, others have corroborated its findings using speckle 
tracking.(261) However the overall collection of data from various studies at this timepoint 
remains limited. Further work is needed to evaluate right ventricular dysfunction in a patient 
undergoing CRT implantation and whether it ultimately has a role in patient selection.  
 
Secondly the use of cardiac magnetic resonance (CMR) in heart failure is expanding. Late 
gadolinium enhancement (LGE) has been demonstrated in several cohorts to be associated 
with adverse prognosis and increased morbidity. The position of LGE within the left ventricle 
and its location in relation to a contiguous LV lead has also been shown to carry adverse 
prognosis.(262) Thus the right ventricular data from this study also supports another purpose 
 188 
of CMR within this group of patients. Ultimately all of these findings from CMR based 
studies have been performed on small cohorts, often single centre studies with non-
randomised groups. Each finding need to be further characterised in larger prospective 
cohorts but in the longer term, a CMR study may become a part of the evaluation process for 
potential CRT recipients.  
 
8.1.4  Optimisation of biventricular pacing in ITU setting (BiTU) 
 
This study was conceived as a response to comments at the upgrade viva. It was designed as a 
validation pilot study for ICG equipment in the role of pacemaker optimisation in an 
alternative setting.  
 
A series of 6 patients was recruited prospectively who were scheduled for cardiac surgery. All 
received epicardial pacing leads as part of their routine clinical care.  
Following their transition from intensive care to the high dependency unit, the haemodynamic 
profiles in conjunction with echocardiographic assessment was performed at various heart 
rates and pacing modes. The findings were documented and the degree of correlation was 
investigated.  
 
In conclusion there was some limited agreement between ICG equipment and 
echocardiographic measures - this was more so at lower heart rates. At certain levels of heart 
rate and pacing modes there was little correlation.  
 
One point of note is that the optimal cardiac output for each patient differed significantly from 
their baseline setting in the post-operative period. This may be of some clinical benefit and a 
larger study with different protocol would be needed to answer this question. 
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8.2 Future Research  
 
Cardiac Resynchronisation Therapy (CRT) has become an established therapy for heart 
failure over the last twenty years. Its transition from theory and initial pilot studies to large 
scale randomised controlled trials has been relatively rapid. It should be remembered as the 
CRT literature has expanded, medical therapy for heart failure has also improved with several 
large randomised trials reporting recently.  
 
The evidence base has grown and there is clear evidence from various trials that CRT is 
effective at improving morbidity and mortality within selected populations of LVSD. 
However like any other technology, what is unknown is the ability of CRT to be beneficial in 
patients outside of the current evidence base. The current recommendations for a patient to be 
considered for a CRT device are broadly similar in terms of European and American 
guidelines (British guidelines are currently being revised).(22, 98) Currently this is a left 
ventricular ejection fraction (LVEF) of <35 percent, a surface QRS duration of >120 
milliseconds on the electrocardiogram (ECG), optimal tolerated medical therapy and New 
York Heart Association (NYHA) class II to IV. However despite the number of trials and 
several thousand participants, it still unknown as to why a third of patients do not derive the 
clinical benefit anticipated prior to the procedure of CRT implantation. The reasons behind 
this are likely to be multifactorial. Each step of the process looking after a potential patient 
who is a CRT candidate is crucial and may have variation which ultimately impacts on the 
clinical experience and outcome for that individual.  
 
Prior to CRT implantation, the patient should be assessed by a heart failure pacing specialist 
and suitability deemed by the guidelines and also clinical status. The decision to proceed to 
CRT implantation should be performed only once pharmacotherapy has been reviewed and 
co-morbidities addressed. The implantation stage of the procedure has become standardised 
with simplified transvenous techniques.  However the left ventricular (LV) lead position and 
maybe the right ventricular lead (RV) is critical. Current fluoroscopic techniques preclude the 
on table demonstration of myocardial scar, but it is imperative that the LV lead avoids such 
regions and is placed where possible in a lateral or infero-lateral position.  
Following successful implantation of CRT, the patient needs to have pacing checks, detailed 
imaging and frequent careful clinical supervision. The period of six months following CRT 
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implantation is an opportunity to review and uptitrate prognostic medication. They should 
also undergo optimisation of the AV and VV intervals. 
 
Each of these steps has been evaluated in small single centre or limited multi centre studies. 
However none of these steps or processes has yet formed the basis for a larger randomised 
controlled trial. The other noteworthy development in the field is the ongoing technological 
development. Manufacturers of CRT are continuously refining generators and lead to improve 
performance. One such example is the development of a quadripolar left ventricular lead 
which is able to perform multi-site pacing via reconfiguration of pacing vectors.(263) 
Alternatively more sophisticated algorithms are becoming embedded into the device to 
monitor intra-thoracic impedance, pulmonary capillary wedge pressure. These tools when 
monitored, may allow the healthcare team looking after the patient to act and predict 
imminent decompensation.  
 
The clinical trials have recruited and published with speed, several having been published 
over the last ten years. However though the clinical effectiveness of CRT is unquestionable, 
there are notable areas with a paucity of data including females, more elderly patients, 
patients with atrial fibrillation, patients with significant levels of co-morbidities, patients with 
heart failure from the ethnic minorities and patients undergoing ‘upgrade’ procedures from 
conventional dual chamber pacing and ICD systems. The rapid speed whereby CRT has 
become an established therapy for selected patients with heart failure means that to deny a 
patient the benefit of CRT is unethical. Therefore either data needs to be collected and 
published from observational studies or prespecified sub group analyses from the prospective 
randomised controlled trials. Both do exist but often give different results, which leads to 
debate in the sub area. Another alternative is to perform studies in geographical areas of the 
world with less exposure to CRT and thus compare the true effect of CRT versus modern 
heart failure therapy.  
 
The boundaries described by the current recommendations are defined as a QRS 
duration>120 milliseconds and a LVEF <35 percent. Apart from the issues described above 
the other question facing the field is whether CRT would be effective in those patients which 
currently fall outside of the cut points. Some data exists from sub studies from large trial data 
that this may be the case but further larger randomised trials are underway in the area. The 
registry data that exists for the use of CRT highlights the expansion and use of CRT beyond 
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the guidelines.(190) Thus the areas I have described above need further clarification, thought 
and data to support such clinical extension of the technology. This is especially relevant in 
modern healthcare infrastructure, where the focus has shifted onto evidence based application 
of technology in association with the collection of clinical outcomes.  
 
The ideas for future research on the basis of the studies presented within this thesis are: 
 
A direct comparison of conventional ad hoc care of the patient with a CRT implant versus the 
structure approach described within chapter V. The primary endpoint would be the dose of 
evidence based pharmacotherapy. 
 
The longer term follow up of patients described in hypothesis 1. Does this affect clinical 
outcome in terms of HF hospitalisation and mortality? 
 
Optimisation using impedance cardiography versus echocardiographic guided optimisation in 
a prospective randomised study with symptomatic and clinical endpoints. 
 
Optimisation of impedance cardiography should be performed at rest or on exercise- pilot 
study using a symptomatic endpoint 
 
 A long term multi centre prospective study observing all patients following CRT 
implantation and optimisation with endpoints being clinical outcomes. Patients would be 
randomised to different optimisation techniques 
 
A prospective large cohort of patients randomised to CRT or medical therapy implantation on 
the basis of right ventricular dysfunction and current selection criteria and clinical endpoints 
 
The reproducibility and repeatability of RV assessment using cardiac magnetic resonance 
imaging  in patients with CRT implants – a validation study 
 
A comparative study of CMR versus echocardiographic measures of RV function in a cohort 
of patients with CRT on a prespecified endpoint 
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A validation study of impedance cardiography versus echocardiographic monitoring of 
cardiac output in a cardiac intensive care setting 
 
A validation study of impedance cardiography versus echocardiographic monitoring of 
cardiac output in a intensive care setting 
 
Optimisation of AV intervals in patients in a cardiac intensive care setting improves clinical 
outcome 
 
8.3 Clinical Implications  
 
Having studied the field of cardiac resynchronisation therapy in more detail there are 
numerous potential clinical implications derived from the thesis and the studies contained 
within it.  
 
The evidence base for CRT has steadily increased over the last fifteen years. The established 
indications are now non debatable but the boundaries for the application of CRT technology 
are under constant investigation. Logically the use of CRT needs to be evaluated in large 
rigorous randomised clinical studies in populations with narrow QRS durations, patients with 
milder forms of left ventricular systolic dysfunction and those with preserved left ventricular 
systolic function, rarer aetiologies such as infiltrative cardiomyopathy (sarcoidosis, 
haemachromatosis and amyloidosis) and a direct comparison of CRT-P vs CRT-D in 
structured trial format.  
 
Apart from investigating the boundaries of technological application, further work needs to be 
performed in all aspects of the process for a patient undergoing CRT implantation.  
 
Firstly patient selection needs to be investigated further and reliable prognosticators identified 
from larger data sets. The issue of cardiac imaging and its role in patient identification and 
evaluation of mechanical dyssynchrony needs careful thought and carefully constructed 
studies to evaluate whether such techniques justify costly equipment and healthcare resources 
in an environment of diminishing healthcare expenditure.  
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The actual implantation process for CRT has evolved over the last seven years but more 
sophisticated lead technology, wireless systems, more embedded algorithms which may aid 
the diagnostics and ongoing care of a patient with heart failure, and compatibility with cardiac 
magnetic resonance scanning.  
 
In the post implant phase further investigation is badly needed in the field of optimisation 
with more attention paid to device and medical optimisation. Despite the extension of CRT to 
increasing number of patients - the residual problem of response remains poorly characterised 
and understood. A consensual definition is urgently needed which would permit further 
evaluation. In the longer term healthcare infrastructure also needs to be reviewed to cope with 
increasing numbers of patients with CRT implants in situ. Apart from dedicated heart failure 
pacing clinics, increasing numbers of CRT devices have a remote transmission capability and 
modern healthcare needs to evolve and investigate how best to employ such technology.  
 
Concentrating on healthcare within the United Kingdom - there are numerous issues raised 
following further study and partly answered by some of the studies within this thesis.  The 
current model of healthcare in the UK is a public funded system which covers the National 
Health Service. Within this framework control is delegated from the Department of Health to 
regional groups who then are responsible for clinical commissioning locally. However the UK 
along with all other major Western nations is currently in the midst of economic recession and 
has had major recent healthcare structural change. In the new commissioning environment it 
is currently unknown as to what will happen with regards to CRT implantation rates. This 
against the backdrop of a constant increase in CRT implantation rates across particularly 
England and Wales over the last ten years. Currently there is widespread geographical 
variation not only in CRT implant rates but also in the aftercare of such individuals. The study 
performed within this thesis (Chapter  IV) which evaluated individuals passing through a 
dedicated heart failure pacing clinic demonstrated a clear improvement in the initiation and 
uptitration of evidence based pharmacotherapies. Though the study lacked a control group, 
the regional and local variation of patients with CRT implants means that many patients 
remain on sub optimal doses and medication following CRT implantation. This represents a 
potential lost opportunity to review HF medication.  
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Hence one possible implication from this thesis is to consider HF-pacing clinics with 
consultant cardiologists experienced in both heart failure and devices in a more widespread 
format. Whether this  is worthwhile of  further resource allocation and expense needs to be 
considered properly in a prospective study comparing patients passing through such clinics as 
compared to conventional care.  
 
The most recent guidance has been issued by the ESC, this year.(22) The guidelines covering 
CRT are currently being revised by NICE and are awaited. Device based optimisation 
according to the current ESC guidance is now reserved for patients who are non-responders. 
Initial evidence relied on echocardiographic optimisation methods, however due to a limited 
literature these methods are under question. Numerous alternative methods including 
algorithmic and other non invasive methods now exist for device based optimisation. Chapter 
V presents an optimisation study using impedance cardiography.  
 
With increasing numbers of patients with CRT implants in the UK, there is potential for the 
enhanced collection of clinical data. A national audit already exists for patients with heart 
failure and Cardiac Rhythm Devices by combining the two and recording clinical outcomes, 
this would ensure a large collection of data which could be analysed. An increased degree of 
cooperation between local, regional and national bodies would enhance the possibilities of 
meaningful research within the area and also ensure that the UK remains a suitable destination 
for large randomised studies in the field of CRT.  
 
Ultimately the thesis has contributed small amounts of data to certain areas of this field, but in 
my own personal opinion further research is sorely needed to clarify this technology and all of 
its associated aspects. Cardiac resynchronisation therapy is now an established therapy but 
remains complex and with multiple questions which remain unanswered and needing further 
clarification.  
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8.4 Conclusion 
 
This thesis has allowed me to investigate different aspects related to the management of 
patients with CRT implants. The literature for this area has mirrored clinical development and 
has increased rapidly.  
 
However there are still many uncertainties with regards to management of patients following 
CRT implantation and why some derive a much greater clinical improvement than others.  
 
The study chapters focussed on clinical protocol, optimisation and right ventricular 
dysfunction have demonstrated with small amounts of data the ability to improve on certain 
points in the pathway for the care of such patients. Right ventricular function is a prognostic 
marker and may be of use clinically in the longer term. A structured clinical protocol which 
thoroughly re-evaluates the patient following CRT implantation and permits medical 
optimisation is described in chapter IV. This may again be of some clinical merit and needs 
further exploration. The study performed on optimisation demonstrates that ICG is a viable 
option for CRT optimisation but its true effect needs further investigation. Similar to others, 
however it shows that optimisation does result in significant haemodynamic improvement in 
certain individuals.  
 
The thesis chapters and other publications during my research time have shown that there 
gaps of knowledge deficiency which need further investigation but in the longer term may 
yield improved clinical benefits for the patient with CRT.  
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9.1 Appendix I - Minnesota Living with Heart Failure 
Questionnaire 
MINNESOTA LIVING WITH HEART FAILURE® QUESTIONNAIRE 
The following questions ask how much your heart failure (heart condition) affected 
your life during the past month (4 weeks).  After each question, circle the 0, 1, 2, 3, 4 
or 5 to show how much your life was affected.  If a question does not apply to you, 
circle the 0 after that question. 
 
Did your heart failure prevent  
you from living as you wanted during                                               
the past month (4 weeks) by -                     No      Very Little            Very  Much  
       
1.  Causing swelling in your ankles or legs?   0            1        2        3        4        5 
 
2.  Making you sit or lie down to rest during    
     the day?                      0            1        2        3        4        5 
 
3.  Making your walking about or climbing      
     stairs difficult?                  0            1        2        3        4        5 
 
4.  Making your working around the house    
     or yard difficult?                             0            1        2        3        4        5 
 
5.  Making your going places away from           
     home difficult?                  0            1        2        3        4        5 
 
6.  Making your sleeping well at night 
     difficult?                             0            1        2        3        4        5 
 
7.  Making your relating to or doing things 
     with your friends or family difficult?        0            1        2        3        4        5 
 
8.  Making your working to earn a living 
     difficult?                             0            1        2        3        4        5   
                                                             
9.  Making your recreational pastimes, sports 
     or hobbies difficult?                 0            1        2        3        4        5 
 
 
10. Making your sexual activities difficult?    0           1        2        3        4         5 
 
11. Making you eat less of the foods you  
      like?                        0           1        2        3        4        5 
 
 
12. Making you short of breath?                 0           1        2        3        4        5 
 
13. Making you tired, fatigued, or low on 
      energy?                                0           1        2        3        4        5 
 
 220 
 
14. Making you stay in a hospital?                   0          1        2        3        4        5 
 
 
15. Costing you money for medical care?       0          1        2        3        4        5 
 
16. Giving you side effects from treatments?  0          1        2        3        4        5 
  
17. Making you feel you are a burden to your  
       family or friends?            0          1        2        3        4        5 
 
18. Making you feel a loss of self-control 
        in your life?                       0          1        2        3        4        5  
 
 
19. Making you worry?                   0          1        2        3        4        5  
 
20. Making it difficult for you to concentrate 
        or remember things?                   0          1        2        3        4        5  
 
 
21. Making you feel depressed?                  0          1        2        3        4        5 
______________________________________________________________________
___ 
 
©1986 Regents of the University of Minnesota, All rights reserved.  Do not copy or 
reproduce without permission. LIVING WITH HEART FAILURE® is a registered trademark 
of the Regents of the University of Minnesota. 
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